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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, 
reliable and comparable information on drugs and drug addiction. 
In doing so, it provides its audiences with an evidence-based picture 
of the drug phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisers; professionals 
and researchers working in the field of drugs; and, more broadly, the 
media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug 
phenomenon in the EU and is an essential reference book for those seeking 
the latest findings on drugs in Europe.
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•	 	at	the	European	Union’s	representations	or	delegations.	You	can	obtain	their	contact	details		
on	the	Internet	(http://ec.europa.eu)	or	by	sending	a	fax	to	+352	2929-42758.
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5We are proud to present this, the 15th, annual report on 
the state of the drugs problem in Europe. The analysis 
included here is built on the data collected by the Reitox 
network of national focal points, working closely with 
their national experts. The report benefits from our 
collaboration with the European Commission, Europol, the 
European Medicines Agency and the European Centre for 
Disease Prevention and Control.
In this year’s report, as ever, you will find a comprehensive 
overview of Europe’s drug problem and the measures 
being taken to tackle it. However, our task goes beyond 
simply reporting statistics. The report is guided by the 
need to identify and share best practice and to ensure 
that evidence-based interventions are supported. 
This imperative applies equally to actions targeting 
the supply of drugs and to those targeting demand. 
Reading this report, it is clear that we now have a better 
understanding of what works, and that Europe has made 
great advances in some areas. Despite this, approaches 
lacking a sound foundation for their efficacy still attract 
funding. With the current pressures on the public purse, 
there is a heightened need to ensure that public funds 
are wisely spent. Here, our role is to provide a neutral 
and dispassionate assessment of the evidence base for 
interventions.
Though focused on Europe, the report repeatedly 
acknowledges the global nature of the drugs problem. 
You will read, for example, about the growing and 
severe drug-related problems now faced by many of our 
neighbouring countries. These are not just public health 
disasters for the countries concerned; by undermining 
social development and feeding corruption and organised 
crime they represent a real threat for the European Union. 
Europe is committed to a balanced and evidence-based 
drugs policy supported by a sound understanding of 
the problem. We are proud that the European model for 
developing national drug information systems is becoming 
increasingly influential. And we are pleased to report 
on the EMCDDA’s growing role in European initiatives 
to assist non-EU countries in developing capacity in this 
respect.
The estimated 1 million people now in drug treatment 
testifies to the work that has been done to ensure that 
care is made available to those in need. At the same time, 
it is a reminder of the scale of the problem that Europe 
continues to face. Opioid substitution treatment remains 
the biggest sector in this area, and here the mood appears 
to be changing, with questions being asked about the 
long-term outcomes of those in care. These are important 
questions, but it is also important to recognise the 
public health and social benefits delivered by increased 
treatment provision.
The increase in treatment availability is a positive finding, 
but large inequalities in access to care still exist across 
Europe. In practice, treatment is sometimes least available 
to those who need it most. This inequality is not just 
geographical. This year’s report explores the importance 
of the prison setting for targeting those with drug 
problems. While some progress has been made in this 
setting, too often a valuable opportunity to intervene with 
a key group of problem drug users is being lost.
We deliver this report to you at a difficult time. 
The current economic situation presents EU Member 
States with pressing challenges, and the implications 
for levels of drug use and service provision need to be 
carefully assessed. It is too early to predict what impact 
the economic crisis will have on drug use in Europe — but 
we know that marginalised and socially disadvantaged 
communities are the hardest hit by drug problems. 
Services for drug users are increasingly threatened 
by budget cuts, which could have a detrimental effect, 
not only on those who use drugs, but also on the 
communities in which they live. But this is not the only 
challenge facing Europe in the drugs field. Changes in 
the supply of established drugs and the emergence of 
new substances increasingly test our drug control models. 
The problems presented by these changes are complex 
and interconnected. They will require a concerted and 
collective response. The positive message from this report 
is that Europe is improving its capacity to keep track of 
this fast-moving phenomenon. This is a critical prerequisite 
to understanding the challenges now confronting us and 
to ensuring that our policy responses keep pace with an 
evolving drug situation.
João Goulão
Chairman, EMCDDA Management Board
Wolfgang Götz
Director, EMCDDA
Foreword
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9This annual report is based on information provided to 
the EMCDDA by the EU Member States, the candidate 
countries Croatia and Turkey, and Norway in the form 
of a national report. The statistical data reported here 
relate to 2008 (or the last year available). Graphics and 
tables in this report may reflect a subset of EU countries; 
the selection may be made on the basis of those countries 
from which data are available for the period of interest, or 
to highlight certain trends.
Analysis of trends is based only on those countries 
providing sufficient data to describe changes over the 
period specified. Figures for 2007 may substitute for 
missing 2008 values in trend analysis of drug market 
data; for the analysis of other trends, missing data may be 
interpolated.
Background information and a number of caveats that 
should be borne in mind when reading the annual report 
are presented below.
Drug supply and availability data
Systematic and routine information to describe illicit drug 
markets and trafficking is still limited. Production estimates 
of heroin, cocaine and cannabis are obtained from 
cultivation estimates based on fieldwork (sampling on the 
ground) and aerial or satellite surveys. These estimates 
have some important limitations, linked for instance 
with variations in yield figures or with the difficulty of 
monitoring crops such as cannabis, which may be grown 
indoors or are not restricted to certain geographical areas.
Drug seizures are often considered as an indirect indicator 
of the supply, trafficking routes and availability of drugs. 
They are a more direct indicator of drug law enforcement 
activities (e.g. priorities, resources, strategies), while also 
reflecting both reporting practices and the vulnerability of 
traffickers. Data on purity or potency and retail prices of 
illicit drugs may also be analysed in order to understand 
retail drug markets. Retail prices of drugs reported to the 
EMCDDA reflect the price to the user. Trends in price are 
adjusted for inflation at national level. Reports on purity 
or potency, from most countries, are based on a sample of 
all drugs seized, and it is generally not possible to relate 
the reported data to a specific level of the drug market. 
For purity or potency and retail prices, analyses are based 
on the reported mean or mode or, in their absence, the 
median. The availability of price and purity data may be 
limited in some countries and there may be questions of 
reliability and comparability.
The EMCDDA collects national data on drug seizures, 
purity and retail prices in Europe. Other data on drug 
supply come from the information systems and analyses of 
the United Nations Office on Drugs and Crime (UNODC), 
complemented by additional information from Europol. 
Information on drug precursors is obtained from the 
European Commission, which collects data on seizures of 
these substances in the EU, and the International Narcotics 
Control Board (INCB), which is involved in international 
initiatives to prevent the diversion of precursor chemicals 
used in the manufacture of illicit drugs.
The data and estimates presented in this report are the 
best approximations available, but must be interpreted 
with caution, as many parts of the world still lack 
sophisticated information systems related to drug supply.
Prevalence of drug use as measured by general population 
surveys
Drug use in the general or school population can be 
measured through representative surveys, which provide 
estimates of the proportion of individuals that report 
having used specific drugs over defined periods of time. 
Surveys also provide useful contextual information on 
patterns of use, sociodemographic characteristics of users 
and perceptions of risks and availability.
Introductory note
Accessing the annual report and its data 
sources on the Internet
The annual report is available for downloading in 
22 languages on the EMCDDA website. The electronic 
version contains links to all online sources cited in the 
annual report.
The following resources are available only on the Internet.
The 2010 statistical bulletin presents the full set of source 
tables on which the statistical analysis in the annual report 
is based. It also provides further detail on the methodology 
used and about 100 additional statistical graphs.
The national reports of the Reitox focal points give 
a detailed description and analysis of the drugs problem 
in each country.
Country overviews provide a top-level, graphical summary 
of key aspects of the drug situation for each country.
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The EMCDDA, in close collaboration with national 
experts, has developed a set of core items for use in adult 
surveys (the ‘European Model Questionnaire’ — EMQ). 
This protocol has now been implemented in most EU 
Member States. However, there are still differences in 
the methodology used and year of data collection, and 
this means that small differences, in particular between 
countries, should be interpreted with caution.
Surveys are expensive to conduct and few European 
countries collect information each year, although many 
collect it at intervals of two to four years. In this report, 
data is presented based on the most recent survey 
available in each country, which in most cases is between 
2005 and 2008. Prevalence data for the United Kingdom 
refer to England and Wales, unless otherwise stated, 
although separate data for Scotland and Northern Ireland 
are also available.
Of the three standard time frames used for reporting 
survey data, lifetime prevalence (use of a drug at any 
point in one’s life) is the broadest. This measure does 
not reflect the current drug use situation among adults, 
but can be helpful to understand patterns of use and 
incidence. For adults, the EMCDDA’s standard age 
ranges are 15–64 years (all adults) and 15–34 years 
(young adults). Countries using different upper or 
lower age limits include: Denmark (16), Germany (18), 
Hungary (18), Malta (18), Sweden (16) and the United 
Kingdom (16–59). The focus is on the last year and last 
month time frames (use during the last 12 months or last 
30 days before the survey) (for more information, see 
the EMCDDA website). For school students, lifetime and 
last year prevalence are similar, as illicit drug use before 
age 15 is rare.
The European school survey project on alcohol and other 
drugs (ESPAD) uses standardised methods and instruments 
to measure drug and alcohol use among representative 
samples of 15- to 16-year-old school students. Surveys 
have been conducted in 1995, 1999, 2003 and 2007. 
In 2007, data were collected in 35 countries, including 
25 EU Member States, Norway and Croatia.
Treatment demand
In reports on treatment demand, ‘new clients’ refers to 
those who have entered treatment for the first time in their 
lives and ‘all clients’ refers to all those entering treatment. 
Clients in continuous treatment at the start of the year 
in question are not included in the data. Where the 
proportion of treatment demands for a primary drug is 
given, the denominator is the number of cases for which 
the primary drug is known.
Interventions
Information on the availability and provision of various 
interventions in Europe is generally based on the informed 
judgement of national experts, collected through structured 
questionnaires. However, for some indicators, quantitative 
monitoring data are also available.
Drug law offences
The term ‘reports’ for drug law offences may describe 
different concepts in different countries.
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The need to avoid paying a high price for cost-cutting 
measures 
As Europe enters a period of economic austerity, with 
rising levels of youth unemployment, there are fears that 
this may be accompanied by an increase in problematic 
forms of drug use. Depressed and marginalised 
communities have always been at elevated risk of 
experiencing drug problems and the collateral damage 
of crime and unsafe communities. Europe now faces the 
double jeopardy that at a time when the need for effective 
responses may be growing, austerity measures could 
lead to cuts in provision. Over the last decade, important, 
if uneven, gains have been made in addressing drug 
problems. Treatment numbers have grown dramatically 
and considerable progress has been made in addressing 
some of the most harmful health consequences of drug 
use, such as HIV infection. Moreover, studies have 
demonstrated that interventions can be cost-effective, 
reducing expenditure on related health, social and crime 
problems. The risk exists that today’s economic situation 
may provoke policy decisions that result in Europe 
accruing long-term costs that far outweigh any short-term 
savings. 
In the spotlight: guidelines, frameworks and improving  
the evidence base for assessing supply reduction
The Lisbon Treaty, which came into force on 1 December 
2009, gives new emphasis to the European Union’s role 
in establishing guidelines, indicators and supporting the 
exchange of best practice in the drugs field. In times of 
economic austerity, it is particularly important to ensure 
that expenditure is directed towards interventions of 
proven effectiveness. The European approach to drugs 
can be characterised as one in which evidence takes 
priority over ideology. However, there are still many 
areas where investments are directed towards approaches 
that lack robust evidence for effectiveness or have been 
poorly evaluated, while approaches of proven value are 
not always implemented. This is an ongoing problem in 
the prevention field, but not limited to this area. Good 
programme models exist in many areas of demand 
reduction, and there is a growing understanding of what 
is likely to constitute effective action. The challenge is to 
build the consensus necessary to codify this knowledge 
into a set of guidelines and frameworks that are sufficiently 
prescriptive to support service improvement, while still 
being sensitive to the different contexts found across the 
European Union.
The public health field is long used to the discipline of 
having to justify the impact of its interventions. The need 
to extend this approach to supply reduction activities has 
become an increasingly common theme in the EU policy 
debate. Expenditure on supply reduction is often difficult 
to identify in national budgets, but studies suggest that 
it is considerable and generally exceeds expenditure on 
public health responses. Recent Council deliberations 
concluded that evaluation of supply reduction activities 
is handicapped by the lack of standard indicators and 
measures. Establishing key indicators for supply reduction 
is an objective in the current EU drugs action plan. 
In 2009, the European Commission and the EMCDDA 
launched a joint initiative to address this problem, and the 
identification of key supply indicators and a mechanism 
for their implementation can be expected in 2011. 
Policy perspectives: challenges for the European drug 
policy model
Virtually all EU Member States have adopted a common 
approach based on a national drug strategy, usually 
supported by an action plan, which has concrete targets 
and is time based. This policy model is a rational one as 
it allows a regular audit of progress and the opportunity 
to redirect policy where it is found to be lacking. It is 
also a demanding approach, as new drug strategies 
have to be developed, agreed and adopted, often while 
the old strategy is being evaluated. These difficulties are 
highlighted in this year’s report, where for the first time 
we report a decrease in the number of countries having 
a valid national drug strategy in place. This is largely 
because of the practical challenges of evaluating and 
renewing national strategy documents that expired in 
2008 or 2009. The EMCDDA is working with Member 
Commentary
Old realities, new threats and economic austerity: the current landscape 
for European drug policy
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States to develop policy evaluation tools to allow an 
ongoing review of drug policy developments. There are 
no simple solutions to the problem of evaluating drug 
policies, but it would be a shame if failings in processes 
and planning undermined an important achievement of the 
European response to drug problems. 
As noted in last year’s report, the link between alcohol 
and drug problems is a strong one. Despite this, no 
common approach is observable in terms of uniting drug 
and alcohol policies across the EU Member States. Some 
countries maintain separate drug and alcohol policies, 
others link them, and some have not yet developed an 
alcohol strategy. Strong arguments exist for the need to 
seek synergies between drug and alcohol policies, not 
least of which is the fact that they will often be targeting 
the same populations and settings. Current policy models 
are also challenged by the growth of the ‘legal highs’ 
market, as well as the misuse of pharmaceutical products, 
as discussed below. From a public health perspective, this 
highlights the need for a more comprehensive approach, 
encompassing both illicit and licit substances, and possibly 
other behavioural addictions. The challenge is two-fold: to 
consider to what extent this overarching vision is justified, 
and how this perspective might be translated into an 
appropriate regulatory and control framework. 
New developments in national drug laws reveal 
commonalities and differences
An example of the differences that exist between EU 
Member States in policy implementation, even where 
a general consensus prevails, can be found in the area 
of penalties for drug offences. In most EU countries, the 
legal systems take into account the type and ‘harmfulness’ 
of the drug in question and whether the offence relates 
to involvement in the drug market or to personal use or 
possession for personal use. These distinctions vary greatly 
between countries. They may also be codified in law or 
result from processes operating within the criminal justice 
system. It is unclear what benefits the different approaches 
bring or what constitutes good practice, suggesting the 
value of a comparative analysis in this area. Currently, 
comparisons between countries should be made with 
caution, as differences between offences may be as much 
determined by the legal practice of the country in question 
as the nature of the offence itself. A second question is 
the extent to which the policy distinction made between 
those profiting from the sale and transport of drugs and 
those who are using them is translated into practice. 
The most recent data show a slightly downward trend in 
supply-related offences, while the number of use-related 
offences continues to rise. 
Drug treatment: more available than ever, but inequalities 
evident
Effectively treating those who have problems with their 
substance use is a central pillar of Europe’s response to 
drugs. It is an area in which both the quality and quantity 
of care available continues to grow. The EMCDDA 
estimates that more than a million people annually 
receive some form of treatment for drug problems in the 
European Union. Treatment expansion has been led by 
a growth in specialist outpatient care, supported by low-
threshold services and outreach. Importantly, in some 
countries, drug services combine specialist care with the 
involvement of primary healthcare services and general 
practitioners. Some types of drug problems, in particular 
the more intractable cases, are likely to be best handled 
by specialist teams. However, an appropriate mix of 
specialist and generic care can be an important element 
in increasing the overall availability of care, especially 
when referral and support channels are well established. 
Although treatment provision has increased, inequalities 
are evident in treatment access across Europe. In most 
eastern European and some southern European countries, 
treatment availability is relatively limited, as reflected 
in long waiting lists. Levels of treatment availability 
can only be meaningfully assessed in relation to the 
relative coverage of the population in need of care. It 
is still difficult to comment with certainty on the extent 
to which available care meets needs, although some 
progress has been made in respect to opioid substitution 
therapy. Overall, the EMCDDA estimates that about 
670 000 Europeans now receive opioid substitution 
treatment, representing about half of the estimated 
number of problem opioid users. This figure varies greatly 
between countries, with national estimates ranging from 
less than 10 % to more than 50 % of problem opioid users 
receiving care. Differences in the availability of care are 
further illustrated by the observation that only around 
2 % of substitution treatments occur in the 12 Member 
States who joined the European Union since 2004.
Substitution treatment is also considered a harm-reduction 
measure. Together with needle and syringe exchange, it 
has been widely promoted as an important component 
in a comprehensive HIV prevention strategy for injecting 
drug users. With overall stable or declining trends in 
injecting levels and drug-related HIV infection, the 
European Union’s situation in respect to drug-related 
HIV transmission looks positive in comparison with many 
parts of the world. The EMCDDA published a scientific 
monograph on harm reduction in 2010, which charted 
the mainstreaming of the concept of harm reduction, 
with both substitution treatment and syringe exchange 
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now accepted components of European drug policies. 
The monograph also highlighted the need to improve the 
evidence base for other harm-reduction interventions and 
the scarcity of well developed harm-reduction models for 
problems with stimulant and polydrug use, patterns of use 
that are becoming increasingly important in Europe. It also 
noted that responses in Europe are still failing to impact 
significantly on hepatitis C virus infection among injectors 
and drug overdose deaths, and that harm-reduction 
approaches could have an important role to play here.
Developing models of care and response for Europe’s 
evolving drug problem
Current patterns of drug use are challenging services to 
develop more complex and differentiated needs-based 
responses, with better linkage to generic health and social 
care resources. In respect to substitution treatment, this can 
be seen in an ageing and more chronic group requiring 
care, a topic addressed in a Selected issue accompanying 
this report. The need for treatment and other responses 
for non-opioid related problems is also growing, with 
increased numbers of cannabis and stimulant users coming 
into contact with services. Complex patterns of polydrug 
consumption, which commonly include alcohol-related 
problems, represent another challenge. Models of care 
are improving in these areas, although considerable room 
for improvement still exists for developing and sharing best 
practice. While purely pharmacological therapy options 
for stimulant users still appear unlikely, increased research 
interest in this area has yielded encouraging findings, 
including a better understanding of the contribution of 
psychosocial approaches. 
Cannabis: regional variations important 
Cannabis remains the most popular illicit drug in Europe, 
but with large differences in prevalence of use observable 
between countries, illustrated by the fact that the highest 
estimates reported are more than 30 times greater than 
the lowest. Overall, trends in consumption show stable 
or declining levels of use. Within this general long-term 
picture, however, divergent patterns can be identified. 
Of particular note are some countries in eastern Europe 
where consumption levels still appear to be increasing 
and, in some cases, now rival or exceed prevalence levels 
found in western Europe. 
There is a growing understanding of the public health 
implications of cannabis use, which mostly focuses 
on those users reporting daily and chronic patterns of 
consumption. Recent reviews examining the adverse health 
consequences of the drug identify a number of effects, 
including anxiety, panic reaction and psychotic symptoms. 
These acute effects account for a substantial number of 
drug-related hospital emergencies in the few countries that 
monitor them. 
Commentary: the current landscape for European drug policy
At a glance — estimates of drug use in Europe
The estimates presented here relate to the adult population 
(15–64 years old) and are based on the most recent data 
available (surveys conducted between 2004 and 2008). 
For the complete set of data and information on the 
methodology see the accompanying statistical bulletin.
Cannabis 
Lifetime prevalence: at least 75.5 million  
(22.5 % of European adults)
Last year use: about 23 million European adults (6.8 %) or  
a third of lifetime users
Last month use: about 12.5 million Europeans (3.7 %)
Country variation in last year use:  
overall range 0.4 % to 15.2 % 
Cocaine
Lifetime prevalence: about 14 million  
(4.1 % of European adults)
Last year use: 4 million European adults (1.3 %) or  
a third of lifetime users
Last month use: around 2 million (0.5 %)
Country variation in last year use:  
overall range 0.0 % to 3.1 %
Ecstasy 
Lifetime prevalence: about 11 million  
(3.3 % of European adults)
Last year use: about 2.5 million (0.8 %) or  
a quarter of lifetime users 
Country variation in last year use:  
overall range 0.1 % to 3.7 %
Amphetamines 
Lifetime prevalence: about 12 million  
(3.7 % of European adults)
Last year use: around 2 million (0.6 %) or  
a sixth of lifetime users
Country variation in last year use:  
overall range 0.0 % to 1.7 %
Opioids
Problem opioid users: estimated at between  
1.2 and 1.5 million Europeans
Drug-induced deaths accounted for 4 % of all deaths of 
Europeans 15–39 years old, with opioids being found in 
around three quarters
Principal drug in more than 50 % of all drug treatment 
requests 
About 670 000 opioid users received substitution treatment 
in 2008
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In the most recent data, the overall number of new 
treatment clients with cannabis as the main drug is 
decreasing in most countries. The factors behind this 
change are unclear but merit investigation, as it could 
indicate either a reduced service capacity to accept 
new clients or a decrease in the number of people being 
referred to cannabis-related treatment. 
Europe’s considerable appetite for cannabis is reflected 
in annual seizures of about 1 000 tonnes of the drug. 
Overall, the data suggest that cannabis, in its various 
forms, may be becoming more rather than less available 
on the European market. Despite indications that 
domestically produced herbal cannabis has become 
more common, the quantities of herbal cannabis seized 
in the European Union have remained stable, while resin 
seizures have increased. In volume terms, the discrepancy 
between seizures of cannabis resin and herbal cannabis 
is in the order of ten to one. Any conclusion on the 
availability of the different types of cannabis in Europe 
needs to be made with considerable caution as herbal 
cannabis is produced closer to its intended market and 
is therefore less likely to be interdicted. There have also 
been increasing reports of the involvement of organised 
crime in domestic cannabis production, prompting new 
action by both national and European law enforcement 
bodies. 
Understanding Europe’s complex market for stimulant 
drugs 
Cocaine remains the second most commonly used illicit 
drug in Europe, although prevalence levels and trends 
differ considerably between countries. High and still-
increasing levels of cocaine use are observed only in 
a small number of mostly western European countries, 
while elsewhere the use of this drug remains limited. 
Whether this situation will continue or cocaine use will 
diffuse to other parts of Europe, notably eastern Europe, 
remains an open question. Worries have been prompted 
by some evidence that the drug is being increasingly 
trafficked through the region, as well as by sporadic 
reports of cocaine use in some settings.
New routes through eastern Europe are not the only issue 
of concern in relation to cocaine trafficking. The drug 
continues to enter Europe mainly through the Iberian 
Peninsula and the Low Countries. However, a relatively 
new development is the interdiction of secondary 
extraction facilities that recover cocaine hydrochloride 
or cocaine base from carrier materials such as beeswax, 
fertiliser, clothing, herbs, plastics and liquids. Thirty 
such facilities were reported to Europol by Spain in 
2008. This development is indicative of high levels of 
innovation and technological sophistication among those 
importing cocaine into the European Union. Because of 
its high value, cocaine may also be cut or mixed with 
other substances. The use of levamisole (l-tetramisole) as 
a cocaine adulterant has been increasingly reported in the 
United States and Europe, leading to the European early-
warning system issuing a warning in 2009. This drug may 
pose additional health risks to cocaine consumers. 
Although drug treatment services in Europe are still 
dominated by clients with opioid problems, cocaine users 
now represent about a quarter of new treatment entrants. 
The majority of these are reported from a small group of 
countries, principally Spain, Italy and the United Kingdom, 
and include two distinct groups: socially integrated males 
who sniff the drug; and marginalised drug users who inject 
cocaine or use crack cocaine alongside other substances. 
An additional concern is the increasing mortality 
associated with cocaine use. About 1 000 cocaine-related 
deaths are now reported annually, with notable increases 
in Spain and the United Kingdom, two countries where 
the use of the drug is long established and at high levels. 
Although other drugs are generally also found to be 
present, this rise is worrying, especially given the ongoing 
concerns about under-reporting of cocaine’s role in deaths 
of users with pre-existing cardiovascular problems.
Use of amphetamines remains overall lower than cocaine 
use in Europe, but in many countries amphetamine or 
methamphetamine remains the most commonly used 
stimulant drug. Problem amphetamine use is mainly 
reported by countries in the north of Europe, while 
problem methamphetamine use remains largely restricted 
to the Czech Republic and Slovakia. This may be slowly 
changing, however, as methamphetamine production 
is now also reported in Lithuania and Poland, with 
production mainly servicing the Scandinavian markets. 
Here it may be sold as a replacement for amphetamine. 
Problem amphetamine and methamphetamine use is the 
topic of a Selected issue that accompanies this annual 
report.
Opioids and drug injecting 
Heroin use, particularly injecting the drug, still accounts 
for the greatest share of morbidity and mortality related 
to drug use in the European Union. The number of 
problem opioid users in Europe is cautiously estimated 
at 1.35 million, and most treatment entrants still report 
opioids as their primary drug. Data from a range of 
sources point to an overall stable to increasing opioid 
problem in the European Union since 2003/04. Heroin 
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seizures have increased in number, but not in quantity; 
although this has to be seen in the context of increasing 
seizures of the drug in Turkey. Trend data from prevalence 
estimates appear stable, new treatment demand has 
been slowly increasing in several countries, drug-induced 
deaths have increased, as have drug law offences for the 
last two years. To some extent, this may reflect the long-
term nature of opioid problems where, once addicted, 
users tend to remain dependent for long periods of time. 
Thus, even a relatively small number of new recruits are 
sufficient to maintain the overall population. The number 
of injecting drug users in Europe is estimated to be 
between 750 000 and 1 million, with large differences 
in prevalence between countries. Data quality issues 
mean that this estimate must be treated with considerable 
caution. Trends in injecting use are particularly difficult 
to gauge, but data from treatment monitoring suggest 
that the medium-term trend is downwards and injectors 
are now in the minority among new opioid users entering 
treatment services in Europe. 
Injecting remains, however, the most common route of 
administration for opioid users in many eastern European 
countries. This adds to considerable concern about 
the public health consequences of drug use in some of 
the countries neighbouring the European Union. At the 
eastern border of the European Union, both Russia and 
Ukraine appear to have levels of problem opioid use two 
to four times higher than the EU average. The problems 
associated with opioid use in this region include high rates 
of HIV infection and drug-induced deaths. 
Overdose represents the biggest cause of avoidable 
mortality associated with illicit drug use in Europe, and 
toxicological analysis shows the presence of heroin in 
most drug-induced deaths. This underlines again the 
importance of opioids for understanding the public 
health impact of drug use in Europe. Since 2003, the 
number of drug-induced deaths has been increasing 
in most European countries, as has the age of those 
dying, suggesting an ageing population of chronic 
users. Provisional data suggest a modest increase of 
reported drug-induced deaths in 2008: with estimates 
of 7 371 cases in 2008 in EU Member States and 
Norway, as compared to 7 021 in 2007. These estimates 
are likely to be conservative. It can also be estimated 
that for each fatal overdose there are 20–25 non-fatal 
overdoses, or around 150 000 annually in the European 
Union. Moreover, it is now recognised that non-fatal 
overdoses may result in significant health damage as well 
as indicating increased risks of future overdoses. From 
a public health perspective, one of the most important 
challenges for drug services in Europe is to develop 
effective measures for reducing both fatal and non-fatal 
overdoses. Currently, this challenge is not being met. 
‘Legal highs’: an ongoing challenge for drug monitoring 
and response 
Attempts to identify and respond appropriately to new 
psychoactive substances struggle to keep pace with 
a sophisticated, innovative and fast-moving market, which 
is actively seeking new products and marketing strategies. 
With 24 new synthetic drugs identified for the first time in 
Europe, 2009 was a record year for the European early-
warning system. This pattern has continued unabated 
in 2010, with 15 new substances detected by mid-July, 
including synthetic cathinones, synthetic cannabinoids, 
as well as new cocaine and amphetamine-like synthetic 
derivatives. 
In July 2010, the scientific committee of the EMCDDA 
carried out a formal risk assessment of the synthetic 
cathinone mephedrone. This was prompted by a growing 
concern that this drug was being marketed as a legal 
alternative to stimulants like cocaine and ecstasy. The risk 
assessment was conducted as part of Europe’s fast-track 
mechanism for controlling new psychoactive substances. 
However, the pace of development in this area is such 
that not only had some Member States already introduced 
legislation banning mephedrone, but some websites selling 
it had already closed down, sometimes to be quickly 
replaced by sites offering replacement substances. 
There is a need to remain vigilant and to be able to 
respond rapidly to new developments, such as new 
chemical groups of psychoactive substances identified in 
‘legal-high’ products. This is illustrated by the examples of 
aminoindanes (methylenedioxyaminoindane, MDAI) and 
synthetic cocaine derivatives (such as fluorotropacocaine). 
While still rare, after action was taken against 
mephedrone in 2010, such substances began to be 
more frequently detected, and the first reports of users 
experiencing problems were received by the early-warning 
system. The EMCDDA is monitoring the availability and 
possible health impact of these substances.
The example of mephedrone highlights how EU Member 
States can come under considerable media and public 
pressure to respond quickly to a potential new threat. 
The EMCDDA, in close cooperation with Europol and 
the European Medicines Agency, has been working to 
provide timely information that is reliable and considered. 
In this rapidly developing area, there is a growing need 
to improve Europe’s capacity to monitor developments 
proactively and, in particular, to test and identify the 
chemical constituents of the product mixtures available 
Commentary: the current landscape for European drug policy
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and assess their potential impact on public health. Lack of 
standard reference material is a problem here. In terms of 
control strategies, the way these products are produced 
and marketed makes a strong argument that effective 
measures will require action at the European level to 
support national initiatives. 
Organised crime recognises the potential of new synthetic 
substances
Legislating for these new substances is complicated by 
many factors. Some Member States have introduced 
generic legislation that covers substances from the same 
chemical group. This legal option is only available in 
some countries, and can be difficult to put into practice. 
Further difficulties arise from the fact that some of these 
substances may have legitimate non-medical uses, 
be sold for supposedly legitimate purposes, or be 
used for research and development purposes by the 
pharmaceutical industry. That said, even well conceived 
control measures may not solve all the problems in 
this area, and the danger exists that they may even 
increase the momentum for an undesirable transition from 
a mostly online ‘legal-highs’ market to one that involves 
organised crime. Cathinone drugs, such as mephedrone, 
methylone and MDPV, have all appeared on the illicit 
market, where they are sold as replacements for cocaine, 
ecstasy and amphetamine, or as the drugs themselves. 
Europol has noted the interdiction of a number of large 
illicit ecstasy production sites that were found to be 
tabletting mephedrone, and more than 20 European 
countries reported finding this drug in seizures. It is 
difficult to predict the extent to which new synthetic drugs 
will become a major part of Europe’s future illicit drug 
market. Criminal organisations, however, are likely to be 
quick to recognise the potential of substances that can be 
bought cheaply in large quantities, can in the future be 
synthesised relatively easily and are attractive alternatives 
to controlled drugs.
To ‘design’ a drug to replace a controlled substance is 
not a new concept. In the past, though, designer drugs 
were illicitly produced and marketed directly on the illicit 
market. An important difference today is that we are 
seeing a new interaction between the illicit and non-illicit 
markets, whereby chemicals are legally sourced but then 
sold as replacements for illicit psychoactive substances. 
Things to come: medicinal products, counterfeit drugs and 
new designer medicines
The United States has a long-established drug problem, 
and developments in this market have sometimes 
had implications for Europe. Currently, the misuse of 
prescription drugs, especially opioids such as OxyContin, 
is a major concern for US drug policy. In Europe, misuse 
of prescription drugs, with the exception of opioid 
substitution drugs, has not been regarded as a major 
problem. This is partly due to the regulatory framework 
and prescribing practices, which differ from those of the 
United States. The potential for misuse is also an issue 
considered within the European pharmacovigilance 
system, which operates under the responsibility of the 
European Medicines Agency, with the collaboration 
of the EMCDDA on drug misuse issues. The spread of 
counterfeit medicines, manufactured and sold in place 
of legitimate products, is a growing problem. In 2009, 
the early-warning system received reports of substances 
that were based on slight modifications of the chemical 
structures of medicines with known abuse potential. The 
rise of new designer medicines would be an unwelcome 
addition to the task of ensuring that prescribed medicines 
are not diverted and misused. It is also another example 
of how innovation in the illicit market requires a robust 
and joined-up response from pharmaceutical and 
drug control regulatory frameworks. This issue is more 
of a potential threat than an immediate problem, but 
given the speed at which new developments occur in 
this area, it is important to anticipate future challenges. 
The suggestion that in the future we will see increasing 
numbers of new drugs based on existing pharmaceutical 
products but intended for non-therapeutic use would be 
particularly worrying.
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Introduction
Monitoring and evaluating drug strategies and action 
plans is an important topic both at national and 
international levels. Recent developments in this field 
reported in this chapter include a new monitoring system 
that is being built up by the United Nations and first 
results of the implementation of the new EU action plan on 
drugs. Also described here are some of the achievements 
and difficulties related to the demanding drug policy 
evaluation and renewal cycles that most EU Member 
States have adopted.
Also reviewed in the chapter are the different legal 
approaches used in Europe to distinguish between 
drugs. These include the use of a wide range of laws, 
drug classification schemes and prosecutorial or judicial 
discretion. Another form of distinction is the threshold 
quantities that differentiate between personal use and 
trafficking offences. New data and trends on drug-related 
public expenditure and recent developments regarding 
drug-related research in Europe are also covered in this 
chapter.
International and EU policy developments
Monitoring the UN political declaration and plan of action
At the 2009 session of the United Nations’ Commission on 
Narcotic Drugs (CND), the UN Member States adopted 
a new political declaration and plan of action to tackle the 
world drug problem (EMCDDA, 2009a). They also passed 
a resolution (52/12) to improve data collection, reporting 
and analysis, in order to monitor the implementation of 
these new drug policy documents.
In view of difficulties experienced in the final review of 
the previous 10-year political declaration and action 
plans, the resolution called for the development of data 
collection tools and mechanisms to provide reliable and 
comparable data. High on the list of considerations were 
the need to encourage better reporting by UN Member 
States, and the aim to avoid unnecessary duplication 
with existing international monitoring systems, including 
those of other UN agencies or of regional bodies such as 
the EMCDDA.
The new UN data collection tool will merge the Annual 
Reporting Questionnaire (ARQ), a monitoring tool 
associated with the UN drug control conventions, with 
a new set of questions related to the newly adopted 
political declaration and plan of actions. The new 
questionnaire should be adopted at the 2011 session of 
the CND, with the first data collection round implemented 
shortly afterwards.
Chapter 1
Policies and laws
Responding to drugs under the Lisbon Treaty
The Treaty of Lisbon, which entered into force on 
1 December 2009, is meant to provide the European Union 
with simplified working methods and voting rules, as well 
as streamlined and modern institutions (1). It also improves 
the European Union’s ability to act in several areas of drug 
policy.
The trafficking of illicit drugs is addressed in the area of 
freedom, security and justice (Article 83), which provides 
for the establishment of minimum rules concerning the 
definition of criminal offences and sanctions. The Treaty 
allows for the establishment of a European Public 
Prosecutor’s Office, with the possibility of expanding its 
power to include serious crime having a cross-border 
dimension (Article 86). This could, eventually, lead to 
certain drug trafficking offences being prosecuted at 
EU level.
The Lisbon Treaty also addresses public health and, as in 
the past, empowers the European Union to complement 
the Member States’ action to reduce ‘drugs-related health 
damage including information and prevention’. Under the 
new article on public health, the European Commission 
may take the initiative, in close contact with the Member 
States, to establish guidelines and indicators, organise the 
exchange of best practice and prepare necessary elements 
for periodic monitoring and evaluation. This reinforces the 
work carried out by the Commission and the EMCDDA in 
these areas.
(1) For more information, see the Treaty of Lisbon on the Europa 
website.
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(1) Europa press release MEMO/09/548. 
(2) SEC(2009) 1090 final.
(3) 13405/09 CORDROGUE 63.
(4) Improving cooperation with third countries and improving research and information were the two other key principles.
(5) Czech Republic, Estonia, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Poland, Portugal, Romania, Slovenia, Turkey.
(6) The term ‘national drug-policy document’ means any official document approved by a government that defines general principles and specific 
interventions or objectives in the field of drugs, where officially represented as a drug strategy, action plan, programme or other policy document.
EU drugs strategy and action plan
The first year of the new EU drugs action plan (2009–12) 
saw a number of activities carried out. During their 
presidencies of the European Union, both the Czech 
Republic and Sweden supported the action plan’s 
implementation with the adoption of Council conclusions. 
One of these conclusions called for the development of 
key indicators in the field of drug markets, drug-related 
crime and supply reduction, a second called for the 
exchange of good practice, guidelines and quality 
standards for universal prevention and a third urged the 
strengthening of the European Union’s research capacity 
on illicit drugs.
The European Commission released a report on 
the implementation of the Council Framework 
Decision 2004/757/JHA of 25 October 2004 laying down 
minimum provisions on the criminal acts and penalties 
applicable in the field of drug trafficking. The Commission 
found that, although marking a first step towards 
a common approach in combating drug trafficking, the 
framework decision has not brought about a substantial 
approximation of national laws (1). The Commission 
also published a working paper describing the existing 
mechanisms for detecting, monitoring and responding to 
emerging trends in the European Union and proposing 
guidelines for future work (2). In addition, a new project 
was launched to support the implementation of an 
EU-wide system for forensic profiling of synthetic drugs (3). 
By providing a kind of ‘fingerprint’ for the drugs, forensic 
profiling can help trace manufacturers and chart drug 
distribution channels. Other activities by the Commission, 
regarding collaboration with civil society and drug-related 
research, are described elsewhere in this chapter. The first 
comprehensive progress review of the implementation 
of the current EU drugs action plan (2009–12) will be 
published in late 2010.
Civil society and drug policy
The European Commission’s Civil Society Forum on Drugs 
held its third meeting in March 2009. The European 
Action on Drugs (see below) was one of the two main 
topics on the agenda. The other main item was the future 
of the Forum, with the discussion focusing on practical 
issues such as the selection of participants and the 
organisation of meetings. The meeting also considered 
the future role of the Civil Society Forum on Drugs and 
whether it should remain an informal exchange platform 
or become a formal advisory body to the Commission.
Another measure with the aim to involve and mobilise civil 
society is the European Commission’s European Action 
on Drugs. The project invites authorities, institutions, 
associations, non-governmental organisations, companies 
and individuals to make a commitment for a specific 
action in the drugs field. In this way, the project intends to 
provide civil society with a platform to increase awareness 
regarding drugs and the risks related to drug use and to 
promote dialogue and exchanges of best practice. Some 
640 applicants had registered their commitment by early 
March 2010.
Mobilising civil society should also be one of the key 
principles for the next EU drugs strategy (4). This was 
stated in the Stockholm Programme adopted by the 
European Council. The programme provides a framework 
for EU action on the questions of citizenship, justice, 
security, asylum and immigration for the area of justice, 
freedom and security for the years 2010–14.
National drug strategies
New developments
Drug strategies and action plans are now core instruments 
of national drug policies in Europe. Almost all of the 
30 countries monitored by the EMCDDA have adopted 
such policy documents, which they renew periodically. 
In 2009, new drug strategies or action plans were 
adopted by seven European countries (see Table 1), 
while a further 12 were drafting new national drug policy 
documents in early 2010 (5).
Challenges in renewing drug policy documents
Several countries have recently reported a delay in the 
renewal of their national drug policy documents (6). Five of 
the countries whose drug strategy or action plan expired 
in December 2008 had yet to adopt new documents one 
year later (Italy, Latvia, Lithuania, Portugal, Romania). 
Similarly, another set of countries with policy documents 
ending in 2009 had not renewed them during that year. 
As a result, for the first time since the mid-1990s, Europe is 
seeing a decrease in the number of countries with a valid 
national drug strategy or action plan.
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(7) See the box ‘Evaluating national drug strategies and action plans’.
The renewal of drug policy documents is a complex 
process comprising several steps. First, there is the final 
evaluation of the existing or recently expired strategy or 
action plan (7). Stakeholders, and sometimes the public, 
are also consulted during the development phase of the 
new policy. As drug strategies and action plans coordinate 
the role of various government departments, writing them 
usually involves the submission of successive drafts to 
different ministries. Finally, the policy documents must be 
approved by the government or parliament. Recent reports 
suggest that it can take between six months and two years 
to complete the whole process. Against this, the time span 
for national drug policy documents is generally in the range 
of four to eight years. This implies that the renewal process, 
in order to be timely, should sometimes be started shortly 
after mid-term, or at least several months before the expiry 
of the existing policy document. Final evaluations, however, 
cannot be performed until the strategy or action plan is 
finished, and possibly even later, when its impact might be 
assessed with epidemiological and other data.
The European Union and several European countries 
have recently faced the challenge of performing almost 
simultaneously both the final evaluation of an existing 
policy document and the drafting of its replacement. As 
the situation is likely to occur again in the coming years, 
some suggestions have been made to handle it differently 
in the future. One is to insert a transitional year between 
two successive plans or strategies, dedicated to evaluation 
and policy renewal.
Links between drugs and alcohol strategies
The use of multiple substances — polydrug use — is 
widespread among European drug users, and almost 
all patterns of polydrug use include alcohol (EMCDDA, 
2009d). Professionals in the fields of prevention, treatment, 
harm reduction and social reintegration are familiar 
with the overlap between drugs and alcohol problems, 
and have worked towards finding practical solutions 
that address both issues simultaneously. At policy level, 
however, the situation appears to be more complex 
(Muscat, 2008).
A review of both drug strategies and alcohol strategies 
in Europe shows many different national situations 
including: no national strategy at all; a strategy for illicit 
drugs but none for alcohol; separate strategies for drugs 
and alcohol; two interlinked strategies; and a policy 
document covering both illicit drugs and alcohol. There 
is also no clear shift towards one of these models. While 
many countries now seem to adopt an alcohol strategy 
(European Commission, 2009b) in addition to their drug 
strategy, other countries have enlarged the scope of 
their drug policy document, an example being Ireland’s 
decision to include alcohol in a new substance misuse 
strategy.
The absence of a shared European model and trend 
reflects the multiple issues that governments have to 
consider when drawing up strategies on substance use. 
Reasons for keeping strategies separate include the need 
to address specifically problems related to alcohol, which 
are often of a different magnitude to those caused by illicit 
drugs, or simply acknowledging the legal boundaries 
between licit and illicit drugs. Conversely, the importance 
of alcohol use among illicit drug users or the need to 
adopt public health approaches focusing on lifestyles 
and behaviours, and not on individual substances, call 
for a combined strategy. These conflicting issues have 
Table 1: Drug policy documents adopted in 2009
Country Name of policy document Time span Scope Notes
Bulgaria National strategy for the fight against 
drugs
2009–13 Illicit drugs Complemented by an action plan 
(2009–13)
Ireland National drugs strategy — interim 2009–16 Illicit drugs Will be replaced by a substance misuse 
strategy also covering alcohol
Spain National drug strategy 2009–16 Illicit drugs, alcohol 
and tobacco
Complemented by an action plan 
(2009–12)
Cyprus National strategy on drugs 2009–12 Illicit drugs
Hungary National strategy for tackling the drugs 
problem
2010–18 Illicit drugs Will be complemented by action plans
Slovakia National anti-drug strategy 2009–18 Illicit drugs Will be complemented by action plans
Croatia Action plan on combating narcotic drugs 
abuse
2009–12 Illicit drugs Second action plan under the national 
strategy 2006–12
Sources: Reitox national focal points.
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(8) See Table PPP-10 in the 2010 statistical bulletin.
led some countries to develop pragmatic solutions, 
such as linking separate drugs and alcohol strategies 
through an overarching public health strategy or through 
a single national drugs and alcohol coordination body 
(e.g. Portugal). Future work in this area will be to assess 
the qualities of different models of linking drugs and 
alcohol strategies in Europe.
Public expenditure and social costs
Public expenditure on all aspects of the drugs 
phenomenon in Europe was estimated at EUR 34 billion 
in 2005 (EMCDDA, 2008d). This figure includes ‘labelled’ 
expenditure, which is planned by government for tasks 
related to drugs and identified as such in the budget. 
Labelled expenditure is traced in official accountancy 
documents. The greater part of drug-related public 
expenditure is, however, ‘unlabelled’ — that is, not 
identified as such in the national budget. Unlabelled 
expenditure must be estimated by a cost-modelling 
approach.
Data for different years are only available for labelled 
expenditures. In 2008, 22 EU Member States reported 
a total labelled expenditure on the drugs problem of 
EUR 4.2 billion. For the 16 countries that reported in both 
2005 and 2008, total labelled public expenditure rose 
from EUR 2.10 billion to EUR 2.25 billion. As a proportion 
of gross domestic product, total labelled expenditure 
decreased in nine countries, increased in six countries and 
remained unchanged in one country (8).
Public expenditure related to drugs can be classified 
according to the international classification of the functions 
of government (COFOG) system. Of the total labelled 
expenditure categorised by seven reporting countries 
(EUR 1.82 billion), most came within two government 
functions: health (60 %) and public order and safety 
(34 %) (that is, police services, law courts, prisons). This 
imbalance can be explained by the fact that expenditure 
on public order and safety tends to be embedded in 
broader and more general programmes of action against 
crime (unlabelled expenditure) (EMCDDA, 2008d).
Social costs of drug use
Determining the social cost of drug use reveals the 
amount that would be saved if drug use were abolished, 
and identifies the different components of cost and the 
size of the contribution of each sector in society. This 
information can help to determine funding priorities. Public 
expenditure is a fraction of social costs, in the form of 
direct costs only from the general government perspective. 
Social costs also include indirect costs (e.g. loss of 
productivity due to morbidity and mortality) and costs from 
private stakeholders (e.g. private healthcare).
Social cost studies are time-consuming and expensive. 
For this reason, information on the social costs of drug 
use in Europe is scarce. Recent estimates of the social 
costs of drugs have been made for Finland and the 
United Kingdom (Scotland). Direct costs related to the 
use of illicit drugs and misuse of pharmaceuticals in 
Finland were estimated at between EUR 200 million and 
EUR 300 million in 2007. Indirect costs were estimated 
between EUR 500 million and EUR 1 100 million in the 
Evaluating national drug strategies and  
action plans
It is now common practice for European countries to 
perform a final review or evaluation of their national drug 
strategy or action plan. Usually, the aim is to assess the 
level of implementation achieved, as well as the changes 
in the overall drug situation, in order to develop the next 
strategy or action plan.
Assessing the logic, relevance and internal consistency 
of the policy document is a preliminary evaluation step in 
some countries. Content analysis, sometimes including the 
development of problem trees or logical frameworks, is 
used to clarify the policy’s underlying theory and also to 
identify inconsistencies between objectives, actions and 
needs.
The implementation of the actions foreseen in policy 
documents is assessed with different methods. In some 
countries, data are routinely provided by the institutions 
responsible for implementation. In others, service providers 
or regional authorities are asked to fill in a questionnaire 
on the level of implementation and, sometimes, about the 
difficulties encountered.
The difficulty of establishing the effects of a drug strategy 
on the drug problem is acknowledged by most evaluators. 
Nevertheless, a review of the drug situation, based 
on epidemiological indicators and other health or law 
enforcement data, is generally provided in conjunction 
with attempts to link some policy elements with observed 
changes in the drug situation. Unfortunately, the analysis 
rarely includes a European comparison, and this has led to 
some countries connecting declines in cannabis use to the 
content of their national drugs policy, while data point to 
a larger international trend.
The interpretation of data is one of the key steps of an 
evaluation. In some countries, this is the sole responsibility 
of the national drug coordination body, while in others 
external evaluators, special commissions or expert groups 
are mandated to take stock of the data, assess the results 
and formulate recommendations for the next strategy or 
action plan.
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same year. Social welfare accounted for the largest 
portion, nearly a third, of all direct costs, followed by the 
enforcement of public order and safety, which accounted 
for about a quarter. The largest portion of indirect costs 
came from the value of life lost due to premature death.
In Scotland, the most recent estimate of the economic and 
social costs of drug misuse is EUR 5.1 billion in 2006. 
Half of these costs were attributed to ‘wider social costs’, 
including the costs to victims of crime perpetrated by 
problem drug users and the emotional pain experienced 
by the families of drug users who have died as a result 
of their drug use. Of the total social and economic cost, 
96 % was attributed to problem drug use and 4 % to 
recreational drug use.
National legislation
Most European countries have examined or implemented 
distinctions between drugs in their legal frameworks. 
Recent examples are the new Czech Penal Code, in 
which offences of possession for personal use that 
involve cannabis, or its active component THC, attract 
a lower maximum penalty than those involving other 
substances. A similar option was discussed in Estonia 
in 2009, but 10 of 13 experts interviewed by the Ministry 
of Justice were against substance-based differentiation 
of offences and it was decided not to change the 
law. In the Netherlands, the government accepted the 
recommendation of the Advisory Committee on Drugs 
Policy to reconsider the number of schedules.
Legislatures in the European Union have a wide range of 
distinctions and control measures available, depending 
on the extent to which the substance is intended for licit 
marketing and sale due to its commercial, industrial or 
medicinal properties. A first set of options are controls 
outside of drug laws, which may be split into three 
categories: unrestricted sale; restricted sale without 
medical supervision, and restricted sale with medical 
supervision. In the first category, consumer protection law 
has been used to control the sale of certain goods — for 
example, arguably psychoactive substances by smart 
shops, or new and not yet controlled substances. The 
second category refers to restrictions such as age limits of 
the purchaser, and sometimes the user, or the licensing of 
sales outlets. This describes alcohol and tobacco control, 
but may also include cannabis sales in coffee shops in 
the Netherlands and sale of certain volatile substances 
in, for example, the United Kingdom. The third category 
encompasses laws regulating pharmacy sales, including 
over-the-counter cough and cold remedies, as well as 
prescription medication. In the last few years, the Czech 
Republic and the United Kingdom have introduced 
restrictions on the sale of cold remedies containing 
pseudoephedrine, as they are purchased to make illicit 
amphetamines. Medicines law was also used effectively 
in Austria to restrict the sale of ‘Spice’ products without 
criminalising users (EMCDDA, 2009a).
Drug laws offer a second set of options to differentiate 
substances. These options can be presented in the form 
of a pyramid of distinctions (Ballotta et al., 2008). At 
its base is the system of distinction using classification 
by law. The penalty for a drugs offence officially varies 
according to the class or harmfulness of the substance 
involved, as defined by lists which are established in 
or directly linked to the laws. For example, in Bulgaria, 
Cyprus, the Netherlands, Portugal, Romania and the 
United Kingdom, the law instructs or requests the 
prosecuting authorities to distinguish between types of 
drugs for any offence; in Spain, Latvia and Malta, the 
penalty is only varied for a charge of drug trafficking. 
At the second level of the pyramid, drugs may be equally 
classified, but the law provides specific exemptions, in 
Economic recession and drug problems
The European Commission (2009a) estimates that 
the current economic downturn is comparable to the 
1930s recession. In 2009, the gross domestic product of 
the EU Member States slumped by 4.0 %, much more than 
in earlier crises. EU labour markets weakened dramatically, 
with unemployment increasing by one third (from 6.7 % in 
2008) and predicted to reach 11 % in 2010. Employment 
declined substantially: the creation of 9.5 million jobs 
in 2006–08 is expected to give way to a loss of 
8.5 million in 2009–10.
The consequences of an economic recession on drug use 
and drug-related problems were examined during the 
2010 conference of the International Society for the Study of 
Drug Policy (ISSDP). One of the overall findings is that there 
is a wide set of possible impact mechanisms. For instance, 
more unemployed teenagers may sell drugs and thereby 
increase the availability and use of cannabis among their 
peers. Some young adults may also use drugs to cope with 
stress and economic difficulties, though a decline in income 
could lead others to cut their expenditure on drugs. Existing 
drug-related problems can be affected too, either directly, 
with poorer drug users turning to more efficient and risky 
routes of administration, or indirectly, through a reduction of 
services due to cuts in public spending.
Assessing the full impact of the current recession will 
take time, notably because of the multiple mechanisms 
described above and because the effects will unfold over 
years. Now, however, governments that are considering 
cutting expenditure in the drugs field need to take into 
account the cost-effectiveness of existing measures.
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the form of lower penalties, for the possession of a small 
amount of cannabis for personal use, without aggravating 
circumstances, as in Belgium, the Czech Republic, Ireland 
and Luxembourg. At the third level, distinctions are made 
according to prosecutorial guidance or judicial precedent. 
In Denmark, for example, a State Prosecutor directive 
advises different fines to be requested for possession 
of different drugs, while in Germany, a Constitutional 
Court decision, noting the constitutional ban on excessive 
punishment, calls for less severe measures for minor 
offences of possession of cannabis for personal use.
The tip of the pyramid of distinctions is formed 
by prosecutorial or judicial discretion during the 
implementation of the law. Here, the nature of the 
substance is one of the criteria considered when 
deciding not to prosecute an offender or to give 
a lower punishment. Although the data were limited, 
the EMCDDA (2009e) found that sentences could differ 
even when drugs were viewed equally under the law. 
In the Czech Republic, where all drugs are classed 
equally by law, 44 % of sentences for heroin offences 
were prison sentences, compared to 39 % for pervitin 
(methamphetamine) and 11 % for cannabis. In the United 
Kingdom, for those given immediate custody, the average 
sentences for possession offences were five months for 
cocaine, seven months for ecstasy and 10 months for 
heroin. The average sentences for trafficking offences 
(excluding import and export offences) were 29 months for 
ecstasy and 37 months for cocaine and heroin. Yet these 
three substances are all in the same class. This suggests 
that judiciaries perceive differences in the levels of harm 
or seriousness associated with the various drugs other than 
any signalled by the legislation.
Threshold quantities that delimit offences, such as those 
seen for possession for personal use, are an additional 
element of distinction at all levels of the pyramid. The 
recent EMCDDA ‘Topic overview’ on threshold quantities 
identified significant differences in the legal basis and 
in the amounts of substances. These thresholds may be 
established in laws or government or ministerial decrees 
(e.g. Czech Republic, Greece, Italy, Cyprus, Lithuania, 
Hungary, Austria), or in prosecutorial guidelines (Denmark, 
Netherlands, Finland, Norway) or both (Belgium, Portugal) 
and even in sentencing guidelines (Finland). Thresholds 
can differ between countries for similar offences; for 
example, the start of criminal prosecution for possession 
of cannabis resin may be for any quantity in Lithuania 
or 6 grams in many German Länder. The thresholds also 
show no consistency in the relationship between drugs, 
with the weight threshold for cannabis varying from three 
times (Cyprus) to 10 times (Netherlands) that of heroin. 
The weight threshold of cocaine may be equal to that of 
heroin (e.g. Denmark) or 10 times heavier (e.g. Latvia).
Overall, it appears that distinguishing between drugs 
in EU Member States is not only a matter of formal 
classification under drugs laws. It also stems from the type 
of law used to control drugs, prosecutorial guidelines 
and judicial precedent, the relative quantity thresholds 
established and the attitudes of the judiciary when 
implementing the law.
Drug-related research
Strengthening EU research capacity
Strengthening research capacity in the drugs field has 
been on the European agenda in recent years. In 2008, 
the European Commission funded a study ‘Comparative 
analysis of research into illicit drugs in the European 
Union’ and, in September 2009, organised a conference 
to discuss ways to improve drug-related research capacity 
in the European Union (9). The study and the discussions 
offered a number of important insights into the way drug-
related research is carried out in Europe.
The bulk of drug-related research in Europe is conducted 
by the Member States, which set research priorities 
according to their national needs. This is generally done 
in the absence of a coherent drug research strategy 
with dedicated funding. Instead, drug-related research 
Research findings and language barriers
Most peer-reviewed research findings are published 
in English and, for a significant number of European 
researchers, practitioners and policymakers, this limits 
their accessibility. The same applies to work published in 
peer reviewed journals in other languages. In 2008, the 
EMCDDA identified 27 such journals in Europe, published 
in Czech, Danish, French, German, Greek, Hungarian, 
Norwegian, Polish, Portuguese, Spanish and Swedish. 
Many governmental and non-governmental organisations 
also provide research results in reports only available in 
their national languages. Most of this information remains 
accessible only to a limited number of individuals.
The importance of language barriers was highlighted by 
the study ‘Comparative analysis of research into illicit 
drugs in the European Union’ and also discussed during 
the Commission’s conference ‘Bridging the research gap 
in the field of illicit drugs research in the EU’. As a first 
step to overcoming such barriers, the EMCDDA developed 
a research thematic web area, which provides a list of 
national studies with links to published and unpublished 
reports.
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is usually embedded in health, social science or other 
programmes. Moreover, the research is heavily biased 
toward epidemiology and evaluation of interventions, 
with drug supply and supply reduction as well as policy 
evaluation being under-represented. Overall, coordination 
between policy, research and practice also lacks 
a coherent long-term approach. National research activity 
is complemented by the seventh framework programme 
of the European Community for research, technological 
development and demonstration activities (2007–13).
This insight provided input for EU Council conclusions on 
‘Strengthening EU research capacity on illicit drugs’ (10), 
which identify future priorities: research into the cause 
and nature of, and responses to, drug problems; and 
evaluation research in both supply and demand reduction. 
Member States are also invited to strengthen their research 
capacity and coordination mechanisms and to explore, 
with the help of the European Commission, opportunities 
provided by the seventh research framework programme, 
for instance, the European research area networks 
(ERA-NET) and Marie-Curie fellowships. Additionally, 
Member States and the research community are 
encouraged ‘to actively contribute to consultations on the 
future European research policy and the future objectives 
of drug-related research under the next EU drugs strategy’. 
The Council also agreed to establish an annual exchange 
on drug-related research in order to promote cross-border 
research cooperation. It acknowledged the need to 
improve access to research findings for policymakers and 
professionals, and called on the EMCDDA to provide and 
disseminate, via its thematic web area on research and its 
‘Best practice portal’, drug-related research information 
and findings.
Research information from Member States
In their 2009 Reitox national reports, European countries 
referred to more than 650 research projects undertaken 
or published between 2007 and 2009, approximately 
twice as many as in the previous period. This increase 
was verified in 26 of the 29 reporting countries. The 
United Kingdom referred to the highest number of 
research projects (over 100), followed by Germany, the 
Netherlands and Finland (each with over 50) and the 
Czech Republic, Ireland and Sweden (over 30).
As in previous years, research on responses to the drug 
situation and on prevalence, incidence and patterns of 
drug use each accounted for approximately a third of the 
recent studies, and the consequences of drug use for a fifth 
(Figure 1). Compared with last year, about 40 more studies 
on supply and markets were cited. While this was largely 
due to a special data collection on cannabis markets 
coordinated by the EMCDDA in 2009, it also indicates 
a growing interest in studies in the supply area.
Figure 1: Research subjects of national drug-related studies cited 
in the 2009 Reitox national reports (percentage of all studies 
cited)
Methodology
Mechanisms and
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%
NB: Some 29 Reitox national reports (2009) were surveyed for 
references to drug-related studies in the period 2007–09. The 
studies were categorised according to the context in which they 
were cited.
Source: Reitox national reports (2009).
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Introduction
This chapter presents an overview of the responses to drug 
problems in Europe, where possible highlighting trends, 
developments and quality issues. Prevention measures are 
first reviewed, followed by interventions in the areas of 
treatment, harm reduction and social reintegration. Taken 
together, all these measures form a comprehensive drug 
demand reduction system. They can be considered as 
complementary, and are sometimes provided in combination 
and by the same facilities. This is, for example, increasingly 
the case for treatment and harm-reduction measures.
The responses developed in the framework of drug law 
enforcement are also addressed in a section which 
includes the most recent data on drug law offences. The 
chapter ends with a review of the available data on the 
needs of drug users in prisons and the existing responses 
in this particular setting.
Prevention
Drug prevention can be divided into different levels or 
strategies, which range from targeting society as a whole 
(environmental prevention) to focusing on at-risk individuals 
(indicated prevention). Ideally, the different strategies 
do not compete but complement each other. The main 
challenges for prevention policies are to match these 
different levels of prevention to the degree of vulnerability 
of the target groups (Derzon, 2007) and to ensure that 
interventions are evidence-based and sufficient in coverage.
Environmental strategies
Environmental prevention strategies aim at altering 
the immediate cultural, social, physical and economic 
environments in which people make their choices about 
drug use. These strategies typically include measures such 
as smoking bans, alcohol pricing or health promoting 
schools. Evidence shows that environmental prevention 
measures at societal level and targeting the social climate 
in schools and communities are effective in altering 
normative beliefs and, consequently, substance use 
(Fletcher et al., 2008).
Partial or full smoking bans are now implemented in 
almost all European countries, and tobacco advertisement 
is banned by an EU directive of 2003 (2003/33/EC). 
Proposals of minimum pricing for alcohol and clampdowns 
on alcohol promotion are also being debated in several 
European countries. Efforts to develop positive and 
protected school climates, including strict rules regarding 
substance possession and use, were reported in 2009 by 
10 EU Member States. Countries in the north of Europe 
have also developed the concept of positive protected 
environments at community level, for example through 
municipal alcohol action plans.
Universal prevention
Universal prevention addresses entire populations, 
predominantly at school and community levels. It aims 
to deter or delay the onset of drug use and drug-related 
problems by providing young people with the necessary 
competences to avoid initiation into substance use. Evidence 
shows that well-designed and structured universal prevention 
interventions can be effective. A recent example of this is 
a Dutch combined school–parents programme that reduced 
alcohol use (Koning et al., 2009). For other interventions, 
notably mass media campaigns, there is little evidence for 
effectiveness, and some studies have observed detrimental 
effects. Despite this, a majority of European countries still 
report allocating resources to warning campaigns.
School-based universal prevention is reported in all 
European countries, although with varying content 
and levels of coverage. Information provision followed 
by life skills training are the two main intervention 
types provided. Structured intervention protocols 
(‘programmes’) are still relatively scarce. The need to 
improve school-based universal prevention is increasingly 
recognised in Europe. Eleven EU Member States report, 
for example, on efforts to define prevention standards.
Selective prevention
Selective prevention intervenes with specific groups, 
families or communities which, due to their scarce social 
ties and resources, may be more likely to develop drug use 
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(11) The treatment demand indicator received data from 29 countries for specialised drug centres, with a coverage of more than 60 % of units in most 
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or progress into dependency. Because of the difficulty of 
implementing experimental evaluation designs, evidence of 
the effectiveness of selective prevention is still limited. This 
does not apply, however, to interventions for vulnerable 
families, which have been shown to be effective in different 
studies (Petrie et al., 2007). Recent examples in this 
area include an adaptation of the ‘strengthening families 
programme’ evaluated in Spain, which was found to be 
effective in reducing predictors for drug use, such as 
disruptive behaviour at school and depression symptoms. 
Positive results were also reported in the United Kingdom, 
with reductions in risks to children, reported cases of 
antisocial behaviour, educational issues, youth crime, 
domestic violence, mental and physical health problems 
and substance misuse among the first 699 families to have 
completed ‘Family intervention projects’.
European countries report, on average, limited provision of 
selective prevention, with most interventions targeting young 
offenders, vulnerable families and ethnic groups. Overall, 
the data indicate that the coverage of selective prevention 
has not increased in recent years. There may be some 
exceptions to this observation, such as interventions for 
vulnerable families in some countries and FreD, a systematic 
intervention protocol for young offenders, which is now 
implemented in over a third of EU Member States.
Indicated prevention
Indicated prevention aims to identify individuals with 
behavioural or psychological problems that may be 
predictive for developing substance use problems later 
in life, and to target them individually with special 
interventions. Indicated prevention programmes are usually 
evaluated, and often show high levels of effectiveness 
(EMCDDA, 2009c). Overall, interventions in this field 
remain limited, with six countries reporting interventions 
for children with attention-deficit/hyperactivity disorder 
or disruptive behaviour and 10 countries reporting early 
intervention and counselling to individuals who have 
started using drugs. One recent development is the Dutch 
‘Cannabis show’, which is based on an existing cannabis 
prevention programme (entertaining peer education) 
and is carried out in a school for young people with 
behavioural and other psychiatric problems.
Treatment
In Europe, the main modalities used for the treatment of 
drug problems are psychosocial interventions, opioid 
substitution and detoxification. The relative importance 
of the different treatment modalities in each country is 
influenced by several factors, including the organisation of 
the national healthcare system.
There is no data set allowing a description of the full 
population of drug users currently undergoing drug 
treatment in Europe. Information on an important subgroup 
of this population is, however, gathered by the EMCDDA’s 
treatment demand indicator, which collects data on those 
entering specialised drug treatment services (11). In 2008, 
the indicator registered about 440 000 treatment entrants, 
40 % of whom were entering drug treatment for the first 
time in their life. 
Based on a range of different sources, including the 
treatment demand indicator, a conservative estimate is that 
1 million people received treatment for illicit drug use in 
the European Union during 2007. Of these, more than half 
Learning from prevention trials
The effectiveness of European prevention measures 
remains poorly researched (1). Universal and indicated 
prevention in school settings are the areas receiving the 
most attention. In parallel, there is a debate about the 
transferability of research findings from other parts of the 
world, mainly from the United States.
The EU-DAP study, a European multicentric trial involving 
about 7 000 pupils aged 12–14 in seven EU Member 
States, is contributing to the development of prevention 
research and shows that interventions can have similar 
results within Europe and across different continents.
Significant risk reduction for tobacco, alcohol and 
cannabis use after one year was reported for ‘Unplugged’, 
a 12-session programme. ‘Unplugged’ aims to correct 
normative beliefs about substance use, while also providing 
life-skills training and substance information. Persistent 
beneficial effects at 18 months follow-up were also found 
for episodes of drunkenness and frequent cannabis use in 
the past 30 days, whereas the short-term effect on daily 
cigarette smoking faded out (Faggiano et al., 2010).
A mediation analysis showed that outcomes on cannabis 
use were mostly due to the correction of normative beliefs, 
of positive expectancies towards the substance and of 
positive attitudes towards illicit drugs. Strengthening skills 
in communication, decision-making and refusal was less 
effective.
European and American researchers are now conducting 
parallel analyses with EU-DAP and other data in order 
to understand how children and adolescents respond to 
prevention in different contexts. The differential influence 
of gender, social context and psychological characteristics 
are particularly explored.
(1) This has led to the foundation of the European Society for 
Prevention Research.
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received opioid substitution treatment. Germany, Spain, 
France, Italy and the United Kingdom accounted for nearly 
80 % of the drug users in contact with treatment.
This estimate of drug treatment in the European Union, 
though in need of refinement, suggests a considerable 
level of treatment provision. It also highlights the great 
increases that have taken place in treatment provision 
since the mid-1990s, when greater availability and better 
access to drug treatment became priorities of drug policy. 
The past two decades have witnessed the expansion 
of specialist outpatient services and the development 
of outreach and low-threshold approaches. Several 
countries scaled up their substitution treatment by involving 
additional service providers, such as general practitioners. 
As a result, the number receiving substitution treatment in 
Europe has grown almost 10-fold since 1993 (12). Changes 
in treatment provision were also prompted by new client 
groups, such as cannabis and stimulant users, which have 
accessed treatment in growing numbers during the last 
15 years.
While it has become more available in many countries, 
there are still barriers impeding or discouraging drug 
users from accessing either drug treatment or some of 
its modalities. These barriers include regulations such 
as stringent admission criteria and legal frameworks, 
treatment costs for patients, lack of trained staff or low 
geographical density of treatment providers. Other 
obstacles faced by drug users in need of treatment 
include inadequate opening hours, requirement of daily 
attendance and lack of childcare support (e.g. during 
inpatient treatment), which conflict with their personal 
and professional situation. Personal beliefs and 
preconceptions, among both professionals and drug users, 
regarding the appropriateness, effects and results of 
specific treatment approaches can also impede treatment 
access.
Extended waiting times for drug treatment can be one 
of the consequences of barriers to treatment access. 
According to information provided by national experts 
in 2008, limited availability of treatment and lack of 
resources, as well as delays due to procedural reasons, 
are the main causes for the existing waiting times, which 
differ between treatment modalities (see below).
Outpatient treatment
Information is available on about 383 000 drug users 
entering outpatient treatment in Europe during 2008. Most 
of these drug users entered treatment in specialised drug 
treatment services, and only a few countries reported 
on those entering treatment with a general practitioner 
or in low-threshold services. More than half of the 
treatment entrants (53 %) report opioids, mainly heroin, 
as their primary drug, while 22 % report cannabis and 
18 % cocaine (13). The most common route to treatment is 
self-referral (36 %), followed by referral by the criminal 
justice system (20 %). The remaining clients are referred 
through social and health services or informal networks, 
including family and friends (14).
Clients entering outpatient treatment are predominantly 
young men, with an average age of 31 years and males 
four times as numerous as females. Clients entering 
treatment for the first time and female clients are on 
average slightly younger. Younger average ages are 
also reported for cannabis clients (25) and those using 
stimulants other than cocaine (29), while older mean 
ages are reported for primary users of cocaine (32) and 
opioids (34). On average, the youngest drug clients are 
reported by the Czech Republic (26) and the oldest by 
Spain (33) (15). Male to female ratios are highest among 
cannabis (5:1) and cocaine (4.8:1) clients and lowest 
for those using stimulants other than cocaine (2.2:1). 
Regardless of the primary drug, gender ratios are highest 
in countries in the south of Europe and lowest in countries 
in the north (16).
The two main modalities of outpatient treatment in Europe 
are psychosocial interventions and opioid substitution 
treatment. For opioid users, they are often provided in 
combination. Psychosocial interventions offer support 
EMCDDA ‘Selected issue’ on treatment and care 
for older drug users
The number of older drug users in Europe is predicted 
to double between 2001 and 2020 and adequate and 
innovative approaches will be required for the treatment 
and care of this growing population. A ‘Selected issue’ 
published this year by the EMCDDA examines the 
development and causes of this ageing phenomenon over 
the last two decades. The health and social characteristics 
of older drug users are also presented in order to specify 
their current needs. The report ends with an overview of 
current interventions for older drug users and best practices 
in Member States.
This ‘Selected issue’ is available in print and on the 
EMCDDA website in English only.
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to users as they attempt to manage and overcome their 
drug problems. These interventions include counselling, 
motivational enhancement, cognitive-behavioural therapy, 
case management, group and family therapy and relapse 
prevention. They are mostly provided, depending on the 
country, by public institutions or by non-governmental 
organisations. In 2008, experts from nine of the 
27 reporting countries estimated that there is no waiting 
time for this type of treatment. In 10 other countries 
national experts estimated that average waiting times are 
no longer than one month. In Norway, the average waiting 
time is estimated to be 10 weeks, while Denmark requires 
by law that treatment takes place within 14 days. Experts 
from seven countries could not provide an estimate.
Substitution treatment is the predominant treatment option 
for opioid users in Europe. It is generally provided in 
outpatient settings, though in some countries it is also 
available in inpatient settings and is increasingly provided 
in prisons (17). Opioid substitution is available in all EU 
Member States, as well as Croatia and Norway (18). In 
Turkey, substitution treatment has yet to be introduced, 
though it is permitted under a 2004 regulation on 
treatment centres. In most countries, specialised public 
outpatient services are the main providers of substitution 
treatment. However, office-based general practitioners, 
often in shared-care arrangements with specialised 
centres, play an increasing role in the provision of this 
type of treatment. These providers are, at different levels, 
involved in 13 countries.
In 2008, about 670 000 opioid users are estimated to 
have received substitution treatment in Europe (19). Experts 
from 10 of the 26 reporting countries estimated that 
there is no waiting time for this type of treatment. In four 
countries (Czech Republic, Denmark, Italy, Portugal), the 
average waiting time was estimated to be less than one 
month. In the Czech Republic, waiting times only apply 
to methadone, since high-dosage buprenorphine can 
be prescribed by office-based general practitioners — 
although the client has to cover the costs of the 
medication. In another four countries (Hungary, Romania, 
Finland, Norway), the estimated waiting time ranges 
between one and six months, while in a further three 
countries (Bulgaria, Greece, Poland) it is over one year. 
Among these, Greece reports an average waiting time 
of 38 months, with data showing 5 261 problem opioid 
users registered as waiting for admission to substitution 
programmes in 2008. National average waiting times 
may, however, mask considerable regional variation. 
For example, in Ireland the average waiting time for 
substitution treatment varies from less than 3.5 months in 
Dublin to 18 months in the south-east (Comptroller and 
Auditor General, 2009). Experts from four countries could 
not provide an estimate of waiting times.
Inpatient treatment
Data are available for about 42 000 drug users who 
have entered drug treatment in inpatient settings in Europe 
during 2008. More than half of them report opioids as 
their principal drug (57 %), with most of the other clients 
identifying their principal drug as either cannabis (13 %), 
stimulants other than cocaine (13 %) or cocaine (7 %). 
Inpatient clients are mainly young men, with a mean age 
of 30 years and a male to female ratio of 3.5:1 (20).
Inpatient or residential treatment requires clients to stay 
overnight for a duration of several weeks to several 
months. In many cases, these programmes aim to 
enable clients to abstain from drug use and do not allow 
substitution treatment. Drug detoxification, a short-term, 
medically supervised intervention aimed at resolving 
the withdrawal symptoms associated with chronic drug 
use, is sometimes a prerequisite to initiate long-term, 
abstinence-based inpatient treatment. Detoxification is 
usually provided as an inpatient intervention in hospitals, 
specialist treatment centres or residential facilities with 
medical or psychiatric wards.
In inpatient settings, clients receive accommodation and 
individually structured psychosocial treatments and take 
part in activities geared towards rehabilitating them into 
society. A therapeutic community approach is often used 
in this context. Inpatient drug treatment is also provided 
by psychiatric hospitals, notably for clients with co-morbid 
psychiatric disorders.
Access to inpatient psychosocial treatment is rated as 
immediate by national experts from Greece, Hungary 
and Turkey. Experts estimate the average waiting time to 
be less than one month in 12 countries and 25 weeks in 
Norway. In Austria, the waiting time is reported to be up 
to several months, depending on region and treatment 
facility. Experts from 10 countries did not provide an 
estimate of the waiting time for this type of treatment.
Detoxification is considered to have no waiting time by 
experts from Hungary, Slovenia, Slovakia, Turkey and 
the Flemish Community in Belgium. In 11 countries, the 
estimated average waiting time is less than two weeks. 
An average waiting time of two weeks to one month is 
estimated in Cyprus, the Czech Republic and Greece, 
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while in Ireland, Austria and Norway it is estimated at 
between one and three months. Experts from five countries 
did not provide an estimate.
Quality assurance
Actions addressing the quality of drug treatment are 
currently being undertaken by most European countries. 
These actions include the development and implementation 
of guidelines, the adoption of national drug action 
plans which address treatment quality issues, quality 
certification and accreditation processes, and studies 
investigating quality differences between treatment centres 
or benchmarking them.
Recent developments include the implementation of 
guidelines for treatment quality in six countries, while 
Cyprus, Turkey and Norway have recently published 
such guidelines. Ten countries adopted new strategic 
documents, in some cases entailing accreditation systems. 
Poland and Slovakia also introduced accreditation 
criteria for treatment centres, with Slovakia introducing 
ISO 9001 certification. Four countries — Estonia, Latvia, 
the Netherlands and Romania — are investigating 
heterogeneity in the quality of service across their 
treatment system.
The United Kingdom has a long history of assessing the 
health system and one of the widest sets of instruments to 
monitor and improve treatment quality. This now includes 
a document on clinical governance in drug treatment 
(NTA, 2009) that addresses lines of responsibility and 
accountability, quality improvement, risk management 
policies and procedures to identify and remedy poor 
performance.
A study commissioned by the EMCDDA identified 
60 national treatment guidelines in 17 out of 22 reporting 
countries in Europe. The modalities most frequently 
covered by the guidelines are psychosocial treatment (29), 
opioid substitution treatment (28) and detoxification (22). 
Countries with high numbers of patients in opioid 
substitution treatment appear to be more likely to have 
developed treatment guidelines for each modality.
Seventeen countries report guidelines specifically for the 
treatment of opioid users. Five countries have guidelines 
targeting the use of different substances, while Hungary 
and Germany have guidelines for amphetamines and 
cannabis use disorders. Ten countries address long-term 
problem drug users and nine have developed guidelines 
for young drug users. Eight countries also address drug 
users with co-occurring disorders.
Almost all guidelines target treatment professionals (58) 
and service providers (52), and close to half of them target 
healthcare planners (25). Portugal is the only country 
reporting guidelines targeting clients, while Denmark 
reports targeting policymakers. Treatment professionals 
were involved in developing the guidelines in 17 countries, 
and other professionals in four countries. Researchers 
also participated in nine countries, policymakers in three 
and clients in one. More information regarding national 
treatment guidelines is provided on the EMCDDA’s ‘Best 
practice portal’.
Harm reduction
The prevention and reduction of drug-related harm is 
a public health objective in all Member States and in the 
EU drugs strategy (21). Reviews of the scientific evidence of 
harm-reduction interventions, as well as studies showing 
the combined impact of these interventions, are now also 
available for service planning (EMCDDA, 2010a). Among 
the main interventions in this field are opioid substitution 
treatment and needle and syringe exchange programmes, 
which target overdose deaths and the spread of infectious 
diseases. These measures are reported to be available in 
all countries except Turkey. While considerable differences 
exist in the range and levels of service provision (see 
Chapters 6 and 7), the general European trend is one of 
growth and consolidation of harm-reduction measures.
Most European countries provide a range of further 
healthcare and social services, including those that are 
recommended by the WHO, UNODC and UNAIDS 
(2009), as part of a ‘comprehensive package’ for HIV 
New EMCDDA monograph on harm reduction
‘Harm reduction: evidence, impacts and challenges’ was 
published in 2010 by the EMCDDA. The monograph 
provides a comprehensive overview of this field through 
16 chapters authored by more than 50 European and 
international experts. The first part of the monograph looks 
back at the emergence and diffusion of harm reduction 
and explores the concept from different perspectives, 
including those of international organisations, researchers 
and drug users. A second part is dedicated to current 
evidence and impacts and illustrates how the concept 
has broadened to cover a wide range of behaviours and 
harms, including those related to alcohol, tobacco and 
recreational drug use. The last part addresses challenges 
and innovations, and the necessity to integrate and match 
interventions to individual and social needs.
This publication is available in print and online on the 
EMCDDA website in English only.
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(22) See Table HSR-8 in the 2010 statistical bulletin.
(23) See the box ‘Anthrax outbreak among heroin users in the United Kingdom and Germany’ in Chapter 7.
(24) See Tables TDI-12, TDI-13 and TDI-15 in the 2010 statistical bulletin.
(25) See the box ‘Economic recession and drug problems’ in Chapter 1. 
prevention among drug injectors. The interventions 
routinely offered depend on the national context, but 
include individual risk assessment and advice, targeted 
information and safer-use education, distribution of 
injecting equipment other than needles and syringes, 
promotion of condom use among injecting drug users, 
infectious disease testing and counselling, antiretroviral 
treatment and vaccination against viral hepatitis. 
Many of these services are provided at low-threshold 
agencies. Harm-reduction responses aimed at preventing 
drug induced deaths are, however, scarce (22), despite an 
increasing awareness of the need for such interventions. 
New initiatives in this field include early warnings or alerts 
about substances associated with higher risks (23). For 
example, all low-threshold facilities in the Czech Republic 
were notified in 2009 about a possible penetration of 
fentanyl into the local drug market.
Following recent improvements in the treatment of 
hepatitis C, most countries are now increasing their efforts 
to prevent, detect and treat hepatitis among drug users, 
including those in substitution treatment. Recent examples 
of this include: the new national hepatitis plan in France; 
a pilot study to develop recommendations for HCV 
prevention in Germany; and hepatitis treatment guidance 
in the Czech Republic, the Netherlands and the United 
Kingdom. Studies and screening campaigns in prison 
settings are also reported by several countries, including 
Belgium, France, Luxembourg and Hungary.
The focus of harm-reduction responses has expanded 
beyond the HIV/AIDS epidemic into the broader perspective 
of catering for the health and social needs of problem 
drug users, especially those who are socially excluded. 
The incorporation of harm reduction into the response to 
drugs has also advanced the collection of data on the 
drug problem. National inventories of services and studies 
of service quality (Czech Republic, Germany, Ireland, 
Finland) and client surveys (Estonia, Lithuania, Luxembourg, 
Hungary) provide a better insight into service provision and 
users’ needs. It also helps to promote quality assessment 
and exchange of best practice, to improve prevention 
materials and techniques and to develop new interventions.
Social exclusion and reintegration
Social reintegration is recognised as an essential 
component of comprehensive drug strategies. It can be 
implemented at any stage of drug use and in different 
settings, and includes capacity building, improvement 
of social skills and measures to facilitate and promote 
employment and to obtain or improve housing. In 
practice, reintegration programmes may include 
vocational counselling, work placements and housing 
support. Prison based interventions, which have an 
impact on relapse and reoffending, may link inmates to 
community based housing and social support services in 
preparation for their release. In general, the outcomes 
of social reintegration measures often rely on efficient 
collaboration between health and social care institutions.
Although there is no direct causal relationship between the 
more problematic forms of drug use and social exclusion, 
they are often associated. Data show that homelessness 
affected 9 % of clients entering outpatient drug treatment 
and about 13 % of those entering inpatient treatment 
in 2008. About 40 % of clients entering treatment in both 
settings had not completed their secondary education, 
while 47 % of those entering outpatient and 71 % of 
those entering inpatient treatment reported to be either 
unemployed or economically inactive (24). This may not 
improve under the current economic situation, where 
growing unemployment rates increase competition in the 
labour market (25).
All reporting countries mention the availability of housing, 
education and employment programmes and services. 
These are either targeted specifically at drug users or 
address the needs of socially excluded groups in general. 
Ireland and Sweden are discussing the ‘housing first 
model’ for homeless individuals with mental health and 
substance problems. This model is often associated with 
integrated community treatment and social services and 
with case management. Access to accommodation is not 
contingent upon being sober and drug-free, as it normally 
is for this problematic group. The housing first approach 
has shown positive outcomes for homeless people across 
a number of social and health variables, including 
substance use (Pleace, 2008).
Improving employability and access to paid work plays 
an important role in the social reintegration of drug 
users. Countries such as Germany, Italy, Austria, Portugal 
and the United Kingdom have increasingly prioritised 
employment-related aspects of the recovery process 
through new initiatives and increased funding allocations.
Drug law enforcement and drug law 
offences
Drug law enforcement is an important component of 
national and EU drug policies and includes a wide range 
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(26) An analysis work file is essentially a secured database containing information provided by participating countries, under strict confidentiality rules. 
It allows Europol to support national law enforcement forces. 
(27) See the box ‘Revenues and profits from illicit cannabis cultivation’ in Chapter 3. 
(28) For a discussion of the relationships between drugs and crime and a definition of ‘drug-related crime’, see EMCDDA (2007a).
of interventions that are mainly implemented by police 
and police-like institutions (e.g. customs). Data on drug 
law enforcement activities are often less developed and 
accessible than those in other areas of drug policy. 
Notable exceptions are data on drug law offences, 
which are reviewed in this section. Also examined 
here are recent law enforcement measures to tackle 
commercial cannabis production and new developments in 
international collaboration in combating drug trafficking.
Drug law enforcement
In 2010, Europol opened an ‘analysis work file’ on 
cannabis (26). The project includes a component on 
cannabis cultivation, which is intended to enhance 
the sharing of intelligence within the European Union 
regarding the involvement of organised crime in cannabis 
production. This follows the reporting by the national 
law enforcement agencies of at least seven countries 
that criminal organisations were involved in commercial 
cannabis cultivation, an activity that apparently can be 
very lucrative (27).
It is difficult to estimate the scope of illicit cannabis 
cultivation in Europe, as data are very limited on the 
number of growers and on the size of plantations. 
Qualitative studies and seizure data (see Chapter 3) 
suggest that domestic production might have increased 
substantially since the 1990s, especially in western 
Europe. Qualitative studies show that the motivations of 
growers range from cultivating a few plants for personal 
use to producing several thousand plants for commercial 
purposes.
Commercial cannabis cultivation, especially in large 
indoor plantations, has been reported to pose crime 
and public safety problems in Belgium, Germany, 
the Netherlands and the United Kingdom. Criminal 
organisations in the United Kingdom are reported to 
exploit young illegal immigrants from Asia. Furthermore, 
the setting up of commercial plantations inside buildings 
often entails converting the premises, which may damage 
the property. A further risk to property and safety is 
related to the heavy consumption of electricity to provide 
artificial light to cannabis plants grown indoors. Unsafe 
methods to bypass electricity meters — to avoid payment 
or raising suspicion — or ill-adapted wiring systems are 
reported to have caused fires in indoor plantations.
Cannabis cultivation is addressed within existing law 
enforcement frameworks against drugs and organised 
crime, but some European countries have recently 
developed specific strategies in this area. Belgium has 
made combating illegal cannabis production a priority 
of its National Security Plan 2008–12, while the 
Netherlands and the United Kingdom have developed 
multifaceted strategies to increase the detection and 
destruction of commercial plantations. These strategies 
include measures such as raising awareness among the 
general population and some key sectors (e.g. electricity 
suppliers, hardware shops) to encourage them to 
report cannabis plantations to the police. In addition, 
partnerships are established between law enforcement 
and electricity suppliers, housing authorities, insurance 
companies and other sectors interested in fighting 
commercial plantations. Steps are also taken to improve 
police efficiency. In the Netherlands, for example, an 
‘organised cannabis cultivation taskforce’ was established 
in July 2008 to coordinate existing efforts by police, 
local governments, magistrates and the tax office. Police 
forces can now be equipped with detection technology 
generally used by the military, including infrared cameras 
for thermal imaging, and conduct larger operations 
to destroy plantations and arrest suspects, such as 
‘Operation Mazurka’ in Northern Ireland, which resulted 
in 101 arrests in 2008.
Measures targeting cannabis cultivation have also 
been reported in other countries. For example, a major 
operation against ‘cannabis factories’ was conducted in 
2008 in Ireland, while in Germany the federal criminal 
police (Bundeskriminalamt) set up a special unit to report 
on cannabis offences throughout the country.
Drug law offences
Initial reports on drug law offences, mainly from the 
police, are the only data on drug-related crime routinely 
available in Europe (28). These data usually refer to 
offences related to drug use (use and possession for use) 
or drug supply (production, trafficking and dealing), 
although other types of offences may be reported 
(e.g. related to drug precursors) in some countries.
Data on drug law offences are a direct indicator of law 
enforcement activity, since they refer to consensual crimes 
which usually go unreported by potential victims. They are 
often viewed as indirect indicators of drug use and drug 
trafficking, although they include only those activities that 
have come to the attention of law enforcement. They are 
also likely to reflect national differences in legislation, 
priorities and resources. Furthermore, national information 
systems differ across Europe, especially in relation to 
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recording and reporting practices. For these reasons, it 
is difficult to make valid comparisons between countries, 
and it is more appropriate to compare trends rather than 
absolute numbers.
An EU index, based on data provided by 21 Member 
States that represent 85 % of the population aged 15–64 
in the European Union, shows that the number of reported 
drug law offences increased by an estimated 35 % 
between 2003 and 2008. If all reporting countries are 
considered, the data reveal upward trends in 15 countries 
and a stabilisation or an overall decline in nine countries 
over the period (29).
Use- and supply-related offences
There has been no major shift in the balance between 
drug law offences related to use and those related to 
supply compared to previous years. In most (23) European 
countries, offences related to drug use or possession 
for use continued to comprise the majority of drug law 
offences in 2008, with Estonia, Spain, France, Austria, 
Slovenia and Sweden reporting the highest proportions 
(81–92 %). Offences related to supply are, however, 
predominant in the Czech Republic (87 %) (30).
Between 2003 and 2008, the number of drug law 
offences related to use increased in 19 reporting 
countries, with only Bulgaria, Germany, Greece, Austria 
and Slovenia reporting a decline across the period. 
Overall, the number of drug law offences related to use 
in the European Union increased by an estimated 37 % 
between 2003 and 2008 (Figure 2).
Offences related to the supply of drugs also increased 
during the period 2003–08, but at a much lower pace, 
with an increase of about 10 % in the European Union. 
Over this period, 17 countries report an increase in 
supply-related offences, while eight countries report an 
overall decline (31).
Trends by drug
Cannabis continues to be the illicit drug most often 
mentioned in reported drug law offences in Europe (32). 
In the majority of European countries, offences involving 
cannabis accounted for between 50 % and 75 % of 
reported drug law offences in 2008. Offences related to 
other drugs exceeded those related to cannabis in only 
three countries — the Czech Republic and Latvia with 
methamphetamine (57 % and 33 %) and Lithuania with 
heroin (26 %).
In the period 2003–08, the number of drug law offences 
involving cannabis increased in 15 reporting countries, 
resulting in an estimated increase of 29 % in the European 
Union (Figure 2). Downward trends are reported by 
Bulgaria, the Czech Republic, Germany, Italy, Austria and 
Slovenia (33).
Cocaine-related offences increased over the period 
2003–08 in 17 reporting countries, while Bulgaria, 
Germany, Italy and Austria reported decreasing trends. In 
Development of interagency platforms in Europe
The concept of interagency platforms, where law 
enforcement and military agencies from different countries 
share intelligence and coordinate seizures of drugs before 
they reach user markets, originates in America. The Joint 
Interagency Task Force-South (JIATF-S), set up in Panama in 
1994 and now based in Key West (Florida), is a model for 
this form of cooperation. JIATF-S, a military-led platform, 
coordinates air and maritime interdiction activities south 
of the United States by US military, intelligence and 
law enforcement agencies, and by associated countries 
including Spain, France, the Netherlands and the United 
Kingdom.
Within Europe, two interagency platforms, both law 
enforcement-led, were recently established to coordinate 
actions against drug trafficking. The Maritime Analysis 
and Operations Centre-Narcotics (MAOC-N) was created 
in 2007, within the framework of the European Union, 
by a treaty between Ireland, Spain, France, Italy, the 
Netherlands, Portugal and the United Kingdom. MAOC-N 
is based in Lisbon and coordinates the interdiction of 
drug shipments transported across the Atlantic. JIATF-S 
was associated with the MAOC-N project at the 
outset, and is now an observer alongside the European 
Commission, Europol, Germany, Greece, Canada, 
Morocco, UNODC and, recently, Cape Verde. The 
second interagency platform, the Centre de Coordination 
de la Lutte Anti-Drogue en Méditerranée (CeCLAD-M), 
was established in 2008. CeCLAD-M is a unit of the 
French police, bringing together representatives of French 
law enforcement agencies and the navy, as well as 
representatives from Greece, Spain, Italy, Cyprus, Portugal, 
the United Kingdom, Morocco and Senegal. The Centre 
is based in Toulon and may propose the interception of 
suspect vessels and aircraft in the Mediterranean Sea.
Similar platforms may be set up in the future in the eastern 
Mediterranean and Black Sea areas. The European 
Commission also recently sponsored a study to explore the 
feasibility of establishing a European intelligence-sharing 
and capacity-building platform in West Africa.
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the European Union, overall, offences related to cocaine 
increased by about 45 % over the same period, showing 
a levelling off in the last year (34).
The change from a downward to an upward trend 
reported last year in heroin-related offences is now 
confirmed: the EU average for such offences increased by 
39 % in 2003–08. The number of heroin-related offences 
has increased in 16 reporting countries, while a decline 
was reported in Bulgaria, Germany, Italy and Austria over 
the same period (35).
The number of offences related to amphetamines reported 
in the European Union continues to show an upward 
trend, with an estimated increase of 24 % between 2003 
and 2008. Ecstasy-related offences, in contrast, have 
decreased by an estimated 35 % over the same period 
(Figure 2).
Health and social responses in prison
On a given day, there are over 600 000 people in penal 
institutions in the European Union (36), giving an average 
rate of about 120 prisoners per 100 000 population (37). 
National prison population rates range from 66 to 
285 prisoners per 100 000 inhabitants, with most 
Member States from central and eastern Europe reporting 
higher than average rates. Nevertheless, the national 
figures and the EU average remain considerably below the 
rates reported from Russia (609) and the USA (753) (38).
Among sentenced prisoners, those incarcerated for drug 
law offences make up somewhere between 10 % and 
30 % of the prison population in most EU countries. An 
unknown proportion of others are sentenced for property 
crimes to support a drug addiction, or other drug-related 
crime.
Drug use in prison populations
There is still a lack of standardisation of definitions, 
research questions and methodologies used in studies on 
drug use in the prison population (Directorate-General for 
Health and Consumers, 2008; Vandam, 2009), though 
existing studies show that drug use continues to be more 
prevalent among prisoners than among the general 
population. Data from several studies carried out since 
2003 show that there are considerable variations in the 
prevalence of drug use among prisoners: for example, 
regular drug use in the month before imprisonment 
was reported by as few as 3 % of respondents in some 
countries and by up to 77 % in others. Studies also 
indicate that the most harmful forms of drug use may be 
more frequent among prisoners, with between 6 % and 
38 % of those surveyed reporting to have ever injected 
drugs (39).
On admission to prison, most users reduce or stop 
consuming drugs, mainly due to problems in acquiring the 
substances. However, the fact that illicit drugs find their 
way into most prisons, despite all the measures being 
Figure 2: Trends in reports for drug-related offences by type of offence and by drug type in the EU Member States
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taken to reduce their supply, is recognised by both prison 
experts and policymakers in Europe. In studies carried 
out since 2003, estimates of drug use in prison vary from 
1 % to 56 % of inmates. Regular drug use during the last 
month in detention was reported by 12 % of detainees 
in a national study carried out in Portugal in 2007 (40). 
A study among 246 prisoners in Luxembourg found that 
31 % had injected drugs in prison, while studies in three 
other countries reported levels of injecting of 10 % or 
more (41). Injecting drug users in custody appear to share 
their equipment more often compared to users not in 
prison. This raises issues around the potential spread of 
infectious diseases among the prison population.
Prison health in Europe
Prisoners are entitled to the same level of medical care 
as persons living in the community, and prison health 
services should be able to provide treatment for problems 
related to drug use in conditions comparable to those 
offered outside prison (CPT, 2006; WHO, 2007). This 
general principle of equivalence is recognised in the 
European Union through the Council recommendation 
of 18 June 2003 on the prevention and reduction of 
health-related harm associated with drug dependence (42), 
and the new EU drug action plan (2009–12) calls for its 
implementation.
Cooperation between prisons and health and social 
services is developing in Europe. Examples of this are the 
transfer of responsibility for prison health from national 
justice to health administrations in France, Italy, Sweden, 
Norway and England and Wales (it is also planned in 
Scotland); the integration of community-based health 
agencies into multidisciplinary prison teams in Luxembourg, 
Portugal, Slovenia and Sweden; and the growing provision 
of intramural services by community-based drugs agencies, 
which now exists in most countries.
National drug strategies and action plans often include 
objectives for care in prisons, such as improvements in the 
equivalence, quality and continuity of prison treatment and 
care. Some countries have elaborated specific strategies 
for the prison system. Spain and Luxembourg have 
implemented prison health policies for more than 10 years 
and documented their effectiveness. More recently, prison 
drug policy coordinators have been nominated in Belgium, 
and a central unit, where prison staff and drug specialists 
cooperate to link prisoners with treatment upon release, 
was set up. A committee for drug affairs was established 
within the Hungarian prison service in 2008. The drug 
policy action plan 2007–09 of the Czech prison service 
guides the implementation of new services and includes 
a monitoring and evaluation component. In the United 
Kingdom, the drug strategy 2008–11 of the National 
Offender Management Service (NOMS, 2009) seeks 
to provide early interventions for young people and to 
manage offenders with drug misuse problems in order to 
reduce the harm caused by drugs and alcohol.
Assistance to drug users in prison
Prisoners in Europe may access a range of services related 
to drug use and its associated problems. These include 
information on drugs and health, healthcare for infectious 
diseases, treatment for drug dependence, harm-reduction 
measures and preparation for release (43).
Information and guidance regarding the management of 
infectious diseases in prison has been developed in recent 
years by international organisations. The UNODC, in 
collaboration with the WHO and UNAIDS, has published 
a series of information materials for prison administrations 
and other decision-makers, which explain how to draw 
up an effective national response to HIV/AIDS in prison 
settings (UNODC, WHO and UNAIDS, 2006). Another 
document provides guidance about how to convey 
information about infectious diseases counselling and 
testing more effectively in prison settings, and to improve 
the communication of results to inmates (UNODC, 
UNAIDS and WHO, 2010).
A clear set of healthcare areas and standards in prisons 
has been defined in a small number of countries, including 
the Czech Republic, Spain, Luxembourg and the United 
Kingdom, and steps in this direction are being taken by 
other countries. Several countries now report that they 
are assessing the availability and quality of healthcare 
for drug users in prisons. In Ireland, for example, the 
need to match the capacities of prison pharmacy services 
with the growth of substitution treatment provision was 
identified in a study (Irish Prison Service, 2009), while 
in France a new supervisory body (Chief Inspectorate of 
Prisons and Other Closed Institutions) found shortcomings 
in prison healthcare and identified risks of infection. The 
Netherlands introduced a new directive for the care of 
drug users in detention, which gives special attention 
to drug-related infectious diseases (44). The quality of 
prison services is also improving in several countries 
through investment in training. In Belgium, all prison staff 
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received training on prison alcohol and drug policies; 
prison doctors in Croatia received training in substitution 
treatment; and a UNODC-led project provided training 
in HIV prevention and drug education to Latvian prison 
doctors, social workers and psychologists, who later 
trained the prisoners. In Finland, new prison treatment 
programmes require accreditation by the Criminal 
Sanctions Agency.
Following the scaling up of opioid substitution treatment 
in the community, many countries report increases in 
the number of opioid substitution clients entering prison. 
Continuity of care for substitution treatment is particularly 
important, given the high rates of overdose death on 
release (EMCDDA, 2009a) and for reducing the risks of 
crimes carried out to fund illicit drug use. In 2008, the 
continuation of opioid substitution treatment in prisons 
became possible in Bulgaria, Estonia and Romania. 
However, this treatment option is not available in prisons 
in Greece, Cyprus, Lithuania, Latvia, Slovakia and Turkey. 
In six Member States, it can be estimated that more than 
10 % of all prisoners receive opioid substitution treatment, 
while in another eight countries the corresponding figure 
is between 3 % and 10 % (Figure 3). In most countries, 
detoxification is still the ‘default’ treatment for opioid users 
entering penal institutions.
Figure 3: Proportion of prison population receiving opioid substitution treatment
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NB: Data are presented for all countries where substitution treatment is available in prisons, except Malta. Data are for 2008, except for Austria and 
Scotland (2007) and Belgium and the Netherlands (2009). For notes and sources, see Table HSR-9 in the 2010 statistical bulletin.
Source: Reitox national focal points.
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Introduction
Cannabis is the illicit drug most widely available in Europe, 
where it is both imported and produced domestically. In 
most countries, cannabis use increased during the 1990s 
and early 2000s, although substantial differences between 
countries still remain. The last few years have also seen 
a growing understanding of the public health implications 
of the long-term and widespread use of this drug, and rising 
reported levels of treatment demand for cannabis-related 
problems. Europe may now be moving into a new phase, 
as data from general population and school surveys point 
to a stabilising or even decreasing trend in cannabis use. 
Levels of use remain high by historical standards, however, 
and what constitutes an effective response to cannabis use 
remains a key question in the European debate on drugs.
Supply and availability
Production and trafficking
Cannabis can be cultivated in a wide range of 
environments and grows wild in many parts of the world. 
It is estimated that cannabis is cultivated in 172 countries 
and territories (UNODC, 2009). These facts taken 
together mean that it is difficult to produce accurate 
estimates of the worldwide production of cannabis. 
The UNODC (2009) estimates global production of 
herbal cannabis in 2008 at between 13 300 tonnes and 
66 100 tonnes.
Cannabis cultivation in Europe is widespread and 
appears to be increasing. In 2008, all 29 European 
countries reporting information mentioned domestic 
cannabis cultivation, though the scale and nature of the 
phenomenon seem to vary considerably. A significant 
proportion of cannabis used in Europe is, nevertheless, 
likely to be the result of intraregional trafficking.
Herbal cannabis in Europe is also imported, mostly from 
Africa (e.g. Nigeria, Cape Verde, South Africa) and less 
often from the Americas, especially the Caribbean islands, 
the Middle East (Lebanon) and Asia (Thailand). Albania, 
the former Yugoslav Republic of Macedonia, Moldova, 
Montenegro and Serbia are also mentioned as sources in 
a recent report (INCB, 2010b).
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Table 2: Production, seizures, price and potency of herbal cannabis and resin
Cannabis resin Herbal cannabis
Global production estimate (tonnes) 2 200–9 900 13 300–66 100
Global quantities seized (tonnes) 1 637 6 563
Quantity seized (tonnes) 
EU and Norway 
(Including Croatia and Turkey)
 
892
(900)
 
60 
(92)
Number of seizures 
EU and Norway 
(Including Croatia and Turkey)
 
367 400 
(368 700)
 
273 800 
(288 600)
Mean retail price (EUR per gram) 
Range 
(Interquartile range) (1)
 
3–10 
(6–9)
 
3–16 
(5–9)
Mean potency (THC content %) 
Range 
(Interquartile range) (1)
 
3–16 
(6–10)
 
1–10 
(5–8)
(1) Range of the middle half of the reported mean prices.
NB: All data for 2008.
Sources: UNODC (2009, 2010b) for global values, Reitox national focal points for European data.
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(45) The data on European drug seizures mentioned in this chapter can be found in Tables SZR-1 to SZR-6 in the 2010 statistical bulletin.
(46) This analysis is preliminary, as data for the United Kingdom are not yet available for 2008.
(47) Due to differences in shipment size and distances travelled, as well as the need to cross international borders, cannabis resin may be more at risk of 
being seized than domestically produced herbal cannabis.
(48) The analysis does not include the seizures reported by Turkey of 31 million cannabis plants in 2003 and 20 million plants in 2004, since data on 
quantities seized are not available for subsequent years.
Global production of cannabis resin in 2008 is estimated 
at between 2 200 tonnes and 9 900 tonnes (UNODC, 
2009), with Afghanistan and Morocco reported as main 
producers. A recent survey suggests that Afghanistan 
may now be the world’s largest producer of cannabis 
resin, with production estimated at between 1 500 and 
3 500 tonnes a year (UNODC, 2010a). The last estimate 
available for Morocco suggested a cannabis resin 
output of about 1 000 tonnes in 2005 (UNODC and 
Government of Morocco, 2007). Although some of the 
cannabis resin produced in Afghanistan is sold in Europe, 
it is likely that Morocco remains Europe’s main supplier 
of this drug. Cannabis resin from Morocco is typically 
smuggled into Europe via the Iberian peninsula and the 
Netherlands.
Seizures
In 2008, an estimated 6 563 tonnes of herbal cannabis 
and 1 637 tonnes of cannabis resin were seized 
worldwide (Table 2), an overall increase of about 17 % 
over the previous year (UNODC, 2010b). North America 
continued to account for the bulk of herbal cannabis 
seized (48 %), while quantities of resin seized remained 
concentrated in western and central Europe (57 %).
In Europe, an estimated 289 000 seizures of herbal 
cannabis, amounting to 92 tonnes, were made in 
2008 (45). The number of seizures increased by two and 
a half times between 2003 and 2008. The amount of 
herbal cannabis seized has remained relatively stable 
since 2003 at just above 90 tonnes, except for 2004–05 
when it decreased to about 65 tonnes (46). The United 
Kingdom has been accounting for approximately half 
of the total number of seizures, amounting to 20 tonnes 
or more per year in 2005–07. Turkey (31 tonnes) and 
Germany (9 tonnes) reported record seizures in 2008.
Seizures of cannabis resin in Europe exceed herbal 
cannabis seizures, both in number and amount seized (47). 
In 2008, about 369 000 seizures of cannabis resin were 
made, resulting in the interception of 900 tonnes of the 
drug — almost 10 times the quantity of herbal cannabis 
seized. Between 2003 and 2008, the number of cannabis 
resin seizures increased steadily, while the amount seized, 
after an initial decline, has been on the increase since 
2006. In 2008, about half of the total number of cannabis 
resin seizures and three quarters of the quantity seized 
continued to be reported by Spain, while record quantities 
of cannabis resin were seized by France (71 tonnes), 
Portugal (61 tonnes) and Italy (34 tonnes).
The number of seizures of cannabis plants has increased 
since 2003, reaching an estimated 19 000 cases in 2008. 
Countries report the quantity seized either as an estimate 
of the number of plants seized or by weight. The number 
of plants seized increased from 1.7 million in 2003 
to 2.6 million in 2007, before falling to 1.2 million in 
2008 (48). The weight of plants seized has increased by 
a factor of 4.5 over the period, to 43 tonnes in 2008, of 
which Spain reported 24 tonnes and Bulgaria 15 tonnes.
Potency and price
The potency of cannabis products is determined by their 
content of delta-9-tetrahydrocannabinol (THC), the primary 
active constituent. Cannabis potency varies widely 
between and within countries, and between different 
cannabis products. Information on cannabis potency is 
mostly based on forensic analysis of cannabis seized, 
selected on a sample basis. The extent to which the 
samples analysed reflect the overall market is unclear and, 
for this reason, data on potency should be interpreted with 
caution.
In 2008, the reported mean THC content of cannabis 
resin ranged from 3 % to 16 %. The mean potency of 
herbal cannabis (where possible excluding sinsemilla — 
the form of herbal cannabis with the highest potency) 
ranged from 1 % to 10 %. The mean potency of sinsemilla 
was reported by a few countries only: it was always 
higher than imported herbal cannabis, and ranged from 
12 % in Norway to just over 16 % in the Netherlands 
and the United Kingdom. Over the period 2003–08, the 
mean potency of cannabis resin has been diverging in the 
11 countries reporting sufficient data, while the potency of 
herbal cannabis increased in six reporting countries and 
decreased in four. Information on the potency of locally 
EMCDDA ‘Insights’: Cannabis production and 
markets in Europe
A new ‘Insight’ on cannabis production and markets will be 
published by the EMCDDA in 2011. The report will focus 
on the supply of cannabis products in European countries 
and examine the type of products available, their origins, 
their respective market shares and other issues related to 
distribution and market structures. Cannabis cultivation 
within European borders, which has become more visible 
in recent years, will receive special attention.
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(49) See Tables PPP-1 and PPP-5 in the 2010 statistical bulletin for potency and price data.
(50) See Figure GPS-1 in the 2010 statistical bulletin.
(51) See Table GPS-4 (part iii) and (part iv) in the 2010 statistical bulletin.
produced herbal cannabis over a number of years is 
available only for the Netherlands, where a decline in the 
mean potency of ‘nederwiet’ was observed, from a peak 
of 20 % in 2004 to 16 % in 2007 and 2008 (49).
The mean retail price of cannabis resin, in 2008, ranged 
from EUR 3 to EUR 10 per gram in the 17 countries 
providing information, with 12 of them reporting values 
between EUR 6 and EUR 9. The mean retail price of 
herbal cannabis ranged between EUR 3 and EUR 16 
per gram in the 16 countries supplying information, with 
10 of them reporting prices of between EUR 5 and EUR 9. 
For cannabis resin, the mean retail price declined or 
remained stable in all countries with data covering the 
period 2003–08 except Belgium and Austria, where it 
increased. Over the same period, the data available for 
herbal cannabis point to stable or increasing prices in 
Europe, with downward trends reported only in Hungary 
and Turkey.
Prevalence and patterns of use
Cannabis use among the general population
It is conservatively estimated that cannabis has been 
used at least once (lifetime prevalence) by about 
75.5 million Europeans, that is over one in five of all 
15- to 64-year-olds (see Table 3 for a summary of 
the data). Considerable differences exist between 
countries, with national prevalence figures varying from 
1.5 % to 38.6 %. For most of the countries, the prevalence 
estimates are in the range 10–30 %.
An estimated 23 million Europeans have used 
cannabis in the last year, or on average 6.8 % of all 
15- to 64-year-olds. Estimates of last month prevalence 
will include those using the drug more regularly, 
though not necessarily in a daily or intensive way. It is 
estimated that about 12.5 million Europeans used the 
drug in the last month, on average about 3.7 % of all 
15- to 64-year-olds.
Cannabis use among young adults
Cannabis use is largely concentrated among young 
people (15–34 years), with the highest prevalence 
of last year use generally being reported among 
15- to 24-year-olds. This is the case in all the reporting 
countries, with the exception of Portugal (50).
Population survey data suggest that, on average, 
31.6 % of young European adults (15–34 years) have 
ever used cannabis, while 12.6 % have used the drug in 
the last year and 6.9 % have used it in the last month. 
Still higher proportions of Europeans in the 15–24 age 
group are estimated to have used cannabis in the last 
year (16 %) or last month (8.4 %). National prevalence 
estimates of cannabis use vary widely between countries 
in all measures of prevalence. For example, estimates 
of last year prevalence of use among young adults in 
countries at the upper end of the scale are more than 
30 times those of the lowest-prevalence countries.
Cannabis use is generally higher among males than 
among females. For example, the ratio of males to 
females among young adults reporting use of cannabis 
in the last year ranges from 6.4:1 in Portugal to 1.4:1 in 
Bulgaria (51).
Cannabis use is particularly high among certain groups 
of young people, such as those frequently attending 
nightclubs, pubs and music events (Hoare, 2009). 
Targeted surveys recently conducted in electronic dance 
Revenues and profits from illicit cannabis 
cultivation
Estimates produced by police forces suggest that the 
cannabis plants seized in 2008 could have generated 
sales of EUR 70 million in Belgium and EUR 76 million in 
the United Kingdom (NPIA, 2009), and wholesale profits 
of between EUR 36 million and EUR 61 million in Germany. 
The total revenue generated by illicit commercial cannabis 
production is, however, difficult to assess as these figures 
refer only to intercepted cannabis plants. Estimating 
the profits also needs to take into account several other 
variables. 
The revenue provided by illicit commercial cannabis 
production is dependent on several factors including: the 
size of the plantation; the number of plants; the average 
yield per plant and the number of harvests per year. 
A high density of plants and frequent harvests generally 
decrease the yield obtained from each plant. The revenue 
generated also depends on whether the harvest is sold on 
retail or wholesale markets, since prices are usually higher 
on retail markets.
The costs associated with illicit commercial cannabis 
production in indoor plantations include: the premises; 
seed or plant stock; soil or mineral wool; nutrients; lights 
and pumps; tools and ventilation; and labour. Electricity, 
when it is not obtained illegally, is also a major element of 
production costs.
To calculate the revenue and profit from illicit cannabis 
plantations, Dutch law enforcement agencies have 
developed technical standards, which they update 
regularly. New methodologies are also under development 
in Belgium and the United Kingdom.
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music settings in the Czech Republic, Austria and the 
United Kingdom reported that over 80 % of respondents 
have ever used cannabis, a rate that is much higher than 
the European average among young adults (Measham 
and Moore, 2009).
Cannabis use among school students
The ESPAD survey, carried out every four years, provides 
comparable data on alcohol and drug use among 15- to 
16-year-old school students in Europe (Hibell et al., 2009). 
Table 3: Prevalence of cannabis use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year Last month
15–64 years
Estimated number of users in Europe 75.5 million 23 million 12.5 million
European average 22.5 % 6.8 % 3.7 %
Range 1.5–38.6 % 0.4–15.2 % 0.1–8.5 %
Lowest-prevalence countries Romania (1.5 %)
Malta (3.5 %)
Cyprus (6.6 %)
Bulgaria (7.3 %)
Romania (0.4 %)
Malta (0.8 %)
Greece (1.7 %)
Sweden (1.9 %)
Romania (0.1 %)
Malta, Sweden (0.5 %)
Greece, Poland (0.9 %)
Lithuania, Hungary (1.2 %)
Highest-prevalence countries Denmark (38.6 %)
Czech Republic (34.2 %)
Italy (32.0 %)
United Kingdom (31.1 %)
Czech Republic (15.2 %)
Italy (14.3 %)
Spain (10.1 %)
France (8.6 %)
Czech Republic (8.5 %)
Spain (7.1 %)
Italy (6.9 %)
France (4.8 %) 
15–34 years
Estimated number of users in Europe 42 million 17 million 9.5 million
European average 31.6 % 12.6 % 6.9 %
Range 2.9–53.3 % 0.9–28.2 % 0.3–16.7 % 
Lowest-prevalence countries Romania (2.9 %)
Malta (4.8 %)
Cyprus (9.9 %)
Greece (10.8 %)
Romania (0.9 %)
Malta (1.9 %)
Greece (3.2 %)
Cyprus (3.4 %)
Romania (0.3 %)
Sweden (1.0 %)
Greece (1.5 %)
Poland (1.9 %)
Highest-prevalence countries Czech Republic (53.3 %)
Denmark (48.0 %)
France (43.6 %)
United Kingdom (40.5 %)
Czech Republic (28.2 %) 
Italy (20.3 %)
Spain (18.8 %)
France (16.7 %)
Czech Republic (16.7 %)
Spain (13.4 %)
Italy (9.9 %)
France (9.8 %)
15–24 years
Estimated number of users in Europe 19.5 million 10 million 5.5 million
European average 30.9 % 16.0 % 8.4 %
Range 3.7–58.6 % 1.5–37.3 % 0.5–22.4 %
Lowest-prevalence countries Romania (3.7 %)
Malta (4.9 %)
Cyprus (6.9 %)
Greece (9.0 %)
Romania (1.5 %)
Greece, Cyprus (3.6 %)
Sweden (4.9 %)
Portugal (6.6 %)
Romania (0.5 %)
Greece, Sweden (1.2 %)
Cyprus (2.0 %)
Poland (2.5 %)
Highest-prevalence countries Czech Republic (58.6 %)
France (42.0 %)
Denmark (41.1 %)
Germany (39.0 %)
Czech Republic (37.3 %)
Spain (24.1 %)
Italy (22.3 %)
France (21.7 %)
Czech Republic (22.4 %)
Spain (16.9 %)
France (12.7 %)
Italy (11.0 %)
European prevalence estimates are based on weighted averages from the most recent national surveys conducted from 2001 to 2008/09 (mainly 2004–08), and therefore 
cannot be attached to a single year. The average prevalence for Europe was computed by a weighted average according to the population of the relevant age group in each 
country. In countries for which no information was available, the average EU prevalence was imputed. Populations used as basis: 15–64 (334 million), 15–34 (133 million) and 
15–24 (63 million). The data summarised here are available under ‘General population surveys’ in the 2010 statistical bulletin.
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(52) See Table EYE-20 (part ii) and (part iii) in the 2010 statistical bulletin.
(53) See Figure EYE-1 (part xii) in the 2010 statistical bulletin.
In 2007, the survey was conducted in 25 EU Member 
States as well as Norway and Croatia. In addition, in 
2008, national school surveys were carried out by Spain, 
Italy, Sweden and the United Kingdom, and Belgium 
(Flemish Community) conducted a regional school survey.
The data from the 2007 ESPAD and 2008 national school 
surveys reveal that the highest lifetime prevalence of 
cannabis use among 15- to 16-year-old school students is 
in the Czech Republic (45 %), while Estonia, France, the 
Netherlands, Slovakia and the United Kingdom report 
prevalence levels ranging from 26 % to 32 %. Lifetime 
prevalence levels of cannabis use of between 13 % and 
25 % are reported by 15 countries. The lowest levels (less 
than 10 %) are reported in Greece, Cyprus, Romania, 
Finland, Sweden and Norway. The gender gap in 
cannabis use is less marked among school students than 
among young adults. Male to female ratios for cannabis 
use among school students range from close to unity in 
Spain and the United Kingdom to 2:1 or higher in Cyprus, 
Greece, Poland and Romania (52).
International comparisons
European figures can be compared with those from other 
parts of the world. For instance, in Canada (2008) lifetime 
prevalence of cannabis use among young adults is 53.8 % 
and last year prevalence is 24.1 %. In the United States, 
SAMHSA (2008) estimated a lifetime prevalence of 
cannabis use of 49 % (16–34 years, recalculated by the 
EMCDDA) and a last year prevalence of 21.5 %, while 
in Australia (2007) the figures are 47 % and 16 % for 
the 14- to 39-year-olds. All these figures are above the 
European averages, which are respectively 31.6 % and 
12.6 %.
Among school students, the Czech Republic, Spain, 
France and Slovakia report levels of lifetime prevalence of 
cannabis use that are comparable to those reported in the 
United States and Australia (53).
Trends in cannabis use
During the period 1998–2008, for the 15 countries that 
are able to provide sufficient data, three major trends can 
be observed in cannabis use among adults (Figure 4). Five 
countries (Bulgaria, Greece, Hungary, Finland, Sweden) 
have reported low (under 9 %) and relatively stable 
prevalence levels for last year cannabis use among young 
adults. Six countries (Denmark, Germany, Spain, France, 
Netherlands, United Kingdom) reported higher prevalence 
levels, but at stable or decreasing levels in recent years. 
Four other countries (Czech Republic, Estonia, Italy, 
Slovakia) also reported higher levels of cannabis use among 
young adults, but with increasing trends in recent years.
When looking at more recent trends in cannabis use among 
young adults, of the 12 countries with repeated surveys 
during the period 2003–08, the majority report a stable 
situation (Denmark, Germany, Spain, Hungary, Sweden, 
Finland, United Kingdom). Five countries report increased 
cannabis use over this period, of at least two percentage 
points in Bulgaria, Estonia and Slovakia, and about eight 
percentage points in the Czech Republic and Italy.
Figure 4: Trends in last year prevalence of cannabis use among 
young adults (aged 15–34)
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reports or scientific articles.
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(54) See Figure EYE-1 (part xii) in the 2010 statistical bulletin.
(55) See Figure GPS-2 in the 2010 statistical bulletin.
(56) The European averages are an estimation based on a weighted average (for the population) for countries with information, and imputed for 
countries without information. The figures obtained are 1.2 % for all adults (15–64 years) and 2.3 % for young adults (15–34 years). See Table 
GPS-10 in the 2010 statistical bulletin.
(57) See the box ‘Risk factors for cannabis initiation and dependence’.
Similar patterns are found across Europe in the time trends 
in cannabis use among school students between 1995 and 
2007 (EMCDDA, 2009a). Seven countries, located mainly 
in northern or southern Europe (Greece, Cyprus, Malta, 
Romania, Finland, Sweden, Norway), report overall stable 
and low lifetime prevalence of cannabis use during the 
whole period. Most west European countries, as well 
as Croatia and Slovenia, which had high or strongly 
increasing lifetime cannabis use prevalence up until 2003, 
have seen a decrease or stabilisation in 2007. Among 
these 11 countries, nine report a decrease and two 
a stable situation. The picture is different in most of central 
and eastern Europe, where the increasing trend observed 
between 1995 and 2003 appears to be levelling out. In 
this region, six countries report a stable situation and two 
report an increase between 2003 and 2007.
Three countries that conducted school surveys in 2008 
(Belgium (Flemish Community), Sweden and United 
Kingdom) report stable or lower lifetime prevalence of 
cannabis use than reported in 2007, while Spain reports 
a decrease of more than three percentage points. School 
survey data from the United States and Australia also 
indicate a decreasing trend, which was first observed in 
Australia in 1999 (54).
Patterns of cannabis use
Available data point to a variety of patterns of cannabis 
use, ranging from experimental use to dependent use. 
Many individuals use the substance only once or twice, 
while others use it occasionally or during a limited period 
of time. Of those aged 15–64 who have ever used 
cannabis, 30 % have done so during the last year (55). 
Among those who have used the drug in the last year, on 
average, half have done so in the last month.
Data from a sample of 13 European countries, accounting 
for 77 % of the adult population of the European Union and 
Norway, show that of the estimated 12.5 million Europeans 
who used cannabis in the past month, about 40 % may 
have consumed the drug on one to three days during that 
month, about one third on four to 19 days and one quarter 
on 20 days or more. From these data it can be estimated 
that over 1 % of European adults, about 4 million, are using 
cannabis daily or almost daily. Most of these cannabis 
users, about 3 million, are aged between 15 and 34 years, 
representing approximately 2–2.5 % of Europeans in this 
age group (56). Daily or almost daily cannabis use may be 
about four times more prevalent in males than in females.
Ten European countries reporting data to the ESPAD study 
among 15- to 16-year-old school students report relatively 
high proportions (5–12 %) of male students having used 
cannabis on 40 or more occasions. This proportion was at 
least double that found among the female students. Most 
of these countries also reported that between 5 % and 
9 % of the respondents had initiated cannabis use at age 
13 or younger. This group is of concern, as early onset of 
use has been associated with the development in later life 
of intensive and problematic forms of drug consumption.
Dependence is increasingly recognised as a possible 
consequence of regular cannabis use, even among 
younger users (57). However, the severity and 
consequences of cannabis dependence may appear less 
serious than those commonly associated with some other 
Risk factors for cannabis initiation and 
dependence
Researchers have tried to find out why some cannabis 
users become dependent while others do not. One of their 
findings is that factors related to initiation of cannabis use 
are often different from those that lead to problematic use 
and cannabis dependence. Some external factors (peers’ 
drug use and cannabis availability) and factors related 
to the individual (e.g. a positive attitude toward future 
drug use) are associated specifically with cannabis use 
initiation (Von Sydow et al., 2002). Some other factors 
are associated, with different strengths, both to cannabis 
initiation and to cannabis dependence. These include 
genetic factors (Agrawal and Lynskey, 2006), individual 
factors such as male gender, mental health disorders and 
other substance use (alcohol, tobacco and other). Familial 
factors such as having a poor relationship with mother and 
growing up without both parents are also associated with 
cannabis initiation, while parental divorce or separation 
and parental death before age 15 are associated with 
cannabis dependence (Coffey et al., 2003; Swift et al., 
2008; Von Sydow, 2002).
Factors specifically associated with progression to 
dependence include intensive or risky patterns of cannabis 
use, persistent use and early onset. Individuals who 
experienced positive effects (e.g. happiness, laughter) 
of their early cannabis use (at age 14–16) had an 
increased risk of cannabis dependence later in life. 
Also associated with the progression to dependence are 
various psychological and mental health factors (including 
low self-esteem, low self-control and coping skills) and 
socioeconomic factors (including low socioeconomic status 
and bad financial situation) (Coffey et al., 2003; Fergusson 
et al., 2003; Swift et al., 2008; Von Sydow, 2002).
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(58) See the box ‘Adverse health effects of cannabis use’.
(59) See Figure TDI-2 (part ii) and Tables TDI-5 (part ii) and TDI-24 in the 2010 statistical bulletin.
(60) See Table TDI-22 (part i) in the 2010 statistical bulletin.
(61) See Figure TDI-1 and Table TDI-3 (part iv) in the 2010 statistical bulletin.
(62) See Tables TDI-10 (part iii) and (part iv) and TDI-21 (part ii) in the 2010 statistical bulletin.
psychoactive substances (e.g. heroin or cocaine). The 
development of cannabis dependence might also be more 
gradual than that found with some other drugs (Wagner 
and Anthony, 2002). It has been reported that half of 
dependent cannabis users who stopped using the drug 
were able to do so without treatment (Cunningham, 2000). 
Nonetheless, some cannabis users — particularly heavy 
users — can experience problems without necessarily 
fulfilling the clinical criteria for dependence (58).
Cannabis use has been correlated with membership 
of a vulnerable or socially disadvantaged group, such 
as with early school leavers, ‘truants’, children in care 
institutions, young offenders and young people living 
in economically deprived neighbourhoods (EMCDDA, 
2008c). It can also be associated with the use of other 
substances. For example, young adults (aged 15–34) who 
reported frequent or heavy alcohol use in the past year 
were between two and six times more likely to report the 
use of cannabis compared to the general population. 
And, although most cannabis users do not use other illicit 
drugs, they are more likely to do so than the general 
population. Adolescent cannabis users also report two 
to three times higher prevalence of tobacco smoking 
compared to the general 15- to 16-year-old school 
population.
Some cannabis users engage in more risky patterns of 
use, such as using cannabis with very high THC content or 
in large amounts, and inhaling from a water pipe (‘bong’) 
instead of a ‘joint’. These users generally report more 
health problems, including dependence (Chabrol et al., 
2003; Swift et al., 1998).
Treatment
Treatment demand
Cannabis was the primary drug in about 21 % of all 
treatment entries (about 85 000 clients) reported by 
27 countries in 2008, making it the second most reported 
drug after heroin. Primary cannabis users account for 
less than 5 % of treatment entrants in Bulgaria, Estonia, 
Lithuania, Luxembourg and Slovenia, and more than 
30 % in Denmark, Germany, France, Hungary and the 
Netherlands, with most cannabis clients entering treatment 
in outpatient settings (59).
These differences may be explained by the prevalence 
of use of cannabis and other drugs, drug treatment 
needs, treatment provision and organisation or referrals 
practices. In one of the two countries with the largest 
proportions of cannabis clients, counselling centres target 
young drug users (France), while in the other (Hungary) 
cannabis offenders are offered drug treatment as an 
alternative to punishment. The criminal justice system 
plays a substantial role in treatment referral in both of 
these countries but, overall, Member States report that 
most cannabis users entering treatment in Europe do 
it on their own initiative. Some users might also enter 
drug treatment because they have other underlying 
conditions, such as mental health problems, and cannot 
find appropriate treatment elsewhere (Zachrisson et al., 
2006).
Many cannabis clients report the use of alcohol or 
other drugs. Based on a data collection in 14 countries, 
65 % of them take another drug, mostly alcohol or cocaine, 
and some report the use of both alcohol and cocaine 
(EMCDDA, 2009d). Cannabis is reported as a secondary 
drug by 24 % of all outpatient drug clients (60).
Trends in new demands for drug treatment
In the 18 countries for which data are available, the 
number of primary cannabis users among those entering 
treatment for the first time in their life increased from about 
23 000 to 35 000 between 2003 and 2007, before 
slightly decreasing to about 33 000 in 2008. Starting 
in 2005 and 2006, 13 countries have reported decreases 
in new cannabis clients (61). This might reflect recent 
declining trends in cannabis use, but could also be linked 
with service capacity saturation or use of other services 
(e.g. primary and mental healthcare).
Client profiles
Clients entering outpatient treatment for primary cannabis 
use in Europe are mainly young males, with a male to 
female ratio of 5:1 and a mean age of 25 years. Among 
drug users entering outpatient treatment for the first 
time, primary cannabis use is reported by 69 % of those 
aged 15–19 years and by 83 % of those younger than 
15 years (62).
Overall, 22 % of primary cannabis users entering 
outpatient treatment are occasional users (or have not 
used it the month before entering treatment), probably 
often referred by the criminal justice system; 11 % use 
cannabis weekly or less often; about 17 % use it two 
to six times a week; and 50 % are daily users, the most 
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(63) See Tables TDI-18 (part ii) and TDI-111 (part viii) in the 2010 statistical bulletin.
problematic group. Considerable differences are observed 
between countries. In Hungary, Romania and Croatia 
more than half of cannabis clients are occasional users, 
while in Belgium, Bulgaria, Denmark, Ireland, Spain, 
France, Malta and the Netherlands more than 50 % are 
daily users (63).
Treatment provision
Cannabis treatment in Europe covers a wide range of 
measures, including Internet-based treatment, counselling, 
structured psychosocial interventions and treatment in 
residential settings. There is also a frequent overlap in this 
field between selective prevention, harm reduction and 
treatment interventions (see Chapter 2).
In France, the network of youth counselling centres, also 
known as cannabis clinics, provides users with services 
varying in duration and approach depending on the 
severity of drug use. In a study carried out in 226 of the 
274 counselling centres in 2007, 47 % of outpatients were 
diagnosed as occasional users showing no symptoms of 
dependence or abuse, and about 30 % of these received 
no further counselling (Obradovic, 2009). In contrast, 
among the 53 % diagnosed with dependence or abuse at 
admission, nearly 80 % were offered further counselling, 
and most others were referred to treatment centres. Half of 
the clients attending a second counselling session reported 
a reduction in their cannabis use. This was more often 
the case among self-referred users and those referred by 
health professionals, while those referred by the criminal 
justice system were more likely to drop out after a few 
sessions.
As an alternative to criminal prosecution, the criminal 
justice system in Hungary refers eligible drug offenders 
to a ‘preventive counselling service’, and the more severe 
cases to specialist treatment facilities. Users referred by 
the criminal justice system, about 85 % of all cannabis 
clients, must take part in drug treatment or psychosocial 
counselling at least once a fortnight for six months, to 
obtain a discharge certificate. Otherwise, they may face 
criminal prosecution.
Germany, the Netherlands and the United Kingdom 
offer Internet-based cannabis treatment in order to 
facilitate treatment access to users who are reluctant to 
seek help within the specialist drug treatment system. 
Online treatment interventions include either a self-help 
programme without contact to counsellors or a structured 
programme with scheduled contacts (see EMCDDA, 
2009b). A quality label and guidelines in this field are 
now being developed in the Netherlands.
The Netherlands also reports the evaluation of a novel 
family motivational intervention for cannabis users 
with recent onset of schizophrenia. This intervention 
aims at reducing cannabis use, increasing medication 
compliance and improving parent–child relations among 
this group. Preliminary results, after three months, show 
a significant reduction in cannabis use compared to usual 
psychoeducation, while the other outcome variables did 
not differ.
Recent studies on treatment of cannabis users
Relatively few studies have assessed the effectiveness 
of targeted interventions for cannabis users (Levin and 
Kleber, 2008), despite the increase in the number of 
treatment demands. Research has been conducted into 
both pharmacotherapeutic and psychosocial interventions, 
but the results are not conclusive.
A recently published randomised controlled trial assessed 
the effectiveness of motivational interviewing compared 
Adverse health effects of cannabis use
Several recent reviews have looked into the adverse health 
effects associated with cannabis use (EMCDDA, 2008a; 
Hall and Degenhardt, 2009). These include acute effects 
such as anxiety, panic reaction and psychotic symptoms, 
which are often reported by first-time users. Such effects 
account for a substantial number of drug-related hospital 
emergencies demands in the few countries that monitor 
them. Cannabis use also appears to increase the risk of 
being involved in a traffic accident by two to three times 
(EMCDDA, 2008b).
Cannabis use can also have chronic effects which may 
be directly linked with the patterns of use (frequency and 
quantities). These include cannabis dependence but also 
chronic bronchitis and other respiratory diseases. Cannabis 
use during pregnancy could reduce birth weight, but 
does not seem to cause birth defects. The association of 
cannabis use with depression and suicide is still uncertain.
The impact of cannabis on cognitive performance, and 
its reversibility, remains unclear. Regular cannabis use in 
adolescence might adversely affect mental health in young 
adults, with evidence of an increased risk of psychotic 
symptoms and disorders that increase with frequency of 
use (Hall and Degenhardt, 2009; Moore et al., 2007).
While the individual risk related to cannabis use seems 
lower than for heroin or cocaine, health problems do exist 
and, due to high prevalence of use, the impact of cannabis 
on public health may be significant. Particular attention 
should be given to cannabis use by adolescents and 
people with mental health problems. Frequent cannabis 
use, use over longer periods and use when driving or 
during other potentially dangerous activities are other 
matters of concern.
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to drug information and counselling, and found no 
significant differences in cannabis use (McCambridge 
et al., 2008). It also found that practitioner effects 
might influence cannabis cessation rates, thereby 
limiting the transferability of the interventions. European 
studies in this area are assessing the effectiveness of 
multidimensional family therapy (Incant), motivational 
enhancement, cognitive-behavioural therapy and 
psychosocial problem solving (Candis) and Internet-
based treatment.
Two studies have recently been published on the 
pharmacotherapy of cannabis dependence, neither of 
which reported significant results. In the Netherlands, 
a randomised controlled trial compared the effects of 
a serotonin uptake inhibitor (olanzapine) and a dopamine 
antagonist (risperidone) on patients with psychotic 
comorbidity (van Nimwegen et al., 2008). In the United 
States, a preliminary study compared the effects of an 
antidepressant (nefazodone), a dopamine uptake inhibitor 
(sustained release bupropion) and a placebo on use and 
withdrawal symptoms among cannabis users (Carpenter 
et al., 2009).
Putting science into practice in drug treatment
Drug treatment has often been slow in adopting 
scientifically tested methods in its clinical practice. The 
limited provision of opioid substitution treatment in several 
European countries and the rare use of contingency 
management for the treatment of cocaine dependence 
are examples of this gap between science and practice. 
Among the reasons put forward to explain this are: 
individual allegiances to particular treatment models; lack 
of training or funding; inefficient knowledge dissemination; 
and lack of organisational readiness and support for new 
practices (Miller et al., 2006).
To overcome these barriers, a conference was organised 
recently in Germany to examine the transfer of experimental 
cannabis treatment projects with evidence of efficacy into 
clinical practice (Kipke et al., 2009). The projects reviewed 
included ‘Candis’, ‘Quit the shit’ and ‘FreD’, all of which 
have been described in earlier EMCDDA publications. 
The conference found that the programme characteristics 
that facilitated transfer into clinical practice included: 
compatibility with existing treatment offers; clear, structured 
protocols; seminars for specialists; and platforms to 
exchange experience. The main obstacles identified were 
problems in cooperation management, for example with 
external partners (such as the police) and lack of funding 
beyond the experimental stage.
Transferability aspects should be integrated into the initial 
planning of experimental interventions. The wider adoption 
of interventions with strong or long-standing empirical 
evidence requires the commitment of all stakeholders.
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Introduction
Amphetamines (a generic term that includes both 
amphetamine and methamphetamine) and ecstasy are 
among the most commonly used illicit drugs in Europe. 
In terms of the absolute numbers, cocaine use may be 
higher, but its geographic concentration means that 
in many countries, after cannabis, the second most 
commonly used illicit substance is either ecstasy or 
amphetamines. Moreover, in some countries, use of 
amphetamines constitutes an important part of the drug 
problem, accounting for a substantial proportion of those 
in need of treatment.
Amphetamine and methamphetamine are central nervous 
system stimulants. Of the two drugs, amphetamine is by 
far the more commonly available in Europe, whereas 
significant methamphetamine use appeared to be 
restricted to the Czech Republic and Slovakia until 
recently, with some countries in the north of Europe now 
reporting the increased presence of this drug on their 
amphetamines markets.
Ecstasy refers to synthetic substances that are chemically 
related to amphetamines, but which differ to some extent 
in their effects. The best-known member of the ecstasy 
group of drugs is 3,4-methylenedioxy-methamphetamine 
(MDMA), but other analogues are also sometimes 
found in ecstasy tablets (MDA, MDEA). Ecstasy use 
was virtually unknown in Europe before the late 1980s 
but increased rapidly during the 1990s. The drug’s 
popularity has historically been linked with the dance 
music scene and, in general, synthetic drug use is 
associated with particular cultural subgroups or social 
settings and increasingly with heavy episodic use of 
alcohol.
The most widely known synthetic hallucinogenic drug in 
Europe is lysergic acid diethylamide (LSD), consumption 
of which has been low and somewhat stable for 
a considerable time. In recent years, there appears to 
have been a growing interest among young people in 
naturally occurring hallucinogens such as those found in 
hallucinogenic mushrooms.
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Table 4: Production, seizures, price and purity of amphetamine, methamphetamine, ecstasy and LSD
Amphetamine Methamphetamine Ecstasy LSD
Global production estimate 
(tonnes) (1)
197–624 (2) 57–136 n.a.
Global quantities seized (tonnes) 23.0 17.9 2.3 0.1
Quantity seized 
EU and Norway  
(Including Croatia and Turkey)
8.3 tonnes
(8.4 tonnes)
300 kilograms
(300 kilograms)
Tablets
12.7 million
(13.7 million)
Units
141 100
(141 800)
Number of seizures 
EU and Norway 
(Including Croatia and Turkey)
37 000
(37 500)
4 700
(4 700)
18 500
(19 100)
950
(960)
Mean retail price (EUR) 
Range 
(Interquartile range) (3)
Gram
6–36
(9–19)
Gram
12–126
Tablet
2–19
(4–9)
Dose
4–30
(7–12)
Range of mean purity or MDMA 
content
3–34 % 22–80 % 17–95 mg n.a.
(1) Figures for production are based on estimates of consumption and seizure data.
(2) Only aggregate estimates of amphetamine and methamphetamine global production are available.
(3) Range of the middle half of the reported mean prices.
NB: All data are for 2008; n.a., not available.
Sources: UNODC (2010b) for global values, Reitox national focal points for European data.
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(64) This analysis is preliminary, as data for the United Kingdom are not yet available for 2008.
(65) The data on European drug seizures mentioned in this chapter can be found in Tables SZR-11 to SZR-18 in the 2010 statistical bulletin.
(66) The data on European drug purities mentioned in this chapter can be found in Table PPP-8 in the 2010 statistical bulletin.
(67) The data on European drug prices mentioned in this chapter can be found in Table PPP-4 in the 2010 statistical bulletin.
Supply and availability
Synthetic drug precursors
Law enforcement efforts target the controlled chemicals 
necessary for illicit drug production, and this area is 
one in which international cooperation is particularly 
valuable. ‘Project Prism’ is an international initiative to 
prevent the diversion of precursor chemicals used in the 
illicit manufacture of synthetic drugs, through a system of 
pre-export notifications for licit trade and the reporting of 
shipments stopped and seizures made when suspicious 
transactions occur. Information on activities in this area 
is reported to the International Narcotics Control Board 
(INCB, 2010a).
The INCB reports reductions in 2008 in world seizures 
of two key precursors of methamphetamine; ephedrine 
with 12.6 tonnes (compared to 22.7 tonnes in 2007 
and 10.3 tonnes in 2006), and pseudoephedrine 
with 5.1 tonnes (compared to 25 tonnes in 2007 and 
0.7 tonnes in 2006). EU Member States (mainly the 
Netherlands and the United Kingdom) accounted for 
0.3 tonnes of ephedrine, about half the amount seized the 
year before, and for over 0.5 tonnes of pseudoephedrine, 
almost all in France.
By contrast, global seizures of 1-phenyl-2-propanone (P2P, 
BMK), which can be used for the illicit manufacture of both 
amphetamine and methamphetamine, increased sharply 
from 834 litres in 2007 to 5 620 litres in 2008. Seizures 
of P2P in the European Union amounted to 2 757 litres, 
compared to 773 litres in 2007.
In 2008, there were no reported seizures of 
3,4-methylenedioxyphenyl-2-propanone (3,4-MDP2P, 
PMK), used to manufacture MDMA, in contrast to global 
seizures of 2 297 and 8 816 litres in 2007 and 2006, 
respectively. World seizures of safrole, which may 
replace 3,4-MDP2P in the synthesis of MDMA, fell to 
1 904 litres from a peak of 45 986 litres in 2007. Most 
of the safrole confiscations in 2008 were made in the 
European Union.
Amphetamine
Global amphetamine production remains concentrated 
in Europe, which accounted for more than 80 % of all 
amphetamine laboratories reported in 2008 (UNODC, 
2010b). Global seizures of amphetamine remained 
broadly stable in 2008, amounting to about 23 tonnes (see 
Table 4). Of this, over a third was seized in western and 
central Europe, reflecting Europe’s role as both a major 
producer and consumer of this drug (UNODC, 2010b).
Most amphetamine seized in Europe is produced, in 
order of importance, in the Netherlands, Poland and 
Belgium, and to a lesser extent in Estonia, Lithuania 
and the United Kingdom. In 2007, 29 sites involved in 
the production, tableting or storage of amphetamine 
were discovered in the European Union and reported to 
Europol. 
In 2008, an estimated 37 500 seizures amounting 
to 8.3 tonnes of amphetamine powder were made in 
Europe (64). The number of amphetamine seizures has 
been fluctuating around a stable trend for the last five 
years, although compared to 2003 they remained at 
higher levels, while quantities have increased over 
2003–08 (65).
The purity of amphetamine samples intercepted in 
Europe in 2008 varied widely, and any comment on 
average values must be made with caution. Nevertheless, 
mean purity of samples ranged from less than 10 % in 
Denmark, Austria, Portugal, Slovenia, the United Kingdom, 
Croatia and Turkey to greater than 25 % in Latvia, the 
Netherlands, Poland and Norway. Over the past five 
years, the purity of amphetamine has been falling or 
stable in most of the 17 countries where sufficient data are 
available to allow analysis of trends (66).
In 2008, the mean retail price of amphetamine ranged 
between EUR 9 and EUR 20 a gram for over half of 
the 17 reporting countries. Amphetamine retail prices 
decreased or remained stable in all 13 countries 
reporting data over 2003–08, except in Spain where 
they dropped to a record low in 2008 after increases in 
previous years (67).
Amphetamine production in Europe
In 2009, the EMCDDA and Europol launched a series 
of publications on the supply of illicit drugs in Europe. 
Following reports on methamphetamine and cocaine, 
the third report in the series published in 2010 provides 
a comprehensive overview of amphetamine production and 
trafficking issues, and reviews the responses at European 
and international levels. Reports on the supply of other 
drugs in Europe, including ecstasy and heroin, will be 
added to the series in the coming years.
The report is available in print and online on the EMCDDA 
website in English only.
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(68) This analysis is preliminary, as data for the Netherlands and the United Kingdom are not yet available for 2008.
Methamphetamine
The number of methamphetamine laboratories reported 
worldwide increased by 29 % in 2008. The strongest 
increase was registered in North America, but reports 
of clandestine laboratories also increased in east 
and south-east Asia. In addition, increased activity 
related to methamphetamine production was reported 
in Latin America and Oceania. In 2008, 17.9 tonnes 
of methamphetamine was seized, continuing a stable 
trend since 2004. Most of the drug was seized in 
east and south-east Asia (notably China), followed by 
North America (UNODC, 2010b).
Illicit production of methamphetamine in Europe 
is largely limited to the Czech Republic, where 
458 production sites were detected in 2008 (Figure 5). 
This is the highest number of methamphetamine ‘kitchen 
laboratories’ yet reported by the Czech Republic. 
Seizures of precursor chemicals also increased in 2008. 
Production of the drug is also reported in Lithuania, 
Poland and Slovakia.
In 2008, almost 4 700 seizures of methamphetamine, 
amounting to approximately 300 kg of the drug, were 
reported in Europe. Between 2003 and 2008, the number 
of methamphetamine seizures steadily increased. Over 
the same period, quantities seized increased to a record 
in 2007 and decreased slightly in 2008, mainly due to 
a decline in the amount recovered in Norway, the main 
seizing country in Europe for this drug.
Ecstasy
Global production of ecstasy in 2008 is estimated at 
between 57 and 136 tonnes (UNODC, 2010b). The 
manufacture of the drug appears to have continued 
to spread geographically, with manufacture occurring 
closer to consumer markets in east and south-east Asia, 
North America and Oceania. Despite this, western and 
central Europe remain the main location for ecstasy 
production, with it concentrated in the Netherlands and 
Belgium.
Worldwide, seizures of ecstasy fell to a very low level in 
2008 (2.3 tonnes) (UNODC, 2010b). In west and central 
Europe, reported seizures fell from 1.5 tonnes in 2007 to 
0.3 tonnes in 2008.
More than 19 100 seizures were reported in Europe 
in 2008, resulting in the interception of an estimated 
13.7 million ecstasy tablets. However, this is a preliminary 
assessment as data for 2008 were not available for the 
Netherlands and the United Kingdom, which reported 
combined seizures of 18.4 million tablets in 2007.
The number of ecstasy seizures reported in Europe has 
been slightly declining, after a stabilisation between 
2003 and 2006, while quantities seized declined overall 
between 2003 and 2008 (68).
In Europe, most ecstasy tablets analysed in 2008 
contained MDMA or another ecstasy-like substance 
(MDEA, MDA) as the only psychoactive substance 
present, with 19 countries reporting that this was 
the case in over 60 % of all tablets analysed. Seven 
countries now report lower proportions of ecstasy tablets 
with MDMA or its analogues (Spain, Cyprus, Latvia, 
Luxembourg, Slovenia, United Kingdom, Croatia). Some 
countries report that mCPP, a drug which is not controlled 
Figure 5: Illicit drug facilities dismantled in the European Union as 
reported to Europol
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NB: Based on data reported to Europol by 11 EU Member States. Drug 
type is denoted by colour, with the number of facilities reported 
in the country indicated. Facilities handling the combinations 
amphetamine and methamphetamine or amphetamine and 
ecstasy are denoted by two-colour symbols. Facilities handling 
other synthetic drugs or combinations are labelled ‘other’. Also 
indicated are facilities for which the substances are unknown. 
The facilities reported included production, tableting and storage 
units, which are not distinguished here. All reported cocaine 
facilities were involved in transformation or secondary extraction 
of the drug.
Source: Europol.
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(69) This analysis is preliminary, as data for the United Kingdom are not yet available for 2008.
(70) See Table EYE-11 in the 2010 statistical bulletin.
(71) See Tables TDI-5 (part ii) and TDI-22 in the 2010 statistical bulletin.
under the international drug conventions, was found in 
a substantial proportion of the ecstasy tablets analysed 
(see Chapter 8).
The typical MDMA content of ecstasy tablets tested in 
2008 was between 5 and 72 mg in the 11 countries 
providing data. In addition, high-dose ecstasy tablets 
containing over 130 mg of MDMA were reported by 
several countries (Belgium, Bulgaria, Germany, Estonia, 
Latvia, Netherlands, Slovakia, Norway). There are no 
clear trends in the MDMA content of ecstasy tablets.
Ecstasy is now considerably cheaper than it was in the 
1990s, when it first became widely available. While 
there are some reports of tablets being sold for less than 
EUR 2, most countries are reporting mean retail prices in 
the range of EUR 4–10 per tablet. The data available for 
2003–08 suggest that the retail price of ecstasy, adjusted 
for inflation, has continued to fall in Europe.
Hallucinogenic substances
Use and trafficking of LSD in Europe is still considered 
marginal. The number of LSD seizures increased between 
2003 and 2008, while quantities, after a peak in 2005 
due to record seizures in the United Kingdom, have been 
fluctuating at much lower levels over the period (69). 
LSD retail prices (adjusted for inflation) remained stable 
or slightly decreased in eight countries since 2003, while 
increases were reported in Belgium and Sweden. In 2008, 
the mean price was between EUR 5 and EUR 12 per unit 
for the majority of the 13 reporting countries.
Prevalence and patterns of use
Relatively high levels of amphetamines or ecstasy use 
among the general population are reported by some 
EU Member States (Czech Republic, Estonia, United 
Kingdom). In a few countries, the use of amphetamine 
or methamphetamine, often by injection, accounts for 
a substantial proportion of the overall number of problem 
drug users and those seeking help for drug problems. 
In contrast to these chronic user populations, a more 
general association exists between the use of synthetic 
drugs, ecstasy in particular, and nightclubs and dance 
events. This results in significantly higher levels of use 
being reported among young people, and exceedingly 
high levels of use being found in some settings or 
specific subpopulations. The overall consumption levels 
of hallucinogenic drugs such as LSD and hallucinogenic 
mushrooms are generally low and have been largely 
stable in recent years.
Amphetamines
Drug prevalence estimates suggest that about 12 million 
Europeans have tried amphetamines, and about 2 million 
have used the drug during the last year (see Table 5 for 
a summary of the data).
Among young adults (15–34 years), lifetime prevalence of 
amphetamines use varies considerably between countries, 
from 0.1 % to 15.4 %, with a weighted European average 
of 5.2 %. Last year use of amphetamines in this age 
group ranges from 0.1 % to 3.2 %, with most countries 
reporting prevalence levels of 0.5–2.0 %. It is estimated 
that about 1.5 million (1.2 %) young Europeans have used 
amphetamines during the last year.
Among 15- to 16-year-old school students, lifetime 
prevalence of amphetamines use ranged from 1 % to 
8 % in the 26 EU Member States, Norway and Croatia, 
surveyed in 2007, though prevalence levels of more than 
5 % were reported only for Bulgaria, Latvia (both 6 %) 
and Austria (8 %). The five countries that conducted 
school surveys in 2008 (Belgium (Flemish Community), 
Spain, Italy, Sweden, United Kingdom) reported lifetime 
prevalence of amphetamines of 3 % or less (70).
Problem amphetamine use
The EMCDDA indicator on problem drug use can be 
applied to amphetamine use, where it defines as such 
the injecting or long duration and/or regular use of the 
substance. Finland has provided the most recent national 
estimate of problem amphetamine users, estimated at 
between 12 000 and 22 000 in 2005, which is about 
four times the estimated number of problem opioid users in 
the country.
The proportion of drug users that reported entering 
treatment for use of amphetamine as the primary drug 
is relatively small (less than 5 %), in most European 
countries (18 out of 27 reporting countries), but accounts 
for a sizeable proportion of reported treatment entries 
in Sweden (32 %), Finland (20 %) and Latvia (15 %). 
Five other countries (Belgium, Denmark, Germany, 
Hungary, Netherlands) report between 6 % and 10 % of 
treatment entries from clients citing amphetamine as their 
primary drug; elsewhere the proportion is less than 5 %. 
Amphetamine is also reported as a secondary drug by 
other treatment clients (71).
Amphetamine users entering treatment are, on average, 
about 30 years old, with inpatients being younger 
(28 years). The male to female ratio among amphetamine 
clients (2:1) is lower than that for any other illicit drug. 
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(72) See Tables TDI-5 (part iv) and TDI-37 in the 2010 statistical bulletin.
(73) See the 2010 ‘Selected issue’ on problem amphetamine and methamphetamine use for a full analysis.
The Czech Republic, Estonia, Latvia, Lithuania, Sweden 
and Finland all report relatively high levels of injecting 
among primary amphetamine clients, ranging from 57 % 
to 82 % (72).
Trends in amphetamine users entering treatment between 
2003 and 2008 have remained broadly stable in most 
countries (73).
Problem methamphetamine use
In contrast to other parts of the world, where the use 
of methamphetamine has increased in recent years, 
levels of use in Europe appear limited. Historically, use 
of this drug in Europe has been concentrated in the 
Czech Republic and Slovakia. In 2008, the number of 
problem methamphetamine users in the Czech Republic 
was estimated to be approximately 20 700–21 800 
(2.8 to 2.9 cases per 1 000 aged 15–64 years), roughly 
Table 5: Prevalence of amphetamines use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year
15–64 years
Estimated number of users in Europe 12 million 2 million
European average 3.7 % 0.6 %
Range 0.0–12.3 % 0.0–1.7 %
Lowest-prevalence countries Romania (0.0 %)
Greece (0.1 %)
Malta (0.4 %)
Cyprus (0.8 %)
Romania, Malta, Greece (0.0 %)
France (0.1 %)
Portugal (0.2 %)
Highest-prevalence countries United Kingdom (12.3 %) 
Denmark (6.3 %)
Sweden (5.0 %)
Czech Republic (4.3 %)
Czech Republic (1.7 %)
United Kingdom, Denmark (1.2 %) 
Norway, Estonia (1.1 %)
15–34 years
Estimated number of users in Europe 7 million 1.5 million
European average 5.2 % 1.2 %
Range 0.1–15.4 % 0.1–3.2 %
Lowest-prevalence countries Romania (0.1 %)
Greece (0.2 %)
Malta (0.7 %)
Cyprus (0.8 %)
Romania, Greece (0.1 %)
France (0.2 %)
Cyprus (0.3 %)
Portugal (0.4 %)
Highest-prevalence countries United Kingdom (15.4 %)
Denmark (10.5 %)
Czech Republic (7.8 %)
Latvia (6.1 %)
Czech Republic (3.2 %)
Denmark (3.1 %)
Estonia (2.5 %)
United Kingdom (2.3 %)
European prevalence estimates are based on weighted averages from the most recent national surveys conducted from 2001 to 2008/09 (mainly 2004–08), and therefore cannot 
be attached to a single year. The average prevalence for Europe was computed by a weighted average according to the population of the relevant age group in each country. 
In countries for which no information was available, the average EU prevalence was imputed. Populations used as basis: 15–64 (334 million) and 15–34 (133 million). The data 
summarised here are available under ‘General population surveys’ in the 2010 statistical bulletin.
‘Selected issue’: Problem amphetamine and 
methamphetamine use, related consequences 
and responses
Amphetamines, and particularly methamphetamine, have 
been reported to cause major problems in several parts of 
the world. In Europe, only a few countries report significant 
harm caused by these drugs and sizeable numbers of 
problem amphetamine and methamphetamine users. A new 
EMCDDA ‘Selected issue’ looks at historical and recent 
developments in these countries. The report covers the 
epidemiology of, mainly chronic or intensive, amphetamine 
and methamphetamine use, and its health and social 
correlates. It also describes the health, social and legal 
responses developed for the problems associated with 
these drugs.
The ‘Selected issue’ is available in print and online on the 
EMCDDA website in English only.
55
Chapter 4: Amphetamines, ecstasy and hallucinogenic substances
(74) See Table TDI-5 (part ii) and (part iv) in the 2010 statistical bulletin.
(75) See Table TDI-3 in the 2010 statistical bulletin.
(76) See Table GPS-7 (part iv) in the 2010 statistical bulletin. 
(77) See Table EYE-11 in the 2010 statistical bulletin.
(78) See Tables TDI-5 and TDI-37 (part i), (part ii) and (part iii) in the 2010 statistical bulletin.
(79) See Table GPS-1 in the 2010 statistical bulletin.
(80) Data from ESPAD for all countries except Spain. See Figure EYE-2 (part v) in the 2010 statistical bulletin.
twice the estimated number of problem opioid users. 
For Slovakia, there were estimated to be approximately 
5 800–15 700 problem methamphetamine users in 2007 
(1.5 to 4.0 cases per 1 000 aged 15–64 years), about 
20 % fewer than the estimated number of problem opioid 
users. Recently, methamphetamine has appeared on the 
drug market in other countries, especially in the north of 
Europe (Norway, Sweden, Latvia and, to a lesser extent, 
Finland), where it seems to partially replace amphetamine, 
being virtually indistinguishable from it to the users. In 
Europe, problem methamphetamine users typically inject 
or snort the drug. Smoking is rarely reported, again in 
contrast to other parts of the world.
Methamphetamine is reported as the primary drug by 
a large proportion of clients entering treatment in the 
Czech Republic (59 %) and Slovakia (29 %). Injecting 
is reported as the main route of drug administration by 
80 % of methamphetamine clients in the Czech Republic 
and 36 % in Slovakia (74). Use of other drugs is also 
often reported, mainly heroin, cannabis and alcohol. 
Both countries report that the use of methamphetamine 
as a secondary substance is common, especially among 
people in substitution treatment.
Methamphetamine users entering treatment in the 
Czech Republic and Slovakia are relatively young, on 
average 25–26 years. The Czech Republic reports that 
the number of women entering treatment for primary 
methamphetamine use is increasing, especially among 
the younger age groups. Between 2003 and 2008, 
the number of first-time treatment entrants for problems 
relating to methamphetamine has been increasing in both 
countries (75).
Ecstasy
Ecstasy use is concentrated among younger adults, with 
males reporting levels of use much higher than females 
in all countries except Sweden and Finland. Of the 
approximately 2.5 million (0.8 %) European adults 
who used ecstasy in the last year, virtually all are in the 
15–34 age group (see Table 6 for a summary of the data). 
Still higher levels of ecstasy use are found among the 
15–24 age group, where lifetime prevalence ranges from 
under 1 % in Greece and Romania to 20.8 % in the Czech 
Republic, followed by Slovakia and the United Kingdom 
(both 9.9 %) and Latvia (9.4 %), though most countries 
report estimates in the 2.1–6.8 % range (76). Last year use 
of ecstasy among this age group is estimated at between 
1.0 % and 3.7 % in the majority of countries, though there 
is a considerable difference between the lowest national 
estimate at 0.3 % and the highest at 11.3 %.
Among 15- to 16-year-old school students, lifetime 
prevalence of ecstasy use ranged from 1 % to 5 % in 
most of the EU countries surveyed in 2007. Only four 
countries reported higher prevalence levels: Bulgaria, 
Estonia, Slovakia (all 6 %) and Latvia (7 %). The five 
countries that conducted school surveys in 2008 (Belgium 
(Flemish Community), Spain, Italy, Sweden, United 
Kingdom) reported lifetime prevalence of ecstasy use 
of 4 % or less (77).
Few drug users seek treatment for problems relating to 
ecstasy. In 2008, ecstasy was mentioned as the primary 
drug by less than 1 % of treatment entrants in 21 of 
the 27 reporting countries. Elsewhere, the proportion 
varied between 1 % and 3 %. With an average age 
of 24 years, ecstasy clients are among the youngest 
entering drug treatment. There are two or three males 
for every female entering treatment. Ecstasy clients often 
report the concomitant use of other substances, including 
alcohol, cocaine and, to a lesser extent, cannabis and 
amphetamines (78).
LSD and hallucinogenic mushrooms
Among young adults (15–34 years), lifetime prevalence 
estimates of LSD use range from zero to 6.1 %, with the 
exception of the Czech Republic where a 2008 drug 
survey reported a higher prevalence (10.3 %). Much lower 
prevalence ranges are reported for last year use (79).
In the few countries providing comparable data, the use 
of LSD is usually exceeded by that of hallucinogenic 
mushrooms. Lifetime prevalence estimates for 
hallucinogenic mushrooms among young adults range 
from 0.3 % to 14.1 %, and last year prevalence estimates 
are in the range of 0.2–5.9 %.
Among 15- to 16-year-old school students, prevalence 
estimates for the use of hallucinogenic mushrooms are 
higher than those for LSD and other hallucinogens in 10 of 
the 26 countries providing data on these substances. Most 
countries report lifetime prevalence estimates for the use of 
hallucinogenic mushrooms of between 1 % and 4 %, with 
Slovakia (5 %) and the Czech Republic (7 %) reporting 
higher levels (80).
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(81) In Denmark, the information for 1994 refers to ‘hard drugs’, which were considered mainly amphetamines.
Trends in the use of amphetamines and ecstasy
The stabilising trends in amphetamines and ecstasy use in 
Europe, noted in previous reports, are supported by the 
most recent data. After general increases in the 1990s, 
population surveys now point to an overall stabilisation 
in the popularity of both drugs, although recent increases 
are seen in a few countries. National trends in general 
population surveys may, however, not reflect trends 
in stimulant use at the local level or among different 
subpopulations. Targeted surveys in nightlife settings 
suggest that the prevalence and patterns of stimulant drug 
use together with alcohol remain high, with some studies 
suggesting that drug use patterns among club-goers are 
becoming increasingly polarised from those in the general 
population (Measham and Moore, 2009). In contrast, 
observations made in Germany recently indicate that 
substance use in the clubbing scene is on the decline in 
that country.
In the United Kingdom, last year use of amphetamines 
among young adults (15–34) declined from 6.2 % in 
1998 to 2.3 % in 2008–09. In Denmark, it increased 
from 0.5 % in 1994 to 3.1 % in 2000 and stabilised 
thereafter (81). Among the other countries reporting 
repeated surveys over a similar time span (Germany, 
Greece, Spain, France, Netherlands, Slovakia, Finland), 
the trends are largely stable (Figure 6). During the period 
2003–08, of the 11 countries with sufficient data on 
last year prevalence of amphetamines use among the 
15–34 age group, only two report a change of more than 
one percentage point (Bulgaria, from 0.9 % in 2005 to 
2.1 % in 2008, and the Czech Republic, from 1.5 % in 
2004 to 3.2 % in 2008).
In countries reporting higher than average levels of 
ecstasy use, use of the drug among 15- to 34-year-olds 
typically peaked at somewhere between 3 % and 
5 % in the early 2000s (Estonia, Spain, Slovakia, 
Table 6: Prevalence of ecstasy use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year
15–64 years
Estimated number of users in Europe 11 million 2.5 million
European average 3.3 % 0.8 %
Range 0.3–9.6 % 0.1–3.7 %
Lowest-prevalence countries Romania (0.3 %)
Greece (0.4 %)
Malta (0.7 %)
Poland (1.2 %)
Romania, Sweden (0.1 %)
Malta, Greece (0.2 %)
Poland (0.3 %)
Highest-prevalence countries Czech Republic (9.6 %)
United Kingdom (8.6 %)
Ireland (5.4 %)
Latvia (4.7 %)
Czech Republic (3.7 %)
United Kingdom (1.8 %)
Slovakia (1.6 %)
Latvia (1.5 %)
15–34 years
Estimated number of users in Europe 8 million 2.5 million
European average 5.8 % 1.7 %
Range 0.6–18.4 % 0.2–7.7 %
Lowest-prevalence countries Romania, Greece (0.6 %)
Malta (1.4 %)
Poland (2.1 %)
Cyprus (2.4 %)
Romania, Sweden (0.2 %)
Greece (0.4 %)
Poland (0.7 %)
Highest-prevalence countries Czech Republic (18.4 %)
United Kingdom (13.8 %)
Ireland (9.0 %)
Latvia (8.5 %)
Czech Republic (7.7 %)
United Kingdom (3.9 %)
Slovakia, Latvia, Netherlands (2.7 %)
European prevalence estimates are based on weighted averages from the most recent national surveys conducted from 2001 to 2008/09 (mainly 2004–08), and therefore 
cannot be attached to a single year. The average prevalence for Europe was computed by a weighted average according to the population of the relevant age group in each 
country. In countries for which no information was available, the average EU prevalence was imputed. Populations used as basis: 15–64 (334 million) and 15–34 (133 million). 
The data summarised here are available under ‘General population surveys’ in the 2010 statistical bulletin.
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United Kingdom; see Figure 6). An exception to this is 
the Czech Republic, where it is estimated that 7.7 % of 
the 15–34 age group have used ecstasy in the last 
year, with an upward trend over the period 2003–08. 
Over this period, most other countries report a stable 
trend, with the exception of Estonia and Hungary, 
where last year prevalence of ecstasy use among young 
adults increased during the early 2000s and has since 
decreased.
In eight countries (Denmark, France, Spain, Ireland, 
Italy, Austria, Portugal, United Kingdom), the most recent 
surveys show that last year cocaine use now exceeds the 
use of amphetamine and ecstasy among young adults.
School surveys conducted in 2007 (ESPAD) and 
2008 suggest, overall, little change in the levels of 
experimentation with amphetamines and ecstasy among 
students aged 15–16. Considering differences of at 
least two percentage points between 2003 and 2007, 
lifetime prevalence of amphetamines use increased in nine 
countries. By the same measure, ecstasy use increased 
in seven countries. A decrease in lifetime prevalence of 
amphetamines use was observed only in Estonia and Italy, 
while the Czech Republic, Portugal and Croatia reported 
a decrease in ecstasy use. The remaining countries report 
a stable trend.
Amphetamines and ecstasy in recreational 
settings: use and interventions
Data on the prevalence of stimulant use from studies 
conducted in nightlife settings in 2008 were provided 
by nine countries. Estimates show considerable variation 
between different countries and settings, ranging from 
10 % to 85 % for lifetime use of ecstasy and from 5 % to 
69 % for use of amphetamines. Three of the studies also 
reported lifetime prevalence estimates for hallucinogenic 
mushrooms, ranging from 34 % to 54 %. Differences 
in the prevalence and patterns of drug use reported by 
customers attending clubs playing different genres of 
electronic dance music have been found in six countries 
(Germany, France, Hungary, Netherlands, Romania, 
United Kingdom), with ecstasy use appearing to be 
consistently more closely associated with some music 
genres than others. Ecstasy use was also more common 
than amphetamines use in the settings sampled in three 
reporting countries (Czech Republic, Netherlands, United 
Kingdom). For example, 9 % of club-goers in Amsterdam 
reported that they had taken ecstasy during the evening of 
the survey and 42 % of club-goers in Manchester reported 
that they had taken or planned to take ecstasy during 
the evening of the survey. The corresponding figures 
for amphetamines were 3.6 % (Amsterdam) and 8 % 
(Manchester).
Only 13 European countries have recently reported 
on interventions in recreational nightlife settings. 
Information provision and harm-reduction materials 
were the main activities reported, but few informative 
strategies addressed the normative beliefs underlying 
the recreational youth culture. Environmental 
approaches, such as healthy clubbing environments, safe 
Figure 6: Trends in last year prevalence of use of amphetamines 
(top) and ecstasy (bottom) among young adults (aged 15–34)
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(82) Defined as having taken two or more illicit drugs within the same time period, e.g. last year.
transportation, selling and policing schemes, chill-out 
zones, alcohol tests and crisis interventions are reported, 
alone or in combination, by seven countries (Belgium, 
Denmark, Germany, Spain, Luxembourg, Netherlands, 
United Kingdom). Cooperation between players involved 
in the nightlife field — municipalities, police and restaurant 
or club owners — is now also reported by Spain and Italy.
The harms associated with alcohol use in nightlife 
settings are increasingly being recognised in Europe. 
Environmental strategies on alcohol are reported 
by Denmark, Luxembourg, Sweden and the United 
Kingdom, as well as by some areas in Spain. The various 
interventions implemented in these countries include 
responsible alcohol serving, staff training, higher tax 
on alcopops, 16-year minimum age for the purchase of 
alcoholic beverages and zero tolerance for young drivers.
As the use of alcohol and other drugs is strongly 
connected in nightlife settings, regulations targeting 
alcohol use could also reduce stimulant use. A recent 
British Crime Survey reported that the frequency of 
nightclub visits was strongly associated with polydrug 
use (82). Data analysed by the EMCDDA from general 
population surveys in nine European countries reveal that, 
among frequent or heavy alcohol users, the prevalence 
of amphetamines or ecstasy use is much higher than 
average (EMCDDA, 2009d). Analysis of ESPAD school 
survey data for 22 countries shows that 85.5 % of the 
15- to 16-year-old students who had used ecstasy during 
the last month had also drunk five or more alcoholic drinks 
on one occasion (EMCDDA, 2009d). And, as reported by 
the Netherlands, users may be taking stimulant drugs such 
as cocaine and amphetamines in order to sober up after 
excessive drinking.
Treatment
Users of amphetamines generally receive treatment 
in outpatient drug services which, in countries with 
a history of a significant amphetamines problem, 
can be specialised in treating this type of drug 
problem. Treatment for the most problematic users 
of amphetamines may be provided in inpatient drug 
services or in psychiatric clinics or hospitals. This is 
particularly the case where amphetamines dependence 
is complicated by co-occurring psychiatric disorders. 
In Europe, pharmaceuticals (antidepressants, sedatives 
or antipsychotics) are administered for the treatment 
of early abstinence symptoms at the beginning of 
detoxification, which is usually provided at specialised 
inpatient psychiatric departments. In the Czech Republic, 
methamphetamine users referred to detoxification centres 
often arrive in a state of acute toxic psychosis, which 
is typically accompanied by aggressiveness towards 
both themselves and their surroundings. Such patients 
often need to be physically restrained, communication 
with them is difficult and they usually reject any care. 
Users with psychotic conditions are treated with atypical 
antipsychotic medications in inpatient psychiatric facilities. 
The Czech Republic also reports that, due to the young 
age of clients and the high frequency of family-related 
problems, it is common to work with methamphetamine 
users within a family therapy context.
The lack of a pharmacological substitute for the treatment 
of amphetamines dependence is mentioned by several 
countries as a problem for maintaining amphetamines 
users in treatment. While dexamphetamine is available 
as a substitute for the treatment of highly problematic 
users of amphetamines in England and Wales, national 
guidelines on clinical management of drug dependence 
recommend against its use for this purpose, due to the lack 
of demonstrated effectiveness (NTA, 2007).
Treatment effectiveness
Chronic use of methamphetamine can lead to cognitive 
impairment, and this can reduce the user’s capacity to 
benefit from psychological, cognitive and behavioural 
therapies (Rose and Grant, 2008). This may help explain 
Evidence-based interventions
Drug and alcohol use in recreational settings can produce 
a wide range of health and social problems through 
violence, involuntary and unsafe sex, traffic accidents, 
underage drinking and social nuisance. A recent review 
of the effectiveness of interventions in this setting found 
that those most widely implemented were not evidence-
based (Calafat et al., 2009). These include the provision of 
information to reduce harms, the promotion of moderation, 
responsible alcohol serving, training of door staff and 
designated driver programmes. In some cases, the lack of 
effectiveness might be linked with poor implementation.
Evidence was found that combining client and staff 
training, mandatory cooperation between authorities 
and the leisure industry, and law enforcement (licensing, 
age verification) was the best strategy to reduce injuries, 
problem drinking patterns and young people’s access to 
alcohol. Unfortunately, outcomes on illicit drug use were 
only rarely assessed.
Other measures at societal level which are effective in 
reducing substance use in nightlife settings include alcohol 
taxation, restricted sales hours, outlet density limitations, 
drink driving checkpoints, reduced blood alcohol 
concentration limits, minimum legal purchasing age and 
licence suspension.
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the considerable research efforts that are being made to 
develop pharmacological interventions. In some cases, 
the medications being studied are intended to enable the 
patients to undertake a psychological intervention.
A number of clinical trials on pharmaceuticals for use 
in treating amphetamines dependence have recently 
been published or are in progress. Out of nine published 
studies, six were carried out in the United States, 
two in Sweden and one in Australia. The substances 
investigated included: the dopamine-reuptake inhibitors 
methylphenidate and bupropion, for promoting 
abstinence in methamphetamine-dependent patients; 
aripiprazole, an antipsychotic agent; ondansetron, 
an anti-anxiety agent; amineptine, a psychotropic 
drug; mirtazapine, an antihistamine; modafinil, 
a neuroprotective agent; and the opioid receptor 
antagonist naltrexone. Among all studies, only naltrexone 
was associated with a significant treatment benefit in 
terms of reduction of use (either proved by urine samples 
or self-reported) and rate of continuous abstinence. 
Studies in the United States are also exploring if 
citicoline, which may improve mental function in 
methamphetamine dependent subjects, improves the 
efficacy of other pharmaceutical treatments.
Finally, a controlled study showed that outpatient 
treatment supervised by a drug court produced better 
results than unsupervised treatment. In a clinical study, the 
addition of contingency management improved the results 
compared to current treatment alone. A possible vaccine 
with antidrug monoclonal antibodies for overdose and 
relapse prevention has also been described in a recent 
dissertation.
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Introduction
Use of cocaine and seizures of the drug have increased 
during the last decade, and cocaine is now the second 
most used illicit drug in Europe, after cannabis. Levels 
of use differ widely between countries, with cocaine 
use concentrated in countries in the west and the 
south of Europe. There is also considerable diversity 
among cocaine users, both in patterns of use and 
sociodemographically. There are occasional cocaine 
users, socially integrated regular users and more 
marginalised and often dependent users, including current 
and former opioid users. This diversity complicates the 
assessment of the prevalence of the drug’s use, its health 
and social consequences and the necessary responses.
Supply and availability
Production and trafficking
Cultivation of coca bush, the source of cocaine, continues 
to be concentrated in three countries in the Andean 
region. The UNODC (2010b) estimated for the year 2009 
that the total cultivation of 158 000 hectares of coca bush 
translated into a potential production of between 842 and 
1 111 tonnes of pure cocaine, compared to an estimated 
865 tonnes in 2008 (UNODC, 2010b). The area under 
cultivation in 2009 is estimated at 158 000 hectares, 
down from 167 600 hectares in 2008 — a decrease of 
5 % largely attributed to a reduction in the area under 
coca in Columbia not offset by increases in Peru and 
Bolivia.
The conversion of coca leaves into cocaine hydrochloride 
is mainly carried out in Colombia, Peru and Bolivia, 
although it may also occur in other countries. Colombia’s 
importance in the production of cocaine is corroborated 
by information on laboratories dismantled and seizures 
of potassium permanganate, a chemical reagent 
used in the manufacture of cocaine hydrochloride. 
In 2008, 3 200 cocaine laboratories were dismantled 
(INCB, 2010b) and a total of 42 tonnes of potassium 
permanganate (90 % of global seizures) was seized in 
Colombia (INCB, 2010a).
Chapter 5
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Table 7: Production, seizures, price and purity of cocaine and crack cocaine
Cocaine Crack (1)
Global production estimate (tonnes) 842–1 111 n.a.
Global quantities seized (tonnes) 711 (2) n.a.
Quantity seized (tonnes) 
EU and Norway  
(Including Croatia and Turkey)
67
(67)
0.06
(0.06)
Number of seizures 
EU and Norway  
(Including Croatia and Turkey)
95 700
(96 300)
10 100
(10 100)
Mean retail price (EUR per gram) 
Range 
(Interquartile range) (3)
37–107
(50–70)
45–82
Range of mean purity (%) 13–62 20–89
(1) Due to the small set of countries reporting information, data should be interpreted with caution.
(2) UNODC estimates this figure to be equivalent to 412 tonnes of pure cocaine.
(3) Range of the middle half of the reported mean prices.
NB: All data for 2008 except the global production estimate (2009); n.a., data not available.
Sources: UNODC (2010b) for global values, Reitox national focal points for European data.
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(83) See Tables SZR-9 and SZR-10 in the 2010 statistical bulletin.
(84) For purity and price data, see Tables PPP-3 and PPP-7 in the 2010 statistical bulletin.
The available information suggests that cocaine continues 
to be trafficked to Europe via different air and sea routes. 
Cocaine consignments transit through countries including 
Argentina, Brazil, Ecuador, Venezuela and Mexico 
before reaching Europe. Caribbean islands are also 
frequently used in the transhipment of the drug to Europe. 
In recent years, alternative routes through West Africa 
have been detected (EMCDDA and Europol, 2010). 
Although a ‘substantive decline’ in seizures of cocaine 
transiting West Africa was reported for 2008 (UNODC, 
2009), it is likely that significant amounts of the drug still 
go through the region (EMCDDA and Europol, 2010).
The Iberian peninsula, especially Spain, and the Low 
Countries, particularly the Netherlands, appear to be the 
points of entry for cocaine being smuggled into Europe. 
France, Italy and the United Kingdom are frequently 
mentioned as important transit or destination countries 
inside Europe. Recent reports also indicate that cocaine 
trafficking may be expanding eastward (EMCDDA and 
Europol, 2010; INCB, 2010b). The aggregate figure for 
10 central and east European countries shows an increase 
in the number of cocaine seizures, from 469 cases in 
2003 to 1 212 in 2008, but these still represent only 
about 1 % of the European total.
Seizures
Cocaine is the most trafficked drug in the world after 
herbal cannabis and cannabis resin. In 2008, global 
seizures of cocaine remained largely stable at about 
711 tonnes (Table 7) (UNODC, 2010b). South America 
continued to report the largest amount seized, accounting 
for 60 % of the global figure (CND, 2009), followed by 
North America with 28 %, and west and central Europe 
with 11 % (UNODC, 2009).
In Europe, the number of cocaine seizures has been on the 
increase for the last 20 years, and more notably since 2004. 
In 2008, the number of cocaine seizures increased to 
96 000 cases, though the total quantity intercepted 
dropped to 67 tonnes, down from 121 tonnes in 2006 and 
76 tonnes in 2007. The fall in the total amount of cocaine 
seized is largely accounted for by decreases in the amounts 
recovered since 2006 in Spain and Portugal (83). This might 
be explained by changes in trafficking routes or practices, 
or changes in law enforcement priorities. In 2008, Spain 
continued to be the country reporting both the largest 
quantity of cocaine seized and the highest number of 
seizures of the drug — about half of the total — in Europe. 
This analysis is preliminary as data for 2008 are not yet 
available for the Netherlands, which reported the second-
largest quantities of cocaine intercepted in 2007.
Purity and price
The mean purity of cocaine samples tested ranged between 
25 % and 55 % for most reporting countries in 2008, 
although lower values were reported in Denmark (retail only, 
23 %) and some parts of the United Kingdom (Scotland, 
13 %), and higher ones in Belgium (59 %), France (60 %) 
and Romania (62 %) (84). Twenty-one countries provided 
sufficient data for analysis of trends in cocaine purity over 
the period 2003–08, with 17 of the countries reporting 
a decline, three a stable situation (Germany, Greece, 
France) and Portugal observing an increase.
In 2008, the mean retail price of cocaine ranged between 
EUR 50 and EUR 70 per gram in half of the 18 reporting 
countries. Lower prices were reported in Poland and Portugal 
and higher ones in the Czech Republic, Italy, Latvia and 
Sweden. With one exception, all countries with sufficient 
data to make a comparison reported a decrease in cocaine 
retail prices between 2003 and 2008. Only Poland reported 
an increase over the period, albeit with a decline in 2008.
Cocaine ‘secondary extraction’ laboratories in 
Europe
Clandestine laboratories set up by drug traffickers to 
process cocaine in Europe perform a different function 
to the cocaine laboratories in South America, where 
cocaine base or hydrochloride is extracted from coca 
leaves or coca paste. Most of the laboratories uncovered 
by European law enforcement agencies appear to extract 
cocaine from materials in which it has been incorporated 
before being exported.
Cocaine hydrochloride and, less frequently, cocaine base 
have been discovered in a range of ‘carrier’ materials as 
diverse as beeswax, fertiliser, clothing, herbs and liquids. 
The incorporation process can vary in sophistication 
from simply soaking clothes in a solution of cocaine and 
water, to incorporating the drug in plastic. In the latter 
case, a reverse chemical process is needed to extract the 
cocaine. After extraction, the substance can be adulterated 
with various cutting agents and pressed into cocaine bricks 
embossed with logos that designate high-purity cocaine in 
producer countries.
Europol received reports of the discovery of about 
30 cocaine ‘secondary extraction’ laboratories of various 
sizes in 2008, all in Spain. In the Netherlands, a mid-
scale laboratory removing cocaine from cacao powder 
and liquor was seized in Roosendaal, in the province of 
Brabant. A year earlier, Dutch authorities had already 
dismantled two ‘secondary extraction’ laboratories in the 
same province, seizing 8 tonnes of plastic (polypropylene) 
containing cocaine. Documentation recovered at the 
laboratories showed that more than 50 tonnes of the 
plastic had been imported from Colombia during that year.
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(85) See Figure GPS-13 in the 2010 statistical bulletin.
(86) See Table GPS-5 (part iii) and (part iv) in the 2010 statistical bulletin.
Prevalence and patterns of use
Cocaine use among the general population
Overall, cocaine remains the second most used illicit 
drug in Europe, after cannabis, though levels of use vary 
greatly between countries. It is estimated that about 
14 million Europeans have used it at least once in their 
life, on average 4.1 % of adults aged 15–64 years (see 
Table 8 for a summary of the data). National figures vary 
from 0.1 % to 9.4 %, with 12 out of 24 countries, including 
most central and east European countries, reporting low 
levels of lifetime prevalence (0.5–2 %).
It is estimated that about 4 million Europeans have used 
the drug in the last year (1.3 % on average), although 
again with variation between countries. Recent national 
surveys report last year prevalence estimates of between 
zero and 3.1 %. The prevalence estimate for last month 
cocaine use in Europe represents about 0.5 % of the adult 
population or about 2 million individuals.
A small number of countries report levels of cocaine use 
above the European average (Denmark, Spain, Ireland, 
Italy, United Kingdom). In all but one of these countries, 
cocaine is the most commonly used illicit stimulant 
drug. The exception is Denmark, which reports similar 
prevalence for cocaine and amphetamines use.
Cocaine use among young adults
In Europe, it is estimated that about 8 million young adults 
(15–34 years), or an average of 5.9 %, have used cocaine 
at least once in their life. National figures vary from 
0.1 % to 14.9 %. The European average for last year use of 
cocaine among this age group is estimated at 2.3 % (about 
3 million) and for last month use at 0.9 % (1.5 million).
Use is particularly high among young males (15–34 years), 
with last year prevalence of cocaine use reported at 
between 4 % and 8.4 % in Denmark, Spain, Ireland, 
Italy and the United Kingdom (85). In 12 of the reporting 
countries, the male to female ratio for last year prevalence 
of cocaine use among young adults is at least 2:1 (86).
Table 8: Prevalence of cocaine use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year Last month
15–64 years
Estimated number of users in Europe 14 million 4 million 2 million
European average 4.1 % 1.3 % 0.5 %
Range 0.1–9.4 % 0.0–3.1 % 0.0–1.5 %
Lowest-prevalence countries Romania (0.1 %) 
Malta (0.4 %) 
Lithuania (0.5 %)
Greece (0.7 %) 
Romania (0.0 %) 
Greece (0.1 %) 
Hungary, Poland, Lithuania (0.2 %)
Malta (0.3 %)
Romania, Greece (0.0 %) 
Malta, Sweden, Poland, Lithuania, 
Estonia, Finland (0.1 %)
Highest-prevalence countries United Kingdom (9.4 %) 
Spain (8.3 %) 
Italy (7.0 %)
Ireland (5.3 %)
Spain (3.1 %)
United Kingdom (3.0 %)
Italy (2.1 %)
Ireland (1.7 %)
United Kingdom (1.5 %)
Spain (1.1 %)
Italy (0.7 %)
Austria (0.6 %) 
15–34 years
Estimated number of users in Europe 8 million 3 million 1.5 million
European average 5.9 % 2.3 % 0.9 %
Range 0.1–14.9 % 0.1–6.2 % 0.0–2.9 %
Lowest-prevalence countries Romania (0.1 %)
Lithuania (0.7 %)
Malta (0.9 %)
Greece (1.0 %)
Romania (0.1 %)
Greece (0.2 %)
Poland, Lithuania (0.3 %)
Hungary (0.4 %)
Romania (0.0 %)
Greece, Poland, Lithuania (0.1 %)
Hungary, Estonia (0.2 %)
Highest-prevalence countries United Kingdom (14.9 %)
Spain (11.8 %)
Denmark (9.5 %)
Ireland (8.2 %)
United Kingdom (6.2 %)
Spain (5.5 %)
Denmark (3.4 %)
Ireland (3.1 %)
United Kingdom (2.9 %)
Spain (1.9 %)
Italy (1.1 %)
Ireland (1.0 %)
European prevalence estimates are based on weighted averages from the most recent national surveys conducted from 2001 to 2008/09 (mainly 2004–08), and therefore cannot 
be attached to a single year. The average prevalence for Europe was computed by a weighted average according to the population of the relevant age group in each country. 
In countries for which no information was available, the average EU prevalence was imputed. Populations used as basis: 15–64 (334 million) and 15–34 (133 million). The data 
summarised here are available under ‘General population surveys’ in the 2010 statistical bulletin.
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(87) Defined as drinking six glasses or more of an alcoholic drink on the same occasion at least once a week during the past 12 months.
Cross-sectional population and targeted surveys have 
shown that cocaine use is associated with specific 
lifestyles and settings. For example, an analysis of data 
from the 2008/09 British Crime Survey found that among 
16- to 24-year-olds who made four or more visits to 
a nightclub in the last month, 14.2 % report last year 
use of cocaine, compared with 4.0 % among those who 
had not visited a nightclub (Hoare, 2009). Targeted 
surveys recently conducted in electronic dance or music 
settings in the Czech Republic, the Netherlands, Austria 
and the United Kingdom reported very high lifetime 
cocaine use, ranging from 17.6 % up to 86 %. Cocaine 
use can also be directly associated with these settings: 
in a survey of Amsterdam club-goers in 2008, 4.6 % of 
the 646 respondents reported having used cocaine 
during the evening of the survey, while an on-site survey 
among 323 clubbers in the United Kingdom reported that 
22 % had taken or planned to take cocaine during the 
evening.
Data from general population surveys also reveal that the 
prevalence of heavy episodic drinking (87) is much higher 
among cocaine users than in the general population 
(EMCDDA 2009d). The Netherlands also reports that users 
may take cocaine in order to sober up after excessive 
drinking.
Cocaine use among school students
Estimates of the prevalence of cocaine use among 
school students are much lower than those for cannabis 
use. Lifetime prevalence of cocaine use among 15- to 
16-year-old school students in the 2007 ESPAD survey 
was between 1 % and 2 % in half of the 28 reporting 
countries. Most of the remaining countries reported 
Figure 7: Last year prevalence of cocaine use among young adults (aged 15–34) in Europe, Australia, Canada and the USA
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NB: Data are from the last survey available for each country. The European average prevalence rate was calculated as the average of the national 
prevalence rates weighted by national population of 15- to 34-year-olds (2006, taken from Eurostat). US and Australian data have been 
recalculated from original survey results to the age bands 16–34 and 14–39 years respectively. See Figure GPS-20 in the 2010 statistical bulletin 
for further information.
Sources: Reitox national focal points.
 SAMHSA (USA), Office of Applied Studies. National survey on drug use and health, 2008.
 Canada: Canadian Alcohol and Drug Use Monitoring Survey.
 Australian Institute of Health and Welfare 2008. 2007 National Drug Strategy Household Survey: detailed findings. Drug statistics series No 22. 
Cat. No PHE 107. Canberra: AIHW.
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(88) See Tables EYE-3 to EYE-10 in the 2010 statistical bulletin.
prevalence levels of between 3 % and 4 %, while 
France and the United Kingdom reported 5 % and 
6 % respectively. Where data are available from older 
school students (17–18 years old), lifetime prevalence 
of cocaine use is generally higher, rising to 8 % in 
Spain (88).
International comparisons
Overall, the estimated last year prevalence of cocaine 
use is lower among young adults in the European Union 
(2.3 %) than among their counterparts in Australia 
(3.4 % among 14–39 years old), Canada (4.0 %) and the 
United States (4.5 % among 16–34 years old). However, 
Denmark reports the same figure as Australia, while 
Spain and the United Kingdom report higher figures than 
Canada and the United States (Figure 7).
Trends in cocaine use
Trends in cocaine use in Europe have followed different 
patterns. In the two countries with the highest prevalence 
of cocaine use (Spain, United Kingdom), the use of 
the drug increased dramatically in the late 1990s, 
before moving to a more stable, though generally 
upward, trend. In three other countries (Denmark, 
Ireland, Italy), the increase in prevalence has been less 
pronounced and occurred later. Nevertheless, levels of 
use in these countries are high by European standards. 
Among the other countries with repeated surveys 
between 1998 and 2008/09, last year prevalence 
among young adults (15–34 years) appears more stable, 
with levels remaining below 2 % during the period 
(Figure 8).
When looking at more recent trends, among the 
15 countries with repeated surveys during the period 
2003–08, last year prevalence among young adults 
(15–34 years) at least doubled but still remained below 
2 % in three countries (Bulgaria, Czech Republic, Latvia). 
It increased by about 50 % in two countries (Ireland, 
United Kingdom) and was stable or decreased in eight 
countries (Germany, Estonia, Lithuania, Hungary, Austria, 
Poland, Slovakia, Finland).
In the ESPAD school surveys carried out in 2007, lifetime 
prevalence of cocaine use among 15- to 16-year-old 
school students had increased by at least two percentage 
points since 2003 in France, Cyprus, Malta, Slovenia 
and Slovakia. The Spanish school survey reported a 
decrease of two percentage points between 2004 and 
2007. Among the five countries that conducted school 
surveys in 2008, no changes greater than 1 % were 
reported.
Patterns of cocaine use
In some European countries, a substantial number of 
people use cocaine experimentally only once or twice 
(Van der Poel et al., 2009). Among more regular or 
intensive cocaine users, two broad groups can be 
distinguished. The first group is made up of ‘socially 
integrated’ users who tend to use cocaine at weekends, 
parties or other special occasions, sometimes in 
large amounts (‘binges’) or frequently. Many socially 
integrated users report controlling their cocaine use by 
setting rules, for example, about the amount, frequency 
or context of use (Decorte, 2000). Some of these 
users may suffer health problems related to their use 
of cocaine or go on to develop compulsive patterns of 
use that require treatment. Studies suggest, however, 
that a substantial proportion of those with cocaine-
related problems may recover without formal treatment 
(Cunningham, 2000).
The second group includes more ‘marginalised’ or ‘socially 
excluded’ users, including former or current opioid users 
who may use crack or inject cocaine. Also in this group 
are intensive cocaine and ‘crack’ users belonging to 
socially disadvantaged groups, such as sex workers or 
immigrants (Prinzleve et al., 2004).
Figure 8: Trends in last year prevalence of cocaine use among 
young adults (aged 15–34)
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
Czech
Republic
Italy
Slovakia
Estonia
%
Spain
France 
United 
Kingdom
Denmark  
Germany
Netherlands
Finland 
Hungary
Greece
0
1
2
3
4
5
7
6
Ireland
Norway
Bulgaria
Portugal 
Lithuania
Poland
Latvia 
Sweden
Austria
NB: See Figure GPS-14 (part i) in the 2010 statistical bulletin for 
further information.
Source: Reitox national focal points.
66
Annual report 2010: the state of the drugs problem in Europe
(89) See the box ‘Deaths caused by cocaine’ in Chapter 7.
(90) See Table PDU-102 (part i) in the 2010 statistical bulletin.
Health consequences of cocaine use
The health consequences of cocaine use are likely to be 
underestimated. This is due partly to the often unspecific 
or chronic nature of the pathologies typically arising 
from long-term use of cocaine, and also to the difficulties 
in establishing causal links between the illness and the 
use of the drug (89). Regular use, including by snorting, 
can be associated with cardiovascular, neurological and 
psychiatric problems, and the risk of accidents and of 
transmission of infectious diseases through unprotected 
sex (Brugal et al., 2009). A study conducted in the United 
States also showed that about 5 % of cocaine users can 
become dependent in the first year of use, though not 
more than about 20 % of users developed dependence in 
the long term (Wagner and Anthony, 2002).
Studies in countries with high levels of use indicate that 
a considerable proportion of cardiac problems in young 
people could be related to cocaine use (Qureshi et al., 
2001). In these countries, cocaine use also appears to be 
involved in a significant proportion of drug-related hospital 
emergencies; for example, 32 % in the Netherlands, and 
the majority in Spain and in the United States. A recent 
study in Spain among 720 18- to 20-year-old regular 
cocaine users, who were not regular heroin users, found 
that 27 % had experienced acute cocaine intoxication 
during the last year. Of these, 35 % presented symptoms 
of psychosis (hallucinations or delirium) and more than 
50 % chest pain (Santos et al., in press).
Cocaine injection and crack use are associated with the 
highest health risks, including cardiovascular and mental 
health problems. These are generally aggravated by 
social marginalisation and additional specific problems, 
such as the risks associated with injection, including 
the transmission of infectious diseases and overdoses 
(EMCDDA, 2007c).
Overall, there are indications of a significant and 
probably increasing health burden related to cocaine use 
in Europe, which is not yet fully identified and recognised. 
Concerns have also been recently raised regarding the 
association between cocaine use and violent crimes in the 
night-time economy (Measham and Moore, 2009).
Problem cocaine use and treatment demand
Regular cocaine users, those who use it over long periods 
and those who inject the substance are defined, by the 
EMCDDA, as problem cocaine users. Estimates of the 
size of this population provide an approximation of 
the number of people potentially in need of treatment. 
Socially integrated problem cocaine users are, however, 
under-represented in these estimates, though they may also 
be in need of treatment. National estimates of problem 
cocaine users are available only for Italy, while regional 
and crack cocaine estimates are available for the United 
Kingdom (England). In Italy, the number of problem 
cocaine users was estimated at about 172 000 (between 
4.2 and 4.6 per 1 000 aged 15–64) in 2008 (90). Trend 
data on problem cocaine use and other data sources point 
to a gradual increase in cocaine use in Italy.
Crack use is very unusual among socially integrated 
cocaine users, and occurs mainly among marginalised 
Levamisole as a cocaine adulterant
Adulterants or ‘cutting agents’ are substances intentionally 
added to drugs, in particular to powdered drugs, to 
increase the sale value and economic benefit. They are 
distinguished from impurities, which are small quantities 
of unwanted substances from the synthetic process (King, 
2009).
Cocaine, because of its high value, may be cut several 
times with one or more substances. These may be inert 
diluents (such as sugars and starch) that increase the 
volume of the drug. Pharmacologically active adulterants 
may also be used to enhance or mimic the drug’s effects or 
improve its appearance. This category includes analgesics 
(e.g. paracetamol), local anaesthetics (e.g. lidocaine), 
antihistamines (e.g. hydroxyzine), diltiazem and atropine 
(Meijers, 2007).
The use of levamisole (l-tetramisole) as a cocaine adulterant 
has been reported in the United States and Europe since 
2004. Levamisole is used as an anti-parasitic agent in 
veterinary medicine and was formerly used in human 
medicine as an immunostimulant. When used over a long 
period and in high doses, it may cause adverse effects, of 
which agranulocytosis (1) is the most alarming.
Levamisole is not routinely identified in cocaine seizures, 
and is rarely quantified. The available information, 
however, indicates an increase in both the proportion 
of cocaine samples adulterated with levamisole and 
the concentration of levamisole in the drug. This led the 
European early-warning system (see Chapter 8) to issue 
a warning and to launch an additional data collection. 
A public health warning issued in the United States 
announced that over 70 % of cocaine seizures analysed 
in 2009 contained levamisole (2) and by the end of that 
year 20 confirmed or probable cases of agranulocytosis 
(with two fatalities) had been reported in the country. The 
number of cases in relation to the number of cocaine users 
appears, however, to be very low.
(1) Agranulocytosis is a haematological condition that can lead to 
rapidly-developing life threatening infections.
(2) SAMHSA news release.
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(91) See Table PDU-103 (part ii) in the 2010 statistical bulletin.
(92) See Figure TDI-2 and Tables TDI-5 (part i) and (part ii) and TDI-24 in the 2010 statistical bulletin; data for Spain refer to 2007.
(93) See Figures TDI-1 and TDI-3 in the 2010 statistical bulletin.
(94) See Table TDI-17 (part iv) in the 2010 statistical bulletin.
(95) See Table TDI-18 (part ii) in the 2010 statistical bulletin.
(96) From 2008, the Netherlands considers cocaine clients reporting ‘smoking’ as the route of administration as crack users. This has led to a marked 
increase on the numbers reported in previous years. Insufficient identification of crack clients may also exist in other countries.
and disadvantaged groups such as sex workers, problem 
opioid users and, sometimes, specific ethnic minorities 
(e.g. France, Netherlands, United Kingdom). It is mainly 
observed in some European cities (Prinzleve et al., 2004; 
Connolly et al., 2008). Most of the treatment demands 
related to crack use and most of the crack seizures in 
Europe are reported by the United Kingdom. Crack use 
is also considered to be a major component of London’s 
drugs problem. Estimates of problem crack cocaine use in 
England from 2006/07 range from 1.4 to 17 cases per 
1 000 inhabitants aged 15–64, with a national average 
of 5.2–5.6 cases per 1 000 (91). It is estimated that more 
than two thirds of problem crack users are also problem 
opioid users.
In the countries with the highest prevalence levels, powder 
or crack cocaine is often used by opioid users undergoing 
substitution treatment (mainly Spain, Italy, Netherlands, 
United Kingdom). Cocaine and alcohol use are also 
correlated among patients in substitution treatment.
Treatment demand
Cocaine, mainly powder cocaine, was cited as the 
principal reason for entering treatment by about 17 % of 
all drug treatment clients in 2008, corresponding to 
about 70 000 cases in 27 European countries. Among 
those entering treatment for the first time in their life, the 
proportion of primary cocaine users was higher (24 %).
There are wide differences between countries regarding 
the proportion and number of primary cocaine clients. 
The highest proportions are reported by Spain (46 %), the 
Netherlands (33 %) and Italy (28 %). In Belgium, Ireland, 
Cyprus, Luxembourg and the United Kingdom, cocaine 
clients represent between 11 % and 15 % of all drug 
clients. Elsewhere in Europe, cocaine accounts for less 
than 10 % of drug treatment clients, with eight countries 
reporting less than 1 % (92).
The number of clients entering drug treatment for primary 
cocaine use has been increasing in Europe for several 
years, though the trend is strongly influenced by a few 
countries (Spain, Italy, Netherlands, United Kingdom). 
Based on 17 reporting countries, the number of cocaine 
clients entering treatment increased from about 37 000 
in 2003 to 52 000 in 2008, while their proportion grew 
from 17 % to 19 % of all clients. Among clients entering 
drug treatment for the first time, the number of cocaine 
clients increased from about 18 000 to 28 000 and their 
proportion from 22 % to 27 % (based on 18 countries). 
Among the countries with the highest numbers of cocaine 
clients, since 2005 a stable situation or a downward 
trend in the number and proportion of new clients citing 
cocaine as their principal drug is reported in Spain, Italy 
and the Netherlands, while the United Kingdom reports an 
increase (93).
Profile of treatment clients
Nearly all cocaine clients are reported by outpatient 
treatment centres, although some cocaine users might be 
treated in private clinics, which are almost unrepresented 
in the current monitoring system.
Outpatient cocaine clients have one of the largest male to 
female ratios (five men for every woman) and one of the 
highest mean ages (about 32 years) among drug treatment 
clients. This is particularly the case in some countries 
with large numbers of primary cocaine clients, especially 
Italy, where their sex ratio is 6:1 and the mean age is 
34 years. Primary users of cocaine report an older age at 
first use of their main drug (22.3 years, 87 % before the 
age of 30) compared to primary users of other drugs, and 
the average time lag between first cocaine use and first 
treatment entry is about nine years.
Most cocaine clients snort (63 %) or smoke (31 %) the 
drug, while only 3 % report injecting it (94). Almost half 
of them have used the drug one to six times a week in 
the month before entering treatment, 26 % have used it 
daily and 25 % have not used it during that period (95). 
An analysis of treatment data from 14 countries in 2006 
revealed that about 63 % of cocaine clients are polydrug 
users. Among them, 42 % also use alcohol, 28 % cannabis 
and 16 % heroin. Cocaine is also mentioned as 
a secondary drug among 32 % of outpatient clients, 
especially primary heroin users (EMCDDA, 2009d).
In 2008, about 10 000 clients are reported to have 
entered outpatient treatment for primary use of crack 
cocaine, representing 16 % of all cocaine clients and 
3 % of all drug clients entering outpatient treatment. Most 
crack clients (about 7 500) are reported by the United 
Kingdom, where they account for 42 % of the cocaine 
clients and 5.6 % of all drug clients. The Netherlands also 
reports that crack clients made up a sizeable proportion 
of all treatment entrants in 2008 (96).
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(97) See Tables TDI-10, TDI-11 (part iii), TDI-21 and TDI-103 (part ii) in the 2010 statistical bulletin.
Overall, two main groups of cocaine clients have been 
identified in treatment: socially integrated individuals 
using powder cocaine; and a more marginalised group of 
clients, using cocaine, often crack cocaine, in combination 
with opioids. The first group typically reports snorting the 
drug, and sometimes consuming it in conjunction with 
other substances such as alcohol or cannabis, but not 
with opioids. Some members of this group are referred 
to treatment by the criminal justice system. The second 
group often reports injecting drugs, uses both cocaine and 
opioids, sometimes smokes crack and presents precarious 
health and social conditions. In this group, which includes 
former heroin users re-entering drug treatment for cocaine 
use, the identification of the primary drug can be difficult 
(NTA, 2010) (97).
Treatment and harm reduction
Treatment provision
In Europe, treatment for dependence on cocaine and 
crack cocaine is generally provided in specialist outpatient 
treatment services. With no effective pharmacotherapy 
currently available, cocaine clients are provided with 
psychosocial treatment such as counselling and cognitive-
behavioural therapies. Some countries provide guidelines 
for the treatment of cocaine problems (e.g. Germany, 
United Kingdom). Guidelines in the United Kingdom 
recommend, depending on the client’s needs, three to 
20 treatment sessions that aim at resolving ambivalence 
about change, improving recognition of and controlling 
cocaine-use cues and urges, reducing cocaine-related 
harm and preventing relapse (NTA, 2006).
Pharmacotherapy is generally used in Europe to provide 
relief for symptoms of cocaine dependence, particularly 
anxiety. A qualitative study investigating current cocaine 
treatment practices in France found that, despite limited 
evidence of effectiveness, specific medications, such as 
methylphenidate, modafinil or topiramate, were prescribed 
to reduce craving or for substitution purposes (Escots and 
Suderie, 2009).
Public drug treatment facilities in Europe are mostly 
oriented towards the needs of opioid users, and socially 
integrated powder cocaine users may be reluctant 
to present for treatment due to the perceived stigma. 
Denmark, Ireland, Italy and Austria have therefore 
developed specific programmes for this population. 
A common feature is that treatment can be provided 
outside regular opening hours to accommodate work 
commitments and provide discretion.
Two recent studies investigated the effectiveness of 
psychosocial treatment provided to powder cocaine 
(NTA, 2010) and crack cocaine users (Marsden 
et al., 2009) in English treatment centres. Both 
compared changes in drug use before and after six 
months of treatment (or earlier in case of discharge). 
In the first study, 61 % of powder cocaine users 
(1 864 out of 3 075) had stopped using the drug and 
a further 11 % had significantly reduced their use. In the 
second study, 52 % of crack cocaine users (3 941 out of 
7 636) were abstinent after six months of treatment. Less 
positively, it was found that opioid substitution treatment 
was not as effective with clients using heroin and crack 
cocaine as with those using only heroin. This finding 
confirms the detrimental effects of concomitant cocaine 
or crack cocaine use on the outcomes of substitution 
treatment, and underlines the need to develop new 
strategies to treat combined heroin and cocaine or crack 
cocaine dependence.
Recent studies for the treatment of cocaine dependence
Over 50 different drugs have been evaluated for treating 
cocaine dependence. Not one has yet been found to be 
clearly effective, and neither the European Medicines 
Agency nor the American Food and Drug Administration 
has approved any drug for the treatment of cocaine 
dependence (Kleber et al., 2007). However, more than 
100 ongoing randomised controlled trials are registered 
to test new substances, sometimes in association with 
psychological interventions.
The use of disulfiram, a substance that interferes 
with the metabolism of alcohol, was associated with 
Cocaine vaccine
A cocaine vaccine was first tested in the early 1990s 
in animal studies. Once administered, it induces the 
production of antibodies that bind to cocaine molecules 
in the bloodstream and, thereby, allow naturally occurring 
enzymes to convert them into inactive molecules.
The first randomised controlled trial of the vaccine was 
conducted in the United States, and involved 115 subjects 
undergoing opioid substitution treatment. The study found 
that subjects who received the vaccine and obtained 
an appropriate level of antibodies remained abstinent. 
However, only about four in 10 (38 %) vaccinated 
opioid users reached a level of antibodies that provided 
a two-month cocaine blockade (Martell et al., 2009). 
Similar results were observed in a later study covering 
10 male cocaine users who smoked the drug, were 
dependent and not seeking drug treatment.
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a reduction in cocaine use among patients also suffering 
from alcoholism. The reduction was attributed to the 
diminution of alcohol-related disinhibition and impaired 
judgement. Recent studies have also found a direct 
impact of disulfiram on the metabolism of cocaine. 
However, given the limited quality of the evidence, it 
was suggested that clinicians should balance possible 
benefits against the potential adverse effects of 
disulfiram (Pani et al., 2010).
The use of a number of anticonvulsant agents was 
assessed in 15 studies covering 1 066 patients (Minozzi 
et al., 2009). The drugs were not significantly better than 
the placebo in keeping patients in treatment, reducing 
the number and type of side effects or reducing cocaine 
use. Antipsychotic agents were assessed in seven studies 
covering 293 patients (Amato et al., 2009). The studies 
were generally too small to confirm possible effects, but 
the available results do not support the use of these drugs 
in the treatment of cocaine dependence.
Among patients undergoing opioid substitution 
treatment, it was found that the use of bupropion, 
dextroamphetamine and modafinil are associated with 
higher rates of sustained cocaine abstinence than are 
achieved with a placebo (Castells et al., 2010).
Among non-pharmacological interventions, some 
psychosocial interventions provided positive results 
in reducing drop-out rates, reducing cocaine use and 
improving attendance, in particular when provided 
along with contingency management with vouchers 
(Knapp. et al., 2007). Several ongoing studies are further 
investigating the effects of incentives-based interventions, 
in some cases in association with behavioural therapy 
and pharmacological interventions. Finally, treatment with 
auricular acupuncture did not provide significant results 
(Gates et al., 2006).
Harm reduction
Harm-reduction interventions targeting problem crack 
and cocaine users are a new area of work in many 
Member States. One reason for the limited provision of 
interventions in this field, in particular for crack users, 
might be a lack of knowledge among key workers about 
the drug, the target group and their needs. A recent 
review of harm-reduction interventions for stimulant 
users concluded that more attention had been given to 
specifying cocaine-related harms than to developing 
interventions to reduce them (Grund et al., 2010).
Member States usually provide cocaine injectors with the 
same services and facilities as are provided to opioid 
users, including recommendations for safer use, training 
for safer injecting and needle and syringe programmes. 
However, cocaine injecting is associated with increased 
risks of equipment sharing and with frequent injection, 
which can lead to vein collapse and to injecting in 
higher-risk parts of the body (e.g. legs, hands, feet and 
groin). Therefore, safer use recommendations should be 
adapted to these specific risks and one-for-one syringe 
exchange policies should be avoided. Due to the potential 
high frequency of injecting, the supply of sterile equipment 
to injectors should not be restricted (van Beek et al., 
2001). Clean crack pipes are also provided in some 
countries by low-threshold agencies (Spain, France).
Harm-reduction interventions targeting powder cocaine 
users in recreational settings focus mainly on raising 
awareness. Programmes offer advice and information 
to young people on the risks associated with alcohol 
and drug use in general, usually including material on 
the risks of cocaine use. Apart from awareness raising, 
harm-reduction options for this target group, which 
constitutes the vast majority of cocaine users in Europe, 
are almost non-existent.
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Heroin use, particularly injecting the drug, has been 
closely associated with public health and social problems 
in Europe since the 1970s. Today, this drug still accounts 
for the greatest share of morbidity and mortality related 
to drug use in the European Union. A decline in heroin 
use and associated problems has been observed during 
the late 1990s and the early years of the present century, 
though more recent data suggest that, in some countries, 
the trend may have changed direction. In addition, 
reports of the use of synthetic opioids, such as fentanyl, 
and the injection of stimulant drugs, such as cocaine or 
amphetamines, reflect the increasingly multifaceted nature 
of problem drug use in Europe.
Supply and availability
Two forms of imported heroin have historically been 
offered on the illicit drugs market in Europe. These are the 
commonly available brown heroin (its chemical base form), 
which comes mainly from Afghanistan, and white heroin 
(a salt form), which typically originates from south-east 
Asia, though this form is considerably less common. 
In addition, some opioid drugs are produced within Europe, 
principally home-made poppy products (e.g. poppy straw, 
concentrate from crushed poppy stalks or heads) in some 
east European countries (e.g. Latvia, Lithuania).
Production and trafficking
Heroin consumed in Europe originates predominantly 
in Afghanistan, which accounts for most of the global 
illicit opium output. The other producing countries are 
Myanmar, which mainly supplies markets in east and 
south-east Asia, Pakistan and Laos, followed by Mexico 
and Colombia, which are considered the largest suppliers 
of heroin to the United States (UNODC, 2009). Global 
opium production is estimated to have decreased from 
a peak in 2007, mainly due to a decline in Afghan 
production, which has fallen from 8 200 tonnes to 
6 900 tonnes in 2009. The most recent estimate of global 
potential heroin production is 657 tonnes, down from 
estimated levels of about 750 tonnes in 2007 and 2008 
(UNODC, 2010b).
Heroin arrives in Europe mainly by two trafficking 
routes. The historically important Balkan route brings 
heroin produced in Afghanistan through Pakistan, Iran 
and Turkey, and then through other transit or destination 
countries (Albania, Hungary, Bulgaria, Czech Republic, 
the former Yugoslav republics, Romania, Slovakia, Austria, 
Italy). Heroin also enters Europe by the ‘silk route’ via 
central Asia and Russia, and then through Belarus, Poland 
and Ukraine to, among others, Scandinavian countries 
via Lithuania (INCB, 2010b). Within the European Union, 
the Netherlands and, to a lesser extent, Belgium play an 
important role as secondary distribution hubs.
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Table 9: Production, seizures, price and purity of 
heroin
Production and seizures Heroin
Global production estimate (tonnes) 657
Global quantity seized (tonnes)
Heroin 
Morphine
75
17
Quantity seized (tonnes)
EU and Norway 
(Including Croatia and Turkey)
8
(24)
Number of seizures
EU and Norway 
(Including Croatia and Turkey)
54 400
(56 600)
Price and purity in Europe (1) Brown heroin
Mean retail price (EUR per gram)
Range
(Interquartile range) (2)
25–133
(33–80)
Mean purity (%)
Range 7–43
(1) Since few countries report the retail price and the purity of white heroin, 
the data are not presented in the table. They can be consulted in Tables 
PPP-2 and PPP-6 in the 2010 statistical bulletin.
(2) Range of the middle half of the reported mean price or purity.
NB: Data are for 2008 except the global production estimate (2009).
Sources: UNODC (2010b) for global values, Reitox national focal points for 
European data.
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(98) See Tables SZR-7 and SZR-8 in the 2010 statistical bulletin. Note that where data for 2008 are absent, the data for 2007 are used to estimate 
European totals.
(99) This analysis is preliminary as data for the United Kingdom are not yet available for 2008.
(100) See Tables PPP-2 and PPP-6 in the 2010 statistical bulletin for purity and price data.
Seizures
Worldwide reported seizures of opium increased markedly 
between 2007 and 2008, from 510 to 657 tonnes 
(Table 9). Iran accounted for more than 80 % of the total 
and Afghanistan for about 7 %. Global reported seizures 
of heroin increased to 75 tonnes in 2008, while global 
seizures of morphine decreased to 17 tonnes (UNODC, 
2010b).
In Europe, an estimated 56 600 seizures resulted in 
the interception of 23.6 tonnes of heroin in 2008. The 
United Kingdom continued to report the highest number of 
seizures, while Turkey again reported the greatest quantity 
seized, with 15.5 tonnes recovered in 2008 (98). Data for 
the years 2003–08 from 26 reporting countries indicate 
that the number of seizures has increased since 2003. 
The overall trend in the quantity of heroin intercepted in 
Turkey differs from that observed in the European Union 
(Figure 9). While Turkey reported a threefold increase in 
the quantity of heroin seized between 2003 and 2008, the 
amount seized in the European Union has shown a limited 
decline during this period, mainly due to decreases 
reported in Italy and the United Kingdom, the two countries 
seizing the largest quantities in the European Union (99).
Global seizures of acetic anhydride (used to manufacture 
heroin) increased from 57 300 litres in 2007 to 
199 300 litres in 2008, with the largest quantities 
seized reported by Slovenia (86 100 litres) and Hungary 
(63 600 litres). The INCB encourages the EU Commission 
and EU Member States to prevent the diversion of acetic 
anhydride from the internal market (INCB, 2010a).
Purity and price
In 2008, the mean purity of brown heroin tested ranged 
between 15 % and 30 % for most reporting countries; 
lower mean values were reported in France (11 %), 
Austria (retail only, 11 %) and Turkey (retail only, 7 %), 
and higher ones in Bulgaria (31 %), Portugal (32 %), 
Romania (43 %) and Norway (31 %). Between 2003 
and 2008, the purity of brown heroin increased in eight 
countries, while in four others it remained stable or 
decreased. The mean purity of white heroin was generally 
higher (30–50 %) in the few European countries reporting 
data (100).
The retail price of brown heroin continued to be higher 
in the Nordic countries than in the rest of Europe, with 
Sweden reporting a mean price of EUR 133 per gram 
and Denmark EUR 107. In eight other reporting countries, 
the retail price of brown heroin ranged between EUR 25 
and EUR 80 per gram. Over the period 2003–08, the 
retail price of brown heroin increased in five of the nine 
European countries reporting time trends, and decreased 
in four. In the few countries reporting the retail price of 
white heroin, it ranged between EUR 24 and EUR 213 per 
gram in 2008.
Prevalence estimates of problem opioid use
Data in this section are derived from the EMCDDA 
problem drug use (PDU) indicator, which includes mainly 
injecting drug use and the use of opioids, although 
in a few countries users of amphetamines or cocaine 
constitute an important component. Given the relatively 
low prevalence and the hidden nature of problem drug 
use, statistical extrapolations are required to obtain 
prevalence estimates from the available data sources 
(mainly drug treatment data and law enforcement data). 
Most countries are able to provide specific estimates of 
‘problem opioid users’, but it is worth noting that these 
are often polydrug users, and prevalence figures are 
often much higher in urban areas and among socially 
excluded groups.
Estimates of the prevalence of problem opioid use 
in European countries during the period 2003–08 
Figure 9: Estimated quantities of heroin seized in the European 
Union, Croatia and Norway, and in Turkey
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NB: The total amount of heroin seized is based on data from all 
EMCDDA reporting countries (27 EU Member States, Croatia, 
Turkey and Norway). Missing data were extrapolated from data 
for adjacent years.
Source: Reitox national focal points.
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(101) This estimate has been adjusted from 1.4 million to 1.35 million on the basis of new data. Because of large confidence intervals and the fact that the 
estimate is based on data from different years, it is not possible to conclude that there was a decrease in the prevalence of problem opioid use in 
Europe.
(102) See Figure TDI-2 (part ii) and Tables TDI-5 and TDI-113 in the 2010 statistical bulletin.
(103) See Table TDI-5 (part ii) in the 2010 statistical bulletin. 
(104) See Table TDI-22 in the 2010 statistical bulletin.
range roughly between one and eight cases per 
1 000 population aged 15–64 (Figure 10); overall 
prevalence of problem drug use is estimated to range 
from two to 10 cases per 1 000. The countries reporting 
the highest well-documented estimates of problem opioid 
use are Ireland, Malta, Italy and Luxembourg, while the 
lowest are reported by the Czech Republic, Cyprus, Latvia, 
Poland and Finland (both the Czech Republic and Finland 
have large estimates of problem users of amphetamines). 
Only Turkey reports figures of less than one case per 
1 000 population aged 15–64.
The average prevalence of problem opioid use in the 
European Union and Norway is estimated to be between 
3.6 and 4.4 cases per 1 000 population aged 15–64. This 
corresponds to some 1.35 million (1.2 million–1.5 million) 
problem opioid users in the European Union and Norway 
in 2008 (101). This estimate includes users in substitution 
treatment, but prisoners, especially those with longer 
sentences, may be under-represented.
Opioid users in treatment
Opioids continued to be cited as the primary drug by 
the majority (53 %) of those entering specialised drug 
treatment in 2008 in Europe, with heroin being cited 
by 48 % of all clients (102). However, considerable 
differences exist across Europe in the proportion of drug 
users entering treatment for problems related to these 
drugs, with opioid clients accounting for more than 
90 % of those entering treatment in Bulgaria, Estonia and 
Slovenia, between 50 % and 90 % in 15 other countries, 
and between 10 % and 49 % in a further nine (103). 
In addition to the about 200 000 treatment entrants 
declaring opioids as their primary drug in 2008, a further 
47 000 users of other drugs cited opioids as a secondary 
drug (104).
Many opioid users are enrolled in programmes providing 
long-term care, in particular substitution treatment. This 
is reflected in the higher proportion of primary opioid 
Figure 10: Estimates of the annual prevalence of problem opioid use (among population aged 15–64)
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NB: A horizontal mark indicates a point estimate; a vertical mark indicates an uncertainty interval: a 95 % confidence interval or one based on 
sensitivity analysis. Target groups may vary slightly, owing to different estimation methods and data sources; therefore, comparisons should be 
made with caution. Non-standard age ranges were used in the studies from Finland (15–54), Malta (12–64) and Poland (all ages). All three rates 
were adjusted to the population aged 15–64. For Germany, the interval represents the highest and lowest bounds of all existing estimates, and 
the point estimate a simple average of the midpoints. Methods of estimation are abbreviated: CR, capture–recapture; TM, treatment multiplier; 
MM, mortality multiplier; CM, combined methods; TP, truncated Poisson; OT, other methods. See Figure PDU-1 (part ii) and Table PDU-102 in the 
2010 statistical bulletin for further details.
Source: Reitox national focal points.
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(105) See Table TDI-38 in the 2010 statistical bulletin. 
(106) See Tables PDU-6 (part ii) and PDU-102 in the 2010 statistical bulletin for full information about the studies, including confidence intervals.
(107) See Figures TDI-1 and TDI-3 in the 2010 statistical bulletin.
(108) Some of the variation over time may be due to changes in data coverage or treatment availability, and overall trends can be strongly influenced by 
Italy and the United Kingdom, which provide the highest numbers of new heroin clients. See Tables TDI-3 and TDI-5 in the 2009 and 2010 statistical 
bulletins.
(109) See Table DRD-2 (part i) in the 2010 statistical bulletin.
users among drug users already in treatment from 
previous years. A recent analysis of data provided by 
nine countries found that primary opioid users accounted 
for 61 % of all reported clients in treatment, while they 
accounted for only 38 % of those entering treatment for 
the first time (105).
Trends in problem opioid use
The limited number of repeated estimates of the incidence 
and prevalence of problem opioid use, together with 
the statistical uncertainty around individual estimates, 
contributes to the difficulty in monitoring time trends. Data 
from eight countries with repeated prevalence estimates 
during the period 2003–08 suggest, however, a relatively 
stable situation. An apparent increase observed in 
Austria up to 2005 is not supported by the most recent 
estimate, which is now below the 2003 level. Ireland 
reported an increase between 2001 and 2006, which 
was less marked in Dublin (21 %) than outside the capital 
(164 %) (106).
Where adequate and up-to-date estimates of the 
incidence and prevalence of problem opioid use are not 
available, it may still be possible to analyse trends over 
time using data from other, mainly indirect, indicators 
such as treatment demand. Based on a sample of 
19 countries, the overall numbers of primary heroin users 
entering treatment, and of those entering treatment for 
the first time, increased between 2003 and 2008 (107). 
Focusing on a more recent time frame, the number of 
primary opioid users entering treatment increased in 
11 countries between 2007 and 2008. For those entering 
treatment for the first time, the overall upward trend 
levelled off in 2008, though six countries still reported 
increased numbers (108).
Data on drug-induced deaths in 2008, which are mostly 
associated with opioid use, provide no indication of 
a return to the decreasing trend observed until 2003 (see 
Chapter 7). Over half of the reporting countries recorded 
increasing numbers of drug-induced deaths between 2007 
and 2008 (109). The number of heroin seizures in Europe 
has also increased since 2003, while the quantities seized 
have decreased in the European Union. The change from 
a downward to an upward trend reported last year in 
heroin-related offences is now confirmed, with increases 
over 2003–08 in most European countries reporting 
sufficient data.
The use of heroin and opioid medicines by new groups, 
including socially integrated individuals and visitors to 
‘techno’ parties, was reported by the French ‘TREND’ 
system, which relies both on qualitative and quantitative 
data. Other qualitative studies (Eisenbach-Stangl et al., 
2009) also reported a small proportion of heroin users 
among targeted samples of socially integrated individuals. 
These may include experimental users and persons who 
are able to control their use of the drug (Shewan and 
Dalgarno, 2005; Warburton et al., 2005).
The available data suggest that the downward trend in 
opioid indicators observed until 2003 has levelled off. 
This is perhaps most clearly visible since 2003 among 
seizures and drug-induced deaths, and after 2004 in new 
treatment demands related to heroin use. These changes 
have occurred alongside increased opium production in 
Afghanistan until 2007, raising concerns that these events 
might be linked through increased availability of heroin on 
the European market.
Problem opioid use and injecting drug use in 
countries neighbouring the European Union
Among the countries neighbouring the European Union, 
Russia has the largest population of opioid users, with 
reported estimates ranging between 1.5 million and 
6 million users (UNODC, 2005). A recent study based 
on a treatment multiplier method — one of the methods 
recommended by the EMCDDA — provided an estimate 
of 1.68 million problem opioid users, which translates into 
16 per 1 000 population aged 15–64 (UNODC, 2009). 
The Russian Federal Drug Control Service estimates that 
10 000 heroin users die from an overdose every year 
(INCB, 2010b). The second-largest population of opioid 
users at the European Union’s borders is likely to be 
in Ukraine, with an estimate of between 323 000 and 
423 000 opioid users. This represents 10–13 cases 
per 1 000 population aged 15–64 (UNODC, 2009). 
Perceived increases in opioid use were also reported to 
UNODC in 2008 by Albania, Belarus and Moldova.
For 2007, it was estimated that there might be 
1 825 000 current injecting drug users (17.8 per 
1 000 inhabitants aged 15–64) in Russia and 375 000 
(11.6 per 1 000) in Ukraine, with close to 40 % of them HIV 
positive in both countries (Mathers et al., 2008). The rate 
of newly reported HIV infection among injecting drug users 
is also much higher in Russia (79 per million in 2006) and 
in Ukraine (153 per million in 2006) than in other countries 
and regions of the world such as Australia, Canada, the 
European Union and the USA (Wiessing et al., 2009).
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(110) See Figure PDU-2 in the 2010 statistical bulletin.
(111) The weighted average is 0.26 %, with an uncertainty range (weighted averages of lower and upper limits of the country estimates) of 0.23 % to 
0.30 %, resulting in an estimate of 886 606 (788 778–1 040 852) for 2008. This estimate must be considered with caution as it is based on data 
available from only 12 of the 27 EU Member States and Norway.
(112) See Table TDI-5 in the 2010 statistical bulletin.
(113) See Table PDU-6 (part iii) in the 2010 statistical bulletin.
(114) See Table PDU-104 in the 2010 statistical bulletin.
Injecting drug use
Injecting drug users are among those at highest risk of 
experiencing health problems from their drug use, such 
as blood-borne infections (e.g. HIV/AIDS, hepatitis) or 
drug overdoses. In most European countries, injection is 
commonly associated with opioid use, although in a few 
countries it is associated with use of amphetamines. Only 
14 countries were able to provide recent estimates of 
the prevalence of injecting drug use (110), despite their 
importance for public health. Improving the level of 
information available on this special population continues 
to be an important challenge for the development of 
health monitoring systems in Europe.
The available estimates suggest large differences 
between countries in the prevalence of injecting 
drug use. Estimates range from less than one to five 
cases per 1 000 population aged 15–64 for most 
of the countries, with an exceptionally high level of 
15 cases per 1 000 reported in Estonia. When the 
latter is excluded as an outlier, the weighted average is 
about 2.6 cases per 1 000 population aged 15–64 (111), 
which, if extrapolated to the population of the European 
Union, would correspond to between 750 000 and 
1 million active injecting drug users. The number of former 
injecting drug users is likely to be larger (Sweeting et al., 
2008), but is not known for most EU countries.
Opioid users entering specialised drug treatment often 
report injecting as the usual mode of administration. 
This is the case for more than half of opioid clients in 
16 countries, between 25 % and 50 % in six countries 
and under 25 % in another five countries. The lowest 
proportions of injectors among opioid users entering 
treatment are reported by the Netherlands (5 %) and 
Spain (19 %), while the highest are reported by Lithuania 
(99 %), Romania (95 %), Estonia (91 %) and Slovakia 
(86 %) (112).
Drawing conclusions on time trends in the prevalence 
of injecting drug use is difficult because of the lack of 
data and the wide confidence intervals of the estimates. 
Available data suggest, however, a stable situation in 
the Czech Republic, Greece, Cyprus and Norway (113). 
A statistically significant decrease was observed in the 
United Kingdom, between the years 2004 and 2006. 
Among heroin users entering treatment, the proportion 
of injectors has decreased overall in the last years, with 
statistically significant decreases between 2002 and 2007 
reported by 13 countries. Increases over this period were 
reported by only three countries (Bulgaria, Lithuania, 
Slovakia) (114). The proportion of injectors is also overall 
slightly lower among opioid users entering treatment for 
the first time (38 %) than among all opioid users entering 
treatment (42 %). This is the case in 20 out of 23 reporting 
countries. More detailed analysis of the prevalence 
and trends of injecting drug use is provided elsewhere 
(EMCDDA, 2010c).
Non-injecting opioid use
Following the stabilisation or decline of opioid injection 
in several European countries, more attention has been 
given to other routes of administration such as inhaling 
the substance as heated vapour (chasing, smoking) or as 
powder (snorting, sniffing) or ingesting it. Few countries 
have reported estimates of populations of non-injecting 
opioid users, with only Norway providing a recent figure. 
In 2008, it was estimated that smoking was the sole route 
of drug administration for 1 450 heroin users, or about 
15 % of all estimated heroin users in Norway. Data on 
users entering specialised drug treatment services confirm 
the presence of sizeable groups of users smoking or 
sniffing the drug within the opioid-using populations in 
some countries. For example, smoking was reported as 
the main route of administration for between half and 
three quarters of primary opioid users entering outpatient 
treatment in Belgium, Ireland, Spain, the Netherlands 
and the United Kingdom. Sniffing was also reported as 
the main route of administration by about one third of 
opioid clients in Austria and by about half in Greece and 
France (1).
The choice of route of administration depends on several 
factors, such as its efficiency, pressure from the social 
environment, concern about health consequences (Bravo 
et al., 2003) and the type of opioid used. For example, 
the commonly available brown heroin (a chemical base 
form), which comes mainly from Afghanistan, is primarily 
smoked and chased. White heroin (a salt form), which 
typically originates from south-east Asia, can easily 
be snorted up the nose in powder form; it can also be 
dissolved in cold water without additives and injected, 
but it can be only very inefficiently smoked or chased. 
Opioid substitution medicines are commonly distributed 
in liquid form instead of tablets or can have added 
substances that reduce or change the drug’s effects when 
injected.
(1) See Table TDI-17 (part ii) in the 2010 statistical bulletin.
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(115) See Tables TDI-10, TDI-32 and TDI-103 in the 2010 statistical bulletin.
(116) See Tables TDI-5 and TDI-21 in the 2010 statistical bulletin.
(117) See also Chapter 2.
(118) See Tables TDI-11, TDI-33, TDI-107 and TDI-109 in the 2010 statistical bulletin.
(119) See Table TDI-24 in the 2010 statistical bulletin.
(120) See Table HSR-3 in the 2010 statistical bulletin.
(121) See Figure HSR-2 in the 2010 statistical bulletin.
Treatment of problem opioid use
Data gathered by the EMCDDA’s treatment demand 
indicator can be used to describe the characteristics of 
a substantial subgroup of drug users entering treatment 
and, more specifically, those who have entered 
specialised drug treatment services during the year.
Clients entering outpatient treatment for primary opioid 
use are on average 34 years old, with female clients and 
those entering treatment for the first time being on average 
younger (115). Almost all countries report an increase in the 
mean age of their opioid clients since 2003. The overall 
male to female ratio among outpatient opioid clients is 
3.5:1, although females make up a higher proportion in 
northern countries (e.g. Sweden, Finland) and a lower 
proportion in southern countries (e.g. Greece, Spain, 
Italy) (116).
Opioid users entering treatment have higher rates of 
unemployment, lower levels of educational attainment and 
higher levels of psychiatric disorders than clients reporting 
other primary drugs (117). Almost all opioid users entering 
treatment report initiation before the age of 30 and about 
half before the age of 20. An average time lag of about 
10 years is reported between first use of opioids and first 
contact with drug treatment (118).
Treatment provision and coverage
Treatment for opioid users is mostly conducted in 
outpatient settings, which can include specialist centres, 
general practitioners’ surgeries and low-threshold facilities 
(see Chapter 2). In a few countries, inpatient centres are 
a major component of the drug treatment system, notably 
in Bulgaria, Greece, Latvia, Poland, Romania, Finland and 
Sweden (119). The range of options available in Europe 
for the treatment of opioid dependence is broad and 
increasingly differentiated, though it varies geographically 
in terms of accessibility and coverage. Drug-free and 
substitution treatments for opioid use are available in all 
EU Member States, Croatia and Norway. In Turkey, the 
use of substitution treatment is currently under study.
Drug-free treatment is a therapeutic approach that 
generally requires individuals to abstain from all 
substances, including substitution medication. Patients 
participate in daily activities and receive intensive 
psychological support. While drug-free treatment can 
take place in both outpatient and inpatient settings, 
the types most commonly reported by Member States 
are residential programmes that apply therapeutic 
community principles or the Minnesota model. France 
and the Czech Republic are currently performing 
outcome evaluations of their therapeutic communities, 
with results expected in 2010. Under the French action 
plan, the availability of this treatment modality is to be 
expanded in the future. Therapeutic communities are 
the largest type of drug treatment in Poland. However, 
for economic reasons and because of changing patient 
profiles, the duration of treatment programmes is 
reported to be gradually shortening. Finally, Croatia 
and Portugal have recently developed guidelines for 
therapeutic communities.
Substitution treatment, generally integrated with 
psychosocial care, is typically provided at specialised 
outpatient centres. Thirteen countries report that it is also 
provided by general practitioners, usually under shared-
care arrangements with specialised treatment centres. 
General practitioners can achieve better results than 
specialised centres in terms of retention in treatment, 
abstinence rates and co-consumption of other drugs. This 
was found in a 12-month naturalistic study of 2 694 clients 
in substitution treatment in Germany (Wittchen et al., 
2008). Other studies have shown that the implementation 
of substitution treatment in primary care settings is not 
only feasible but can also be cost-effective (Gossop et al., 
2003; Hutchinson et al., 2000).
The total number of opioid users receiving substitution 
treatment in the European Union, Croatia and Norway is 
still growing, with an estimated 670 000 clients in 2008, 
up from 650 000 in 2007 (120) and about 500 000 in 
2003. Client numbers showed some increase in several 
central and east European countries, but the countries 
that joined the European Union after 2004 continue to 
make up only about 2 % of the total number of opioid 
substitution clients in the European Union (121).
A comparison of the number of substitution treatment 
clients in the European Union with the estimated number of 
problem opioid users suggests a treatment coverage rate 
of about 50 %. However, coverage varies considerably 
between countries, with rates below 40 % reported 
by seven of the 14 countries for which estimates of the 
number of problem opioid users are available, and four 
of these countries reporting less than 10 % coverage (see 
Figure 11). Nevertheless, it can be estimated that two 
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(122) These estimates should be considered with caution as there is still a lack of precision in the data sets.
out of three problem opioid users in the European Union 
live in countries where substitution treatment coverage is 
high (122).
Most substitution clients in Europe receive methadone 
(70–75 %), but the number of countries where it is the 
only available substance is decreasing. High-dosage 
buprenorphine is now available in all but four EU Member 
States (Bulgaria, Spain, Hungary, Poland), and is used in 
20–25 % of all substitution treatments provided in Europe 
and in more than 50 % in the Czech Republic, France, 
Cyprus, Latvia, Sweden and Croatia. In France, where 
buprenorphine has always predominated, methadone is 
now prescribed to a growing proportion of substitution 
clients. The buprenorphine–naloxone combination, which 
was approved by the European Medicines Agency 
in 2006, has been introduced in 14 countries. Other 
options, which represent a small percentage of all 
substitution treatments, include slow-release morphine 
(Bulgaria, Austria, Slovenia), codeine (Germany, 
Cyprus, Austria) and diacetylmorphine (heroin). Heroin 
prescription has now become an established treatment 
option in Denmark, Germany and the Netherlands; it also 
exists in Spain and the United Kingdom, and pilot projects 
are under preparation in Belgium and Luxembourg.
Access to treatment
Regulations about provision and dispensing of opioid 
substitution treatment are key to its accessibility. Legal 
frameworks may allow all general practitioners (Belgium, 
Czech Republic, Denmark, Germany, France, Italy, 
Cyprus, Netherlands, Portugal, United Kingdom, Croatia) 
or those who have been specifically trained or accredited 
(Germany, Ireland, Luxembourg, Austria, Slovenia, 
Norway) to prescribe one or more substitution substance. 
In other countries (Bulgaria, Estonia, Greece, Spain, 
Lithuania, Hungary, Poland, Romania, Slovakia, Finland, 
Sweden), only specialist treatment centres can provide 
substitution treatment.
In most European countries, substitution medication can 
be dispensed by general practitioners, pharmacies or 
mobile outreach units. This is, however, not the case 
in Bulgaria, Estonia, Greece, Lithuania, Poland and 
Slovakia, where only specialist treatment centres can 
dispense the medication. High-dosage buprenorphine can 
be dispensed by all general practitioners in the Czech 
Republic, or any pharmacy in Latvia. In Romania, Hungary 
and Finland, pharmacies are only entitled to dispense the 
combination buprenorphine–naloxone. It is reported that 
as this medication is only recently available and expensive 
in Hungary and Romania, only small numbers of clients 
receive it in these two countries.
Information on the cost of opioid substitution medication for 
clients has recently been collected. Among the 26 reporting 
countries, 17 indicated that the medication (in most cases 
methadone) is free of charge unless treatment is sought 
from private providers. In Belgium and Luxembourg, the 
client has to pay part of the medication costs only when 
it is prescribed by a general practitioner. In the Czech 
Republic, Latvia, Portugal, Hungary and Finland, treatment 
with methadone is free of charge, but buprenorphine or 
the combination buprenorphine–naloxone have to be paid 
for in full or partially by the client. In Latvia, for example, 
the monthly cost for a daily 8 mg dose of buprenorphine 
is about EUR 250. Methadone is generally cheaper than 
other substitution medications with similar effectiveness, 
such as buprenorphine (WHO, 2009), which partly 
explains why many national health insurances provide 
full reimbursement for methadone in preference to other 
substitution medications. Generic versions of high-dosage 
buprenorphine, which are cheaper, have been available 
since 2006 in France, where they are prescribed to 
approximately 30 000 clients (30 % of all buprenorphine 
clients).
Information on costs, provision of substitution treatment 
and dispensing of substitution medicines show regional 
Figure 11: Estimated proportion of problem opioid users 
undergoing substitution treatment
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differences in Europe. Countries in the north and east of 
Europe often apply a more focused and higher-threshold 
access model, whereas many countries in the west of 
Europe implement a multi-site and low-threshold access 
model. These differences may reflect different models of 
care, with priority given in some countries to the goal of 
abstinence and to psychosocial approaches, and in others 
to the stabilisation and retention of clients and to harm 
reduction approaches.
Treatment effectiveness and quality
Opioid substitution treatment, combined with psychosocial 
interventions, was found to be the most effective 
treatment option for opioid users. In comparison with 
detoxification or no treatment at all, methadone or high-
dosage buprenorphine treatments show significantly 
better outcomes regarding drug use, criminal activity, risk 
behaviours and HIV-transmission, overdoses and overall 
mortality, as well as better rates of retention in treatment 
(WHO, 2009).
The outcomes of opioid withdrawal are generally low 
in the long term (Mattick et al., 2009), but it may help 
patients, if it is their informed choice to undergo this 
type of treatment. In inpatient or outpatient settings, 
detoxification is achieved through diminishing doses of 
methadone or buprenorphine (as preferred treatments) or 
alpha-2 agonists. Accelerated withdrawal techniques that 
use opioid antagonists in combination with heavy sedation 
are not recommended because of safety concerns 
(Gowing et al., 2010). After opioid withdrawal, patients 
who are motivated to remain abstinent from opioid use 
should be advised to consider naltrexone to prevent 
relapse.
The combination of buprenorphine and naloxone 
(marketed as Suboxone) was created to prevent the 
injection of buprenorphine. Nevertheless, its effectiveness 
in preventing intravenous use of buprenorphine is not yet 
clear (Bruce et al., 2009; Simojoki et al., 2008).
EMCDDA ‘Insight’ on heroin-assisted treatment
Heroin-assisted treatment is currently provided to about 
1 500 chronic problem opioid users in five EU Member 
States. Most of these countries, as well as Switzerland 
and Canada, have conducted experimental trials to assess 
the outcomes of this type of treatment. In 2011, with 
the support of a team of international researchers and 
clinicians, the EMCDDA will publish a study on this type of 
treatment, reviewing the scientific evidence accumulated in 
recent years. The ‘Insight’ will also review the development, 
operational delivery and clinical practices for heroin-
assisted treatment, and describe some of the challenges 
associated with its implementation. A set of minimum 
quality standards will also be outlined.
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Introduction
Drug use can produce a wide range of negative 
consequences, such as accidents, mental health 
disorders, pulmonary diseases, cardiovascular problems, 
unemployment or homelessness. Harmful consequences 
are particularly prevalent among problem drug users, 
whose general health and socioeconomic situation can be 
far below those in the general population.
Opioid use and injecting drug use are two forms of drug 
use closely associated with such harms, notably overdoses 
and the transmission of infectious diseases. The number 
of fatal overdoses reported in the European Union in the 
last two decades is equivalent to about one overdose 
death every hour. Research also shows that, in the last two 
decades, a large number of drug users have died from 
other causes, such as AIDS or suicide.
Reducing the mortality and morbidity related to drug use 
is central to European drug policies. The main efforts in 
this area are through interventions that are directed at the 
groups that are most at risk, and targeting the behaviours 
directly associated with drug-related harms.
Drug-related infectious diseases
Infectious diseases such as HIV and hepatitis B and C are 
among the most serious health consequences of drug use. 
Even in countries where HIV prevalence in injecting drug 
users is low, other infectious diseases including hepatitis A, 
B, C and D, sexually transmitted diseases, tuberculosis, 
tetanus, botulism, anthrax and human T-lymphotropic virus 
may disproportionately affect drug users. The EMCDDA 
is systematically monitoring HIV and hepatitis B and C 
infection among injecting drug users (123).
HIV and AIDS
By the end of 2008, the rate of reported new HIV 
diagnoses among injecting drug users has remained 
low in most countries of the European Union, and the 
overall EU situation compares positively in a global 
context (ECDC and WHO-Europe, 2009; Wiessing et al., 
2009). This may, at least partly, follow from the increased 
availability of prevention, treatment and harm-reduction 
measures, including substitution treatment and needle 
and syringe programmes (Wiessing et al., 2009). Other 
factors, such as the decline in injecting drug use that 
has been reported in some countries, may also have 
played an important role. Nonetheless, in some parts 
of Europe, data suggest that HIV transmission related to 
injecting drug use continued at relatively high rates in 
2008, underlining the need to ensure the coverage and 
effectiveness of local prevention practice.
Trends in HIV infection
Data on reported newly diagnosed cases related to 
injecting drug use for 2008 suggest that infection rates 
are still generally falling in the European Union, following 
the peak in 2001–02, which was due to outbreaks in 
Estonia, Latvia and Lithuania (124). In 2008, the overall 
rate of newly diagnosed infections among injecting drug 
users in the 23 EU Member States for which national data 
are available was 2.6 cases per million population, down 
from 3.7 per million in 2007 (125). Of the four countries 
reporting the highest rates of newly diagnosed infections 
(Estonia, Latvia, Lithuania, Portugal), all continued their 
downward trend, with a marked decline in Estonia and 
Latvia (Figure 12). In Estonia, the decrease was from 
86 cases per million in 2007 to 27 per million in 2008, 
and in Latvia from 62 cases per million in 2007 to 
44 per million in 2008.
Overall, marked increases in newly diagnosed HIV 
infection among injecting drug users have not been 
observed between 2003 and 2008, and reported rates 
remain low. However, in Bulgaria, the rate for injectors 
accelerated from 0.0 new cases per million population 
in 2003 to 6.8 per million in 2008, whereas in Sweden 
(123) For details on methods and definitions, see the 2010 statistical bulletin.
(124) Reporting procedures for HIV infection have changed in recent years, and data are now available by year of diagnosis rather than by year of report 
(ECDC and WHO-Europe, 2009). This results in lower figures in some countries that are likely to reflect more accurately true incidence (e.g. Portugal). 
In some cases, however, reporting delays may also have resulted in an underestimation of incidence. See Table INF-104 in the 2010 statistical bulletin. 
(125) National data are not available for Denmark, Spain, Italy and Austria.
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(126) See Table INF-108 in the 2010 statistical bulletin.
(127) See Table INF-109 in the 2010 statistical bulletin.
(128) See Table INF-110 in the 2010 statistical bulletin.
(129) See Figure INF-1 and Table INF-104 (part ii) in the 2010 statistical bulletin.
(130) See Table INF-111 in the 2010 statistical bulletin.
a peak at 6.7 cases was observed in 2007, suggesting 
a continued potential for HIV outbreaks among injecting 
drug users.
Trend data from HIV prevalence monitoring in samples 
of injecting drug users are an important complement 
to data from HIV case reporting. Prevalence data are 
available from 24 countries over the period 2003–08 (126). 
In 16 countries, HIV prevalence remained unchanged. In 
seven countries (Bulgaria, Spain, France, Italy, Poland, 
Portugal, Norway) HIV prevalence showed decreases, six 
of these being based on national samples, while in France 
the trend is based on data from five cities. Regional 
increases were reported in three countries — Bulgaria 
(Sofia), Italy (in two out of 21 regions) and Lithuania 
(Vilnius). There is however a downward trend in the newly 
diagnosed cases of HIV infection among injecting drug 
users in these three countries.
The comparison of trends in newly reported infections 
related to injecting drug use with trends in HIV prevalence 
among injecting drug users suggests that the incidence of 
HIV infection among injecting drug users is declining in 
most countries at national level.
Despite rapidly declining trends, the rate of reported new 
HIV diagnoses in 2008 related to injecting drug use is still 
high in Latvia (44 cases per million population), Estonia 
(27), Portugal (20.7) and Lithuania (12.5), suggesting that 
transmission is still occurring among injecting drug users in 
these countries.
Further indications of ongoing HIV transmission in recent 
years are provided by reports of prevalence levels of 
over 5 % among young injecting drug users (samples of 
50 or more injecting drug users under age 25) in several 
countries: Estonia (two regions, 2005), France (five cities, 
2006), Latvia (one city, 2007), Lithuania (one city, 2006) 
and Poland (one city, 2005) (127). Though caution is 
needed, as some of the sample sizes are small, the data 
show statistically significant increases in HIV prevalence 
among young injectors between 2003 and 2008 in 
Belgium (Flemish Community) and Bulgaria, whereas 
declines can be seen in Sweden and Spain. Data on HIV 
prevalence in new injectors (injecting for less than two 
years) further support a likely decrease in this group in 
Sweden (128).
AIDS incidence and access to HAART
Information on the incidence of AIDS, though not a good 
indicator of HIV transmission, can be important for 
showing the new occurrence of symptomatic disease. High 
incidence rates of AIDS may indicate that many injecting 
drug users infected with HIV do not receive highly active 
antiretroviral treatment at a sufficiently early stage in their 
infection to obtain maximum benefit from the treatment. 
A recent review confirms that this may still be the case in 
some EU countries (Mathers et al., 2010).
Estonia is the country with the highest incidence of AIDS 
related to injecting drug use, with an estimated 30.6 new 
cases per million population in 2008, down from 
33.5 new cases per million in 2007. Relatively high levels 
of AIDS incidence are also reported for Latvia, Lithuania, 
Portugal and Spain: 25.5, 10.7, 10.2 and 8.9 new cases 
per million, respectively. Among these four countries, the 
trend is downward in Spain and Portugal, but not in Latvia 
and Lithuania (129).
Hepatitis B and C
While high prevalence levels of HIV infection are found 
only in some EU Member States, viral hepatitis and, in 
particular, infection caused by the hepatitis C virus (HCV) 
are highly prevalent in injecting drug users across Europe. 
HCV antibody levels among national samples of injecting 
drug users in 2007–08 vary from about 12 % to 85 %, 
with eight out of the 12 countries reporting levels in excess 
of 40 % (130). Three countries (Czech Republic, Hungary, 
Figure 12: Trends in newly reported HIV infections in injecting 
drug users in four EU Member States reporting high rates of 
infection
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(131) See Figure INF-6 (part ii) and (part iii) in the 2010 statistical bulletin.
(132) See Table INF-115 in the 2010 statistical bulletin.
(133) See Table INF-111 in the 2010 statistical bulletin.
Slovenia) report a prevalence of under 25 % in national 
samples of injecting drug users, although infection rates at 
this level still constitute a significant public health problem.
Within countries, HCV prevalence levels can vary 
considerably, reflecting both regional differences and the 
characteristics of the sampled population. For example, in 
Italy, regional estimates range from about 31 % to 87 % 
(Figure 13).
Recent studies (2007–08) show a wide range of 
prevalence levels among injecting drug users under 
25 years and those injecting for less than two years, 
suggesting different levels of HCV incidence in those 
populations across Europe (131). Nonetheless, these studies 
also show that many injectors contract the virus early in 
their injecting career. This implies that there is only a small 
time window for initiating effective HCV prevention 
measures.
The prevalence of antibodies to hepatitis B virus (HBV) 
also varies to a great extent, possibly partly due to 
differences in vaccination levels, although other factors 
may play a role. The most complete dataset available 
for HBV is that for the antibody to the hepatitis B core 
antigen (anti-HBc), which indicates a history of infection. 
For 2007–08, four of the nine countries providing data 
on this virus among injecting drug users report anti-HBc 
prevalence levels of over 40 % (132).
HCV prevalence is observed to be declining in nine 
countries and increasing in three others, while a further 
four countries have data sets showing both types of trends, 
although caution is warranted given the limited sample 
size in some instances (133). Studies on young injectors 
(under age 25) suggest mostly stable prevalence and 
some declining trends, although an increase is reported in 
one region in Greece (Attica). This is confirmed in data for 
new injectors (injecting less than two years) for Greece, 
both in Attica and at national level. Data for new injectors 
also show an increase in Slovenia, although sample sizes 
are small, and declines in Portugal (national) and Sweden 
(Stockholm).
Trends in notified cases of hepatitis B and C show different 
pictures, but these are difficult to interpret as data quality 
is low. However, some insight into the epidemiology of 
these infections may be provided by the proportion of 
Figure 13: Prevalence of HCV antibodies among injecting drug users
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(134) See Tables INF-105 and INF-106 in the 2010 statistical bulletin.
(135) For further information about national priorities and provision levels, see Table HSR-6 in the 2009 statistical bulletin.
(136) See Table HSR-6 in the 2009 statistical bulletin and Table HSR-5 in the 2010 statistical bulletin. For 2007/08, data on the number of syringes were 
not available for Denmark, Germany, Italy and the United Kingdom.
(137) These figures do not include pharmacy sales, which may represent an important source of sterile syringes for drug users in several countries.
injecting drug users among all notified cases where risk 
factors are known (Wiessing et al., 2008). For hepatitis B, 
the proportion of injecting drug users has declined 
between 2003 and 2008 in eight out of 17 countries. 
In the case of hepatitis C, the proportion of injecting 
drug users among notified cases has declined in six 
countries between 2003 and 2008, and has increased 
in three other countries (Czech Republic, Malta, United 
Kingdom) (134).
Preventing and responding to infectious 
diseases
The prevention of infectious diseases among drug users 
is an important public health goal of the European Union 
and a component of most Member States’ drug policies. 
Countries respond to the spread of infectious diseases 
among drug users by a combination of approaches, 
including: drug treatment, particularly opioid substitution 
treatment; the provision of sterile injection equipment and 
other paraphernalia; and community-based activities that 
provide information, education, testing and behavioural 
interventions, often implemented through outreach or 
low-threshold agencies (135). These measures, together 
with antiretroviral therapy and tuberculosis diagnosis and 
treatment, have been promoted by UN agencies as the 
core interventions for HIV prevention, treatment and care 
for injecting drug users (WHO, UNODC and UNAIDS, 
2009).
In Europe, the availability of drug treatment and 
harm-reduction measures has increased considerably 
since the mid-1990s. Both opioid substitution treatment 
and needle and syringe programmes now exist in all 
countries except Turkey. While the provision of these 
interventions remains limited in several countries, it 
is estimated that one in two problem opioid users in 
Europe could be receiving opioid substitution treatment 
(see Chapter 6). A recent review (Kimber et al., 2010) 
concludes that there is now sufficient evidence that 
this type of treatment reduces HIV transmission and 
self-reported injecting risk behaviour but evidence of 
a reduction in hepatitis C transmission is more limited. 
A cohort study in Amsterdam found, however, that ‘full 
participation’ in both needle and syringe programmes 
and opioid substitution treatment was associated with 
a much lower incidence of both HIV and HCV among 
injecting drug users (Van den Berg et al., 2007), while 
a recent cohort study in the United Kingdom linked 
opioid substitution treatment with statistically significant 
reductions in HCV incidence (Craine et al., 2009).
Interventions
The most frequently reported priority is access to sterile 
injecting equipment. Data on syringe provision through 
specialised needle and syringe programmes in 2007–08 
are available for all but four countries (136). They show that 
about 40 million syringes per year are distributed through 
these programmes. This is equivalent to an average of 
80 syringes per estimated injecting drug user in the 
countries providing syringe data.
The average number of syringes distributed in a year per 
injecting drug user can be calculated for 13 European 
countries (Figure 14). In seven of these countries, the 
average number of syringes given out by specialised 
programmes is equivalent to less than 100 per injector, 
five countries give out between 140 and 175 syringes and 
Norway reports the distribution of more than 320 syringes 
per injector (137). For the prevention of HIV, UN agencies 
judge the annual distribution of 100 syringes per injecting 
drug user as low, and 200 syringes per injector as high 
(WHO, UNODC and UNAIDS, 2009).
Anthrax outbreak among heroin users in the 
United Kingdom and Germany
Anthrax is an acute infectious disease caused by the 
bacterium Bacillus anthracis. It most commonly occurs in 
wild and domestic animals, and is endemic in a number of 
mainly agricultural countries, but is very rare in Europe.
In December 2009, an alert reporting an outbreak of 
anthrax among injecting drug users in Scotland was issued 
by the United Kingdom. By 31 May 2010, 42 cases, 
13 of which resulted in death, had been confirmed in 
Scotland, with a further three cases (two fatal) in England 
and two (one fatal) in Germany. The anthrax strain found 
in Germany and England was indistinguishable from 
that found in Scotland, strongly suggesting a common 
source of infection. Furthermore, as all reported cases 
occurred among heroin users, it is likely that the source is 
a contaminated batch of heroin. No evidence of anthrax 
spores was, however, found in samples of heroin analysed 
in Scotland by the end of May 2010.
The European Centre for Disease Prevention and Control 
(ECDC) and the EMCDDA conducted joint risk assessments 
related to this outbreak. Regular information updates were 
also disseminated, leading to subsequent reports of clusters 
of deaths in drug users in other countries. These proved, 
however, not to be related to anthrax infection.
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(138) See ‘Drug-related mortality: a complex concept’ in the 2008 annual report.
A recent study on the cost-effectiveness of needle and 
syringe programmes in Australia, where 30 million 
syringes are distributed each year, estimates that 
they have prevented more than 32 000 cases of HIV 
infection and almost 100 000 cases of hepatitis C 
since their introduction in 2000 (National Centre in HIV 
Epidemiology and Clinical Research, 2009).
New data for 2008 from 14 countries show increases 
in syringe provision to drug users in Belgium (Flemish 
Community), the Czech Republic, Estonia, Hungary, the 
United Kingdom (Northern Ireland) and Croatia, thereby 
confirming earlier trends. Increases were also reported 
in Portugal and Lithuania, where numbers had previously 
declined. A decrease compared to 2007 was reported in 
Greece, Romania and Slovakia, as well as in Luxembourg 
and Poland, where the downward trend was already 
observed the year before. The programme in Cyprus was 
not used by drug users.
Needle and syringe programmes in Europe increasingly 
provide a range of other injecting-related items 
(e.g. mixing containers) to prevent them being shared. 
They also provide equipment that can be used for 
non-injecting forms of drug use, for example pipes or 
aluminium foil, in order to encourage users to discontinue 
injecting. Another example of this is reported by the 
Czech Republic, where low-threshold agencies started to 
provide methamphetamine injectors with hard gelatine 
capsules that can be filled with the drug and swallowed.
Recent developments in the diagnosis, prevention and 
treatment of chronic hepatitis have been reported by 
European countries. These include the adoption of specific 
programmes or action plans (e.g. Denmark, France, 
United Kingdom — England, Scotland and Northern 
Ireland). Existing interventions include: specific information 
materials; safer-injection training targeting new and young 
injectors, implemented by outreach teams (e.g. Romania) 
or through peer education (e.g. in prisons in Spain and 
Luxembourg); and easily accessible and free counselling 
and testing. The United Kingdom also reports the use of 
contingency management to encourage testing. Other 
reported measures aim at keeping injection levels low 
through retention in drug treatment; at the integration 
of viral hepatitis services into settings that serve drug 
users; and at revising HCV treatment guidance to 
improve access to such treatment (e.g. Czech Republic). 
Several countries have also launched initiatives aimed at 
increasing knowledge and awareness about chronic viral 
hepatitis among healthcare and social service providers 
(Austria) and among the public (e.g. Germany, Ireland, 
Netherlands).
Drug-related deaths and mortality
Drug use is one of the major causes of health problems 
and mortality among young people in Europe and 
can account for a considerable proportion of all 
deaths among adults. Studies found that between 
10 % and 23 % of mortality among those aged 15 to 49 
could be attributed to opioid use (Bargagli et al., 2006; 
Bloor et al., 2008).
Mortality related to drug use comprises the deaths 
caused directly or indirectly by the use of drugs. This 
includes deaths from drug overdoses (drug-induced 
deaths), HIV/AIDS, traffic accidents — in particular 
when combined with alcohol — violence, suicide and 
chronic health problems caused by repeated use of drugs 
(e.g. cardiovascular problems in cocaine users) (138).
Drug-induced deaths
During the period 1995–2007, between 6 400 and 
8 500 drug-induced deaths were reported each year by 
EU Member States, Croatia, Turkey and Norway. The 
United Kingdom and Germany reported almost half of 
all drug-induced deaths in 2007. Population mortality 
Figure 14: Syringes distributed through specialised programmes, 
per estimated injecting drug user
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2010 statistical bulletin.
Source: Reitox national focal points.
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(139) See Figure DRD-7 (part i) and Tables DRD-5 (part ii) and DRD-107 (part i) in the 2010 statistical bulletin.
(140) For detailed methodological information, see the 2010 statistical bulletin.
(141) As most of the drug-induced deaths reported to the EMCDDA are opioid overdoses (mainly heroin), the general characteristics of the reported deaths 
are presented here to describe and analyse deaths related to heroin use. See Figure DRD-1 in the 2010 statistical bulletin.
(142) See Figures DRD-2 and DRD-3 and Table DRD-1 (part i) in the 2010 statistical bulletin.
rates due to overdoses vary between countries, ranging 
from two to just under 85 deaths per million population 
aged 15–64 years (average of 21 deaths per million). 
Rates of over 20 deaths per million are found in 14 out 
of 28 European countries, and rates of over 40 deaths 
per million in six countries. Among Europeans aged 
15–39 years, drug overdoses accounted for 4 % of all 
deaths (139). Areas with higher prevalence of problem 
drug use can be disproportionally affected. For example, 
in 2008, the number of drug-induced deaths in Scotland 
was 112.5 per million inhabitants, which is much 
higher than the rate for the United Kingdom as a whole 
(38.7 per million).
The number of drug-induced deaths reported can be 
influenced by the prevalence and patterns of drug use 
(injection, polydrug use), the age and the co-morbidities 
of drug users and the availability of treatment and 
emergency services, as well as the quality of data 
collection and reporting. Improvements in the reliability of 
European data have allowed better descriptions of trends, 
and most countries have now adopted a case definition in 
line with that of the EMCDDA (140). Nevertheless, caution 
must be exercised when comparing countries, as national 
differences exist in the quality of case ascertainment and 
reporting practices.
Deaths related to opioids
Heroin
Opioids, mainly heroin or its metabolites, are present in 
the majority of drug-induced deaths reported in Europe. 
In the 20 countries providing data in 2008, opioids 
accounted for more than three quarters of all cases 
(77–100 %), with 11 countries reporting proportions of 
over 85 % (141). Substances often found in addition to 
heroin include alcohol, benzodiazepines, other opioids 
and, in some countries, cocaine. This suggests that 
a substantial proportion of all drug-induced fatalities may 
occur in a context of polydrug use.
Men account for most overdose deaths occurring in 
Europe (81 %). In the majority of countries, the mean age 
of those dying is in the mid-30s, and in many instances 
it is increasing. This suggests a possible stabilisation or 
decrease in the number of young heroin users, and an 
ageing cohort of problem opioid users. Overall, 13 % of 
overdose deaths reported in Europe occur among those 
aged under 25 years, though Austria, Romania and Malta 
(small numbers) report percentages of 40 % or more. This 
may indicate a younger population of heroin users or 
injectors in these countries (142).
A number of factors are associated with fatal and non-
fatal heroin overdoses. These include injection and 
simultaneous use of other substances, in particular 
alcohol, benzodiazepines and some antidepressants. Also 
related to overdoses are binge drug use, co-morbidity, 
homelessness, poor mental health (e.g. depression), not 
being in drug treatment, having experienced previous 
overdoses and being alone at the time of overdose (Rome 
et al., 2008). The time immediately after release from 
prison or discharge from drug treatment is a particularly 
risky period for overdoses, as illustrated by a number of 
longitudinal studies (WHO, 2010).
Non-fatal opioid overdoses
Studies report that the majority of opioid users (typically 
50–60 %) have survived an overdose, and that 8–12 % had 
had an overdose in the last six months, with some users 
having overdosed more than once. For each drug-induced 
death, it is estimated that there are 20 to 25 non-fatal 
overdoses. The number of non-fatal overdoses occurring 
every year in Europe cannot be estimated with precision, as 
monitoring is very limited and definitions may vary between 
countries. Nevertheless, the available information suggests 
that there could be between 120 000 and 175 000 non-fatal 
overdoses every year in Europe.
Surviving an overdose greatly increases the risk of dying from 
a later overdose (Stoové et al., 2009). Furthermore, non-fatal 
overdoses can cause a wide range of morbidity, including 
pulmonary impairment, pneumonia and muscular impairment. 
Overdoses may also lead to neurological damage, and the 
number of overdoses experienced is a significant predictor of 
poorer cognitive performance. Overall morbidity is likely to 
be greater among older, more experienced and dependent 
users (Warner-Smith et al., 2001).
Early recognition that an opioid overdose is occurring and 
the intervention of emergency services can be essential for 
preventing a fatal outcome. Contact with the emergency 
services, as well as giving treatment for acute poisoning, 
presents an opportunity to receive information on overdose 
prevention and referral for counselling and treatment.
Monitoring non-fatal overdoses can allow cross-validation of 
information on drug-related deaths. In the Czech Republic, 
for example, hospitalisation for non-fatal opioid overdoses 
decreased between 2001 and 2008, reflecting the decrease 
in opioid deaths. At the same time, the numbers of non-fatal 
overdoses and deaths related to methamphetamine use 
increased.
86
Annual report 2010: the state of the drugs problem in Europe
(143) See the box ‘Deaths caused by cocaine’.
(144) For data on deaths related to drugs other than heroin, see Table DRD-108 in the 2010 statistical bulletin.
(145) See Figures DRD-8 and DRD-11 in the 2010 statistical bulletin.
Other opioids
Opioid substitution treatment reduces substantially the 
risk of fatal overdose, as illustrated by a Norwegian 
study on 3 800 persons with up to seven years follow-up, 
which showed a reduction in mortality during treatment 
compared with pre-treatment. The risk reduction was 
significant for both overdose deaths (relative risk 0.2) 
and all-cause mortality (relative risk 0.5) (Clausen et al., 
2008).
Deaths showing the presence of substances used in 
opioid substitution treatment are also reported each 
year. This reflects the large number of drug users 
undergoing this type of treatment and does not imply 
that these substances were the cause of death. Overdose 
deaths among clients in substitution treatment can be 
the result of combining drugs, as some treatment clients 
still use street opioids, engage in heavy drinking and 
use prescribed psychoactive substances. However, 
most deaths due to substitution substances (often in 
combination with other substances) happen among 
people who are not in substitution treatment (Heinemann 
et al., 2000).
Deaths due to buprenorphine poisoning are infrequent, 
despite its increasing use in substitution treatment 
in Europe (see Chapter 6). In Finland, however, 
buprenorphine remains the most common opioid detected 
in forensic autopsies, but usually in combination with other 
substances such as alcohol, amphetamine, cannabis and 
medicines, or taken by injection.
In Estonia, most drug-induced deaths reported in 
2007 and 2008 were associated with the use of 
3-methylfentanyl. In Finland, opioids such as oxycodone, 
tramadol or fentanyl were reported, though the role of 
these drugs in deaths was not specified. 
Deaths related to other drugs
Deaths caused by acute cocaine poisoning seem to be 
relatively uncommon (143). But, as cocaine overdoses are 
more difficult to define and identify than those related to 
opioids, they might be under-reported.
In 2008, about 1 000 deaths related to cocaine were 
reported in 15 countries. There are signs of cocaine being 
detected in increasing numbers of drug-induced deaths 
reported in European countries, but due to the lack of 
comparability in the available data, it is not possible 
to describe the European trend. A marked increase in 
the number of deaths related to cocaine in recent years 
has been observed in the two countries with the highest 
prevalence of cocaine use in the general population. 
In Spain, deaths in which cocaine was present in the 
absence of opioids showed a marked increase between 
2002 and 2007. In the United Kingdom, the number of 
death certificates mentioning cocaine doubled between 
2003 (161) and 2008 (325).
Deaths in which ecstasy is present are infrequently 
reported and, in many of these cases, the drug has 
not been identified as the direct cause of death (144). 
The EMCDDA’s 2010 ‘Selected issue’ on problem 
amphetamine and methamphetamine use reviews the data 
on deaths related to these two substances.
Trends in drug-induced deaths
Drug-induced deaths increased sharply in Europe during 
the 1980s and early 1990s, paralleling the increase in 
heroin use and drug injection, and thereafter remained at 
high levels (145).
Deaths caused by cocaine
Cocaine deaths are a much more complex phenomenon 
than opioid overdoses, which have a relatively clear 
clinical presentation. Therefore, many deaths caused 
by cocaine might not come to the attention of police or 
forensic experts due to the form of their presentation, and 
because of the social profile of the victims.
Cocaine use can cause fatal outcomes through different 
mechanisms. Pure cocaine pharmacological overdoses 
occur, but fatal outcomes are generally only associated 
with a massive ingestion of the drug. Most fatalities 
associated with cocaine use are caused by cardiovascular 
or cerebrovascular accidents (Sporer, 1999). These are not 
dose-dependent, and may also happen among occasional 
users or at low dosages, particularly in people with 
pre-existing cardiovascular or cerebrovascular problems. 
Most deaths showing cocaine use occur, however, among 
problem users affected by pathologies caused by chronic 
drug use (coronary atherosclerosis, ventricular hypertrophy 
or other problems) (Darke et al., 2006). These may be 
aggravated by alcohol use (Kolodgie et al., 1999) and 
tobacco smoking. In an unknown proportion of cocaine-
related deaths, the connection with the use of the drug may 
not be recognised, because of a lack of clinical specificity 
and because the death may occur days or weeks after the 
acute problem. Pathologies caused by regular cocaine 
use can also be the basis for later myocardial infarctions 
triggered by other factors, in a similar way to tobacco use.
Assessing the real burden of health problems and loss of 
life related to cocaine present specific challenges and will 
require different methods to those used for opioid overdose 
deaths.
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(146) For information on mortality cohort studies, see the ‘Key indicators’ on the EMCDDA website.
Between 2000 and 2003, most EU Member States 
reported a decrease (23 %), followed by a subsequent 
increase (11 %) in deaths between 2003 and 2007. 
Preliminary data available for 2008 suggest an overall 
figure at least equal to that for the previous year, with 
increases reported by 11 out of 18 countries where 
a comparison is possible. The United Kingdom and 
Germany, accounting for the bulk of reported cases 
in Europe, show a progressive year-on-year increase 
since 2003 and 2006, respectively. Other countries 
(e.g. France, Finland, Norway) also report an increase.
The reasons for the sustained numbers of reported drug-
induced deaths are difficult to explain, especially given the 
indications of decreases in injecting drug use and increases 
in the numbers of opioid users in contact with treatment and 
harm-reduction services. Possible explanations that require 
further investigation include: increased levels of polydrug 
use (EMCDDA, 2009d) or high-risk behaviour; increases 
in the numbers of relapsing opioid users leaving prison or 
treatment; and an ageing cohort of drug users, possibly 
with a more vulnerable population of chronic drug users. 
For instance, several countries (e.g. Germany, Spain, United 
Kingdom) report an increased proportion of cases aged 
over 35 years, which reflects the upward trend in the mean 
age of drug-induced deaths (Figure 15).
Overall mortality related to drug use
Overall mortality related to drug use comprises drug-
induced deaths and those caused indirectly through the 
use of drugs, such as through the transmission of infectious 
diseases, cardiovascular problems and accidents. The 
number of deaths indirectly related to drug use is difficult 
to quantify, but their impact on public health can be 
considerable. Drug-related deaths are mainly concentrated 
among problem drug users, although some (e.g. traffic 
accidents) occur among occasional users.
Estimates of overall drug-related mortality can be derived 
in various ways, for example by combining information 
from mortality cohort studies with estimates of drug use 
prevalence. Another approach is to use existing general 
mortality statistics and estimate the proportion related to 
drug use.
Mortality cohort studies
Mortality cohort studies track the same groups of problem 
drug users over time and, through linkage with mortality 
registries, try to identify the causes of all deaths occurring 
in the group. This type of study can determine overall 
and cause-specific mortality rates for the cohort, and can 
estimate the group’s excess mortality compared to the 
general population (146).
Depending on recruitment settings (e.g. drug treatment 
facilities) and enrolment criteria (e.g. injecting drug users), 
most cohort studies show mortality rates in the range 
of 1–2 % per year among problem drug users. These 
mortality rates are roughly 10 to 20 times higher than 
those of the same age group in the general population. 
Figure 15: Trends in mean age of drug-induced deaths in some European countries
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NB: For further information, see Figure DRD-3 in the 2010 statistical bulletin. United Kingdom data are based on the drug strategy definition.
Source: Reitox national focal points.
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(147) See Table DRD-5 (part iii) in the 2010 statistical bulletin. 
(148) See Figure DRD-7 (part ii) in the 2010 statistical bulletin.
(149) In particular related to cocaine, see ‘Health consequences of cocaine use’ in Chapter 5.
(150) See Table HSR-8 in the 2009 statistical bulletin.
The relative importance of the different causes of death 
varies between countries and over time. Generally, 
though, the main cause of death among problem drug 
users is drug overdose, accounting for up to 50–60 % of 
deaths among injectors in countries with low prevalence 
of HIV/AIDS. In addition to HIV/AIDS and other diseases, 
frequently reported causes of deaths include suicide 
and alcohol abuse, as illustrated by a recent study in 
Stockholm, which found that 17 % of the deaths among 
a cohort of mainly opioid users were from suicide and 
15 % were accidental. Alcohol was involved in 30 % of 
the deaths (Stenbacka et al., 2010). 
Deaths indirectly related to drug use
By combining existing data from Eurostat and HIV/AIDS 
surveillance, the EMCDDA has estimated that about 
2 100 people died of HIV/AIDS attributable to drug use 
in the European Union in 2007 (147), with 90 % of these 
deaths occurring in Spain, France, Italy and Portugal. 
Following the introduction of highly active antiretroviral 
therapy in 1996, HIV/AIDS mortality decreased markedly 
in most EU Member States, but it has been increasing 
in Estonia and Latvia since 2003. The highest HIV/AIDS 
mortality rates among drug users are reported for 
Portugal, followed by Estonia, Spain, Latvia and Italy; in 
most other countries the rates are low (148).
Other diseases that also account for a proportion of 
deaths among drug users include chronic conditions such 
as liver diseases, mainly due to hepatitis C (HCV) infection 
and often worsened by heavy alcohol use and HIV 
co-infection. Deaths caused by other infectious diseases 
are rarer. Non-infectious causes of death mainly include 
cancer and cardiovascular problems (149).
Other causes of death among drug users have received 
much less attention, despite indications of a considerable 
impact on mortality. A recent WHO study (Degenhardt 
et al., 2009) estimated that, in Europe, suicides and 
trauma could account for about one third of the mortality 
attributable to problem drug use, which would imply 
several thousand deaths every year. Regarding specifically 
suicide, a literature review (Darke and Ross, 2002) found 
that heroin users had a 14 times higher risk of suicide 
death than the general population.
Information on the number of deaths related to drug 
driving remains scarce. Some studies suggest increased 
risks of accidents associated with illicit drug use, and that 
the combined use of drugs and alcohol causes additional 
impairment (EMCDDA, 2008b).
Reducing drug-related deaths
Fifteen European countries report that their national drug 
strategy includes a part dedicated to the reduction of 
drug-related deaths, that such policies exist at regional 
level, or that they have a specific action plan for the 
prevention of drug-related deaths. Austria reports that 
a strategy paper is being prepared.
Interventions
Treatment reduces significantly the mortality risk of drug 
users (Davoli et al., 2007), although risks related to 
drug tolerance arise when entering or leaving treatment. 
Studies show that the risk of drug-induced death on 
relapse after treatment or in the weeks after release from 
prison is substantially elevated. This led to the publishing 
of WHO-Europe recommendations regarding overdose 
prevention in prisons and improved continuity of care after 
release (WHO, 2010).
Denmark and Norway have recently prioritised 
buprenorphine in their guidelines for substitution treatment 
because of its pharmacological safety profile. Spain 
has recently approved the buprenorphine–naloxone 
combination for patients in substitution programmes 
carried out by the national health system, with the aim of 
reducing drug-induced deaths.
Alongside improving access to drug treatment, other 
interventions to reduce overdose risks in drug users have 
been studied. These interventions address personal, 
situational and drug-use related factors. A recent review 
of the evidence (Rome et al., 2008) recommended raising 
awareness among general practitioners of the dangers 
of multiple prescriptions, in particular of antidepressants. 
Measures to control the prescription of multiple drugs to 
substitution clients, and thereby to reduce emergencies 
involving the use of benzodiazepines, have been taken in 
Luxembourg.
The provision of information materials is reported as 
a common intervention to reduce drug-induced deaths in 
Europe (150). Many countries report providing overdose 
prevention, recognition and response education to drug 
users and their neighbours, friends and families, as well 
as to service providers who work with drug users. The 
provision of these interventions is, however, often sporadic 
and limited.
Following an epidemic of fentanyl overdoses, Estonian 
experts are now calling for the introduction of overdose 
prevention programmes in the country. Belgium, the 
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Czech Republic, Estonia and the Netherlands report 
the operation of early-warning systems that collect and 
disseminate information about new drugs or dangerous 
combinations via low-threshold agencies, shelters or 
treatment facilities. In the Netherlands, a monitoring 
system for drug-related acute health incidents was tested 
in 2009 and is now being expanded.
Overdose training combined with a take-home dose of 
naloxone — which reverses the effects of opioids — is 
an approach that could save many lives. The intervention 
targets drug users and their families, the people who 
could be with a user during an overdose, and is aimed 
at enabling them to take effective action while awaiting 
the arrival of emergency services. Studies show that those 
trained demonstrated improved knowledge of the signs of 
overdose and increased confidence in using naloxone. In 
2009, a project providing packs with a syringe pre-filled 
with naloxone to 950 family members of drug users 
started in England. Packs containing one-shot injectors 
of naloxone are also given, as part of an ongoing study, 
to opioid users leaving prison in England, Scotland and 
Wales. Pre-filled syringes are available in Italy via drugs 
agencies, are used in a trial in Portugal and have been 
introduced in Bulgaria. The provision of a nasal spray 
of naloxone has started through a user-led project in 
Copenhagen.
Supervised drug consumption rooms enable rapid 
intervention at the first signs of an overdose. Operational 
data indicate that drug overdoses occurring in these 
facilities are successfully managed, with no fatal 
overdoses reported. Providing immediate help also 
reduces the impact of non-fatal overdose, including 
irreversible damage to the brain and other vital organs, 
due to hypoxia (Hedrich et al., 2010).
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Introduction
New psychoactive substances and new patterns of 
use, though usually first appearing among restricted 
social groups or in a few locations, can have important 
implications for public health and for drug policy. 
Providing timely and objective information to policymakers, 
professionals and the wider public on new threats is 
methodologically and practically challenging. It is also of 
growing importance, given the increasingly dynamic and 
fast-moving nature of the European drugs problem. The 
European Union’s early-warning system has been developed 
as a rapid-response mechanism to the emergence of new 
psychoactive substances on the drug scene.
A large number of new unregulated synthetic compounds 
have appeared in recent years. These substances are 
marketed on the Internet as ‘legal highs’ and are designed 
to circumvent drug controls. They constitute a challenge 
to current approaches for monitoring and controlling new 
psychoactive substances. As reviewed in this chapter, the 
last two years have seen the emergence of new, smokable 
herbal products laced with synthetic cannabinoids and the 
growing popularity of various synthetic cathinones.
Action on new drugs
In 2009, 24 new synthetic psychoactive substances were 
formally notified via the European early-warning system. 
This is the largest number reported in a single year, and 
the increase is mainly due to the identification of nine new 
synthetic cannabinoids in the past year. Also reported in 
2009 were new substances belonging to the chemical 
families usually providing new psychoactive drugs: five 
phenethylamines, two tryptamines and four synthetic 
cathinones. No new piperazines or psychoactive plants 
were reported.
Since the establishment of the early-warning system in 
1997, more than 110 substances have been notified to 
the EMCDDA and Europol. New groups of substances 
have emerged in the last five years. These include 
various piperazines, synthetic cathinones and synthetic 
cannabinoids. However, no piperazines have been 
identified in the last two reporting years. Only six were 
plants or of plant origin, and it is likely that synthetic 
psychoactive substances will continue to be the most 
frequently reported new substances in the future.
Three substances with medicinal properties were reported 
in 2009. These include pregabalin, a prescription 
medicine marketed under the name Lyrica and used to 
treat neuropathic pain, epilepsy and generalised anxiety 
disorder. A recent review of pharmacovigilance data 
indicates concerns related to its misuse in Finland, Sweden 
and Norway. Information from the early-warning system 
also suggests that pregabalin may have been involved 
in the deaths of users in Finland, Sweden and the United 
Kingdom, where it was found in forensic toxicological 
analyses. User reports suggest that pregabalin has effects 
similar to those of alcohol, GHB (gamma-hydroxybutyric 
acid), ecstasy and benzodiazepines. It is also reported to 
alleviate heroin (opioid) withdrawal symptoms.
Chapter 8
New drugs and emerging trends
Monitoring new psychoactive substances in 
Europe
The Council decision on new psychoactive substances (1) 
establishes a European mechanism for the rapid exchange 
of information on new psychoactive substances that may 
pose public health and social threats (EMCDDA, 2007b). 
The EMCDDA and Europol, in close cooperation with their 
networks of national partners, are assigned a central role 
in implementing the early-warning system. Once a new 
psychoactive substance is detected on the European 
market, Member States ensure that information on the 
manufacture, traffic and use of the drug is transmitted to 
the EMCDDA and Europol via the Reitox national focal 
points and Europol national units. The Council decision 
also provides a framework for an assessment of the 
risks associated with new substances (see EMCDDA, 
2010b). Information on substances of established and 
acknowledged medicinal value can also be exchanged via 
the early-warning system, but these may not be subjected 
to risk assessment under the Council decision.
(1) Council Decision 2005/387/JHA of 10 May 2005 on the 
information exchange, risk assessment and control of new 
psychoactive substances (OJ L 127, 20.5.2005, p. 32).
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(151) Mephedrone (4-methylmethcathinone); methylone (3,4-methylenedioxymethcathinone); methedrone (4-methoxymethcathinone); and MDPV 
(3,4-methylenedioxypyrovalerone).
(152) Drug profiles on khat and synthetic cathinone derivatives are available on the EMCDDA website.
(153) Personal communication from Adam Winstock, King’s College London.
The early-warning system also monitors unregulated 
psychoactive products — the so-called ‘legal highs’ — 
sold via the Internet and smart or head shops, advertised 
with aggressive and sophisticated marketing strategies, 
and in some cases intentionally mislabelled with declared 
ingredients differing from the actual composition. The 
‘legal highs’ market is distinguished by the speed at 
which suppliers circumvent drug controls by offering new 
alternatives.
Mephedrone
Synthetic cathinones have been increasingly reported via 
the early-warning system in the last few years. At present, 
15 of these substances are being monitored, including 
mephedrone, methylone, methedrone and MDPV (151). These 
‘designer’ compounds are derivatives of cathinone, which is 
one of the psychoactive principles in the plant khat (Catha 
edulis) and is structurally related to amphetamine (152).
Mephedrone is a derivative of methcathinone — 
a scheduled drug in the 1971 UN Convention. It 
appeared for the first time in Europe in 2007, and seems 
to have gained popularity among young drug users, 
leading to a specific demand for this substance. This 
seems to be particularly the case in the United Kingdom, 
where mephedrone has received attention from the media. 
Reports from other Member States suggest that it is also 
used elsewhere in Europe.
Seizures of significant quantities of mephedrone have been 
reported in 2009 by Germany, the Netherlands, Sweden 
and the United Kingdom. In Sweden, toxicology results 
confirmed the role of mephedrone use in a death and in the 
United Kingdom a number of deaths are being investigated 
for possible involvement of mephedrone. Control measures 
on mephedrone have recently been introduced by 
Denmark, Germany, Estonia, Ireland, Romania, Sweden, the 
United Kingdom, Croatia and Norway.
Mephedrone is readily available on the Internet, where it 
may be sold as a legal alternative to cocaine or ecstasy. 
The substance is variously advertised as a ‘research 
chemical’, ‘bath salts’, ‘for botanical research’, ‘plant food’ 
or ‘plant feeder’, often with a note saying ‘not for human 
consumption’ in order to circumvent potential control 
mechanisms. Often, the list of ingredients gives no indication 
of the presence of psychoactive substances. A search for 
online mephedrone shops conducted in March 2010 in 
English showed that at least 77 websites were selling the 
substance. Most of these websites sold only mephedrone 
and were based in the United Kingdom. Following the 
United Kingdom’s classifying of mephedrone and other 
synthetic cathinones as controlled drugs in April 2010, the 
majority of mephedrone sites have ceased to exist.
Data on the use of 29 substances, including a number of 
‘legal highs’, were collected in an online survey conducted 
in late 2009, in collaboration with the United Kingdom’s 
dance music magazine Mixmag (153). Mephedrone was 
reported as the fourth most commonly used drug (after 
cannabis, ecstasy and cocaine) and the most used 
‘legal high’ among the 2 295 respondents. About one 
third (33.6 %) reported using it in the last month, 37.3 % in 
the last year and 41.7 % ever. The figures for methylone 
were 7.5 %, 10.0 % and 10.8 % respectively. The small 
difference between last month and lifetime prevalence 
suggests a new and rapidly spreading phenomenon. 
These findings cannot, however, be considered as 
representative of the wider population of club-goers, due 
to the methodological limitations of online surveys; such 
surveys may, however, provide rapid access to specific 
populations (Verster et al., 2010).
Monitoring online drug shops
The early-warning system has been monitoring the 
marketing of new psychoactive substances on the Internet 
each year since 2006. Changes in the methods used have 
increased the quality and coverage of the surveys, but 
data for different years are not directly comparable.
In 2010, 170 online drug shops were identified, 30 of which 
offered both ‘legal highs’ and hallucinogenic mushrooms, 
EMCDDA–Europol joint report on mephedrone
The EMCDDA and Europol completed an assessment 
of the available information on mephedrone in January 
2010, based upon the criteria set out in the early-warning 
system’s operating guidelines (EMCDDA, 2007b). These 
include: the amount of the material seized; evidence of 
organised crime involvement; evidence of international 
trafficking; the toxicopharmacological properties of the 
psychoactive substance; evidence of the potential for 
further (rapid) spread; and evidence of cases of serious 
intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
available on mephedrone satisfies the criteria for a joint 
report to be produced. The resulting EMCDDA–Europol 
joint report was presented to the Council of the European 
Union, the European Commission and the European 
Medicines Agency, and a decision was taken to launch 
a formal risk-assessment procedure on the substance.
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(154) See the box ‘Snapshot on online drug shops: methods’.
(155) An agonist is a chemical substance that binds to a specific receptor of a cell and triggers an activity by the cell. An agonist often mimics the action 
of endogenous or naturally occurring substances.
(156) See the Drug profile ‘Synthetic cannabinoids and ‘Spice’’ on the EMCDDA website.
(157) Denmark, Germany, Estonia, Ireland, France, Latvia, Lithuania, Luxembourg, Austria, Poland, Romania, Sweden, United Kingdom.
typically with a wide selection of products from both groups: 
34 offered only hallucinogenic mushrooms; and 106 sold 
‘legal highs’ but not hallucinogenic mushrooms (154).
The number of vendors of hallucinogenic mushrooms 
seems to have increased since 2006, when 39 shops 
were identified selling these products (EMCDDA, 
2006). In 2010, 64 online shops were identified selling 
hallucinogenic mushrooms, with most of them selling grow 
kits, spores and fly agaric mushroom (Amanita muscaria) 
rather than psilocybin-containing mushrooms.
In the 2009 online survey, which focused only on ‘legal 
highs’, the largest number of online shops were based 
in the United Kingdom, followed by Germany and the 
Netherlands. The 2010 snapshot, with its extended scope, 
showed a different pattern, with 38 online shops based 
in the Netherlands, 20 in the United Kingdom and 20 in 
Germany. Countries in which at least five online shops 
were located include Poland, France and Hungary, while 
smaller numbers were based in the Czech Republic, Spain, 
Portugal, Slovakia, Italy and Sweden. Thirty-eight online 
shops were based in the United States, and the location of 
15 online shops could not be determined. Unlike the online 
shops located in the United Kingdom, many of those 
based in the Netherlands are associated with specialist 
shops. Overall, 73 % of the online shops used English, 
with 42 % offering no other language.
The ‘Spice’ phenomenon
‘Spice’ is sold on the Internet and in specialised shops as 
a smoking mixture. In 2008, forensic chemists discovered 
that it is not the harmless herbal product that it claims 
to be. The real psychoactive constituents of ‘Spice’ were 
identified as synthetic additives: substances, such as the 
cannabinoid receptor agonist (155) JWH-018, that mimic 
the effects of tetrahydrocannabinol (THC) in cannabis.
The so-called ‘Spice’ phenomenon continued to receive 
considerable attention in 2009. Throughout the year, the 
names and brand packaging of ‘Spice’-like products have 
diversified. The psychoactive compounds added to these 
products have also being changing, in response to new 
control measures (EMCDDA, 2009f). Nine new synthetic 
cannabinoids were reported through the early-warning 
system in 2009 (156).
The variety and number of synthetic cannabinoids, or 
other substances, that can be added to herbal products 
pose challenges in terms of their identification, monitoring 
and risk appraisal. Almost nothing is known about the 
pharmacology, toxicology and safety profiles of these 
compounds in humans. The type and amount of added 
synthetic cannabinoids may also vary considerably, and 
some of these compounds may be highly active at very 
small doses. As a result, accidental overdosing with a risk 
of severe psychiatric or other complications cannot be 
excluded.
None of the synthetic cannabinoids is controlled under 
the UN conventions, and there is no information on any of 
them having been authorised as medicinal products in the 
European Union. At the time of writing, several Member 
States had banned or otherwise controlled ‘Spice’, 
‘Spice’-like products and related compounds (157). The 
purported herbal ingredients of ‘Spice’ products are not 
internationally controlled, but some Member States (Latvia, 
Poland, Romania) have placed one or more of them on 
their lists of controlled substances. Outside the European 
Union, Switzerland controls ‘Spice herbal mixes’ under its 
food regulation.
In the 2010 online survey, the number of online shops 
offering ‘Spice’ dropped sharply compared with the 
previous year. Despite having a broader coverage, the 
Snapshot on online drug shops: methods
The 2010 survey took place between 25 January and 
5 February, and targeted online drug shops (retailers 
and wholesale) accessible to any European Internet user 
interested in buying ‘legal highs’ (including ‘Spice’), 
GHB/GBL or hallucinogenic mushrooms. Online shops that 
did not provide shipping to at least one EU Member State 
were not included.
Search strings were first tested in English, in order to 
identify those yielding the highest proportion of relevant 
hits. Searches were then carried out in 15 languages 
spoken as a mother tongue by 84 % of the European 
Union’s population (1). Three different search engines were 
used: Metacrawler, Google and a ‘national’ search engine 
depending on the country and language.
Sampling consisted of examining the first 100 links, and 
continued until 20 consecutive links proved irrelevant. 
For each site identified, the following information was 
collected: products on sale, product descriptions, prices, 
availability in stock, countries of delivery, ingredients, 
health warnings and users’ reviews.
(1) Czech, Danish, Dutch, English, French, German, Greek, 
Hungarian, Italian, Maltese, Polish, Portuguese, Slovak, Spanish 
and Swedish.
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(158) 2008 CBOS survey, sample of 1 400 adolescents of final grades at post middle schools; 15 % of participants reported having used drugs in the last 
12 months.
(159) For example: BZP (1-benzylpiperazine); CPP (chlorophenylpiperazine); TFMPP (1-(3-trifluoromethylphenyl)-piperazine) and DBZP 
(1,4-dibenzylpiperazine). CPP has three positional isomers, which are often difficult to distinguish, of which mCPP (1-(3-chlorophenyl)piperazine) is 
the most prevalent.
(160) Council Decision 2008/206/JHA of 3 March 2008 on defining 1-benzylpiperazine (BZP) as a new psychoactive substance which is to be made 
subject to control measures and criminal provisions (OJ L 63, 7.3.2008).
(161) mCPP is not controlled internationally, but a number of European countries have implemented measures to control it in the last few years (Belgium, 
Denmark, Germany, Greece, Cyprus, Latvia, Lithuania, Hungary, Malta, Romania, Slovakia, Croatia, Turkey, Norway).
2010 survey identified only 21 shops offering ‘Spice’-
like products, compared with 55 in 2009. This year, two 
online shops offering ‘Spice’ were based in the United 
Kingdom, down from 23 last year. In the most recent 
snapshot, 15 shops claimed to have ‘Spice’ available, with 
eight of them revealing where they are located: three in 
the United States and one each in Spain, Poland, Portugal, 
Romania and the United Kingdom. The remaining six 
online shops which offered ‘Spice’-like products reported 
to be out of stock, and were possibly using the brand’s 
name to attract customers.
Unlike illicit drugs, no large seizures of ‘Spice’-like 
products were reported, and there is a lack of reports 
of criminality associated with the phenomenon. This, 
combined with the limited knowledge about the chemistry 
and effects of the new compounds, creates a ‘grey zone’ 
around the monitoring of such products.
Prevalence of ‘legal-highs’ use
The term ‘legal highs’ encompasses a wide range of 
products, from herbal mixtures to synthetic or ‘designer’ 
drugs and ‘party pills’, which are used in different ways 
(smoked, snorted, ingested). In addition, these products 
can be marketed as room odourisers, herbal incenses or 
bath salts, though they are intended for a different use. 
This diversity makes it difficult to collect and interpret 
prevalence data on ‘legal highs’.
Few recent surveys report prevalence data on the use 
of ‘legal highs’. A 2008 Polish study among 18-year-old 
students found that 3.5 % had used ‘legal highs’ at least 
once, a figure comparable to the one for hallucinogenic 
mushrooms (3.6 %). The use of ‘legal highs’ during the last 
12 months was reported by 2.6 % of students (158).
A survey conducted among 1 463 students aged between 
15 and 18 years at schools providing general and 
vocational training in Frankfurt found that about 6 % of 
respondents reported having used ‘Spice’ at least once, 
and 3 % had used it during the last 30 days. These 
figures could have been influenced by the media attention 
given to ‘Spice’ at the time of the survey, as just 1 % of 
respondents reported having taken ‘Spice’ more than 
five times. Almost two thirds of those reporting having 
ever used ‘Spice’ also reported using cannabis in the last 
month.
The latest Mixmag online survey, which targets club-goers 
in the United Kingdom, found that 56.6 % of respondents 
reported having used ‘legal highs’. These included the 
herbal products ‘Spice’ and ‘Magic’, BZP party pills 
and other party pills, with last month prevalence of use 
of respectively 2.0 %, 4.6 % and 5.3 %. Respondents 
reported obtaining these drugs from friends (95 %) or 
purchasing them on websites (92 %), in shops (78 %), from 
festival stalls (67 %) or dealers (51 %).
Follow-up on other substances
Piperazines: BZP and mCPP
It has become increasingly complicated to record and 
interpret seizure data on piperazines. This is partly due to 
the multiple mixtures of substances that may be found in 
powders and tablets (159), and partly because piperazines 
are also combined with other drugs such as amphetamine 
and MDMA. In addition, forensic science laboratories do 
not always have the resources to identify all components 
of mixtures and in particular those that are not under 
control.
The availability of BZP appears to have decreased 
following the 2008 Council decision to submit it to control 
measures throughout the European Union (160). Some 
Member States, however, continue to report some large 
BZP seizures.
In 2009, mCPP still appeared to be the most widely 
available ‘new synthetic drug’ (161) on the European 
ecstasy market, either alone or in combination with 
MDMA. Information from the early-warning system, 
including reports from users in the Netherlands and 
seizures in Denmark and the United Kingdom, suggests 
that the proportion of ecstasy tablets containing mCPP (or 
piperazines in general) increased markedly in the first half 
of 2009, possibly exceeding ecstasy tablets containing 
MDMA. The Dutch Drug Information Monitoring System 
also reported that the number of samples submitted by 
users for analysis had doubled compared to previous 
years, probably due to increased concerns regarding the 
adverse effects of piperazines. The proportion of ecstasy 
tablets containing these substances may have fallen in the 
second half of 2009; in the United Kingdom, however, this 
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may have been partly offset by an increased availability 
of cathinone derivatives. 
These changes reflect an increasingly complex ecstasy 
market, which can be explained by fluctuations in the 
availability of the MDMA precursor chemical PMK.
GHB/GBL and ketamine
GHB (gamma-hydroxybutyric acid) has been under 
international control since 2001, while ketamine, which is 
a medicinal product, may be controlled in Member States 
under either their legislation on drugs or on medicines. 
The use of gamma-butyrolactone (GBL), which is rapidly 
converted to GHB when ingested, has also recently raised 
concerns in Europe. GBL is considered a ‘non-scheduled 
drug precursor’ at EU level, and is included in the 
voluntary monitoring scheme for drug precursors. Some 
countries (Italy, Latvia, Austria, Sweden, United Kingdom, 
Norway) control it under their national drug legislation.
The prevalence of GHB and ketamine use in the general 
population is low, but it can be much higher in specific 
groups, settings and geographical areas. The Mixmag 
online survey targeting club-goers in the United Kingdom 
found last month prevalence of use of 1.7 % for GHB and 
1.6 % for GBL, but 32.4 % for ketamine. A survey among 
club-goers in Amsterdam conducted in 2003 and 2008 
(646 respondents) reported a slight increase in last month 
prevalence of GHB use from 4.2 % to 4.7 %. In the Czech 
Republic, a 2008 survey among 363 club-goers found last 
month prevalence of use at 0.3 % for GHB and 0.6 % for 
ketamine. In London, a survey among 173 clubbers 
requesting medical assistance at a club medical room 
found that as many as two thirds requested it because of 
GHB/GBL use (Wood et al., 2009). A survey regularly 
carried out among 15- to 16-year-old school students 
in Frankfurt found that the numbers offered GHB had 
increased from 1 % in 2002 to 5 % in 2008.
The EMCDDA’s 2010 Internet snapshot found no online 
shops registered in the EU offering GHB, but GBL was 
found in four online shops. None of these, however, 
seemed to advertise GBL as a drug or implied that it could 
be used for its psychoactive properties.

97
(162) Hyperlinks to online sources can be found in the PDF version of the annual report, available on the EMCDDA website (http://www.emcdda.europa.
eu/publications/annual-report/2010).
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, 
reliable and comparable information on drugs and drug addiction. 
In doing so, it provides its audiences with an evidence-based picture 
of the drug phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisers; professionals 
and researchers working in the field of drugs; and, more broadly, the 
media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug 
phenomenon in the EU and is an essential reference book for those seeking 
the latest findings on drugs in Europe.
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